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Abstract 
The essential post-translational modification O-linked β-N-acetylglucosamine (O-
GlcNAc) regulates thousands of nuclear, cytoplasmic, and mitochondrial proteins. O-
GlcNAc is dynamically added and removed from proteins by the O-GlcNAc transferase 
(OGT) and the O-GlcNAcase (OGA), respectively. Dysregulation of O-GlcNAc-cycling is 
implicated in the etiology of numerous diseases, including cancer, neurodegeneration, and 
metabolic dysfunction. Underpinning these observations, O-GlcNAc regulates nearly 
every major cellular process including transcription, translation, protein degradation, 
protein localization, and the cell cycle. Furthermore, many forms of cellular stress and 
injury, including oxidative stress, elicit an increase in O-GlcNAcylation on numerous 
proteins, which has been demonstrated to promote cell survival. However, the mechanisms 
by which OGT and OGA are regulated during oxidative stress to alter O-GlcNAcylation 
are not fully characterized. Here, we demonstrate that oxidative stress leads to elevated O-
GlcNAc levels in U2OS cells but has little impact on the activity of OGT. In contrast, the 
expression and activity of OGA are enhanced. We hypothesized that this seeming paradox 
could be explained by proteins that bind to and control the local activity or substrate 
targeting of OGA, thereby resulting in the observed stress-induced elevations of O-
GlcNAc. To identify potential protein partners and regulators, we utilized BioID proximity 
biotinylation in combination with Stable Isotopic Labeling of Amino Acids in Cell Culture 
(SILAC). This analysis revealed 90 OGA-interacting partners, many of which exhibited 
increased binding to OGA upon stress. The associations of OGA with fatty acid synthase 
(FAS), filamin-A, heat shock cognate 70 kDa protein, and OGT were confirmed by co-
immunoprecipitation. The pool of OGA bound to FAS demonstrated a substantial (∼85%) 
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reduction in specific activity, suggesting that FAS inhibits OGA. Consistent with this 
observation, FAS overexpression augmented stress-induced O-GlcNAcylation on a subset 
of proteins. Although the mechanism by which FAS sequesters OGA remains unknown, 
these data suggest that FAS fine-tunes the cell's response to stress and injury by remodeling 
cellular O-GlcNAcylation. Finally, our studies characterized the use of two commercially 
available and three non-commercially available antibodies for detecting and enriching full-
length OGA from lysates of mouse and human origin in order to facilitate future studies 
probing the regulation of OGA in disease.  
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Summary 
O-linked β-N-acetylglucosamine (O-GlcNAc) is a ubiquitous and dynamic post-
translational modification known to modify over 3,000 nuclear, cytoplasmic, and 
mitochondrial eukaryotic proteins. Addition of O-GlcNAc to proteins is catalyzed by the 
O-GlcNAc transferase and is removed by a neutral pH β-N-acetylglucosaminidase. O-
GlcNAc is thought to regulate proteins in a manner analogous to protein phosphorylation, 
and the cycling of this carbohydrate modification regulates many cellular functions such 
as the cellular stress response. Diverse forms of cellular stress and tissue injury result in 
enhanced O-GlcNAc-modification, or O-GlcNAcylation, of numerous intracellular 
proteins. Stress-induced O-GlcNAcylation appears to promote cell/tissue survival by 
regulating a multitude of biological processes including: the phosphoinositide 3-kinase/Akt 
pathway, heat shock protein expression, calcium homeostasis, levels of reactive oxygen 
species, endoplasmic reticulum stress, protein stability, mitochondrial dynamics, and 
inflammation. Here, we will discuss the regulation of these processes by O-GlcNAc and 
the impact of such regulation on survival in models of ischemia reperfusion injury and 
trauma hemorrhage. We will also discuss the misregulation of O-GlcNAc in diseases 
commonly associated with the stress response, namely Alzheimer’s and Parkinson’s 
diseases. Finally, we will highlight recent advancements in the tools and technologies used 





O-linked β-N-acetylglucosamine (O-GlcNAc) is a dynamic post-translational 
modification (PTM) of more than 3,000 nuclear, cytoplasmic, and mitochondrial proteins 
(Torres and Hart 1984; Wells et al. 2002b; Vosseller et al. 2006; Gurcel et al. 2008; Rexach 
et al. 2008; Carapito et al. 2009; Teo et al. 2010; Wang et al. 2010a; Wang et al. 2010b). 
While O-GlcNAc appears more common in metazoans, there is evidence for this PTM in 
simple eukaryotes such as Aspergillus niger (Machida and Jigami 1994) and in some 
prokaryotes (Shen et al. 2006). O-GlcNAc is cycled on and off serine and threonine 
residues by just two enzymes: the O-GlcNAc transferase (OGT) that catalyzes the addition 
of O-GlcNAc and the O-GlcNAcase (OGA) that removes O-GlcNAc (Figure 1-1). 
Highlighting the importance of O-GlcNAc in cellular homeostasis, deletion of OGT, OGA, 
and other key enzymes in the hexosamine biosynthetic pathway (HBP) is lethal in 
mammals (Mio et al. 1999; Boehmelt et al. 2000a; Boehmelt et al. 2000b; Shafi et al. 2000; 
Forsythe et al. 2006; Greig et al. 2007; Yang et al. 2012).  
Intracellular proteins that are O-GlcNAc-modified (O-GlcNAcylated) fall into 
diverse functional groups. Examples of O-GlcNAcylated proteins include chromatin-
associated proteins and histones, transcription factors, ribosomal proteins, proteasomal 
proteins, cytoskeletal proteins, and many different types of signaling proteins such as 
kinases and metabolic enzymes (Wells et al. 2002b; Vosseller et al. 2006; Gurcel et al. 
2008; Rexach et al. 2008; Carapito et al. 2009; Teo et al. 2010; Wang et al. 2010a; Wang 
et al. 2010b). O-GlcNAc is thought to regulate these proteins in a manner analogous to 
protein phosphorylation. O-GlcNAc has been demonstrated to alter numerous protein 
functions that include: DNA binding and transactivation (Jackson and Tjian 1989; Comer 
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and Hart 1999; Gao et al. 2003; Sayat et al. 2008; Ozcan et al. 2010), protein-protein 
interactions (Guinez et al. 2006; Guinez et al. 2007; Guinez et al. 2010; Ise et al. 2010; Lim 
and Chang 2010), protein degradation (Han and Kudlow 1997; Cheng and Hart 2001; 
Zhang et al. 2003), protein and enzyme activity (Zhang et al. 2003; Kim et al. 2006b; 
Rengifo et al. 2007; Dias et al. 2009; Bimboese et al. 2011), and protein localization 
(Dudognon et al. 2004; Sayat et al. 2008) amongst many others (Hart et al. 2011). 
 
Figure 1-1: The hexosamine biosynthetic pathway provides the donor substrate for O-GlcNAcylation 
and other types of protein glycosylation. Upon entry into the cell, a small percentage of Glucose (2-5% in 
adipocytes) is directed into the hexosamine biosynthetic pathway and converted into UDP-GlcNAc via 
glutamine:fructose-6-phosphate amidotransferase (Gfpt1; GFAT), glucosamine-6-phosphate 
acetyltransferase (EMeg32), N-acetylglucosamine-phosphate mutase (Pgm3), and UDP-GlcNAc 
pyrophosphorylase (Uap1). OGT catalyzes the addition of the glycoside to yield O-GlcNAcylated nuclear, 
cytoplasmic, and mitochondrial proteins, whereas the enzyme O-GlcNAcase (OGA) catalyzes the removal 
of O-GlcNAc from proteins. O-GlcNAc-modified proteins are involved in many cellular processes including 





Like phosphorylation, the levels of O-GlcNAc respond to both intracellular and 
extracellular stimuli including insulin, nutrient levels, and cellular stress (Kearse and Hart 
1991; Walgren et al. 2003; Zachara et al. 2004b; Song et al. 2008; Whelan et al. 2008; 
Whelan et al. 2010; Hart et al. 2011), with the latter being the main focus of this review. 
In response to diverse forms of cellular stress, O-GlcNAc levels are elevated on numerous 
proteins (Zachara et al. 2004b). Augmenting O-GlcNAc levels promotes survival while 
suppressing O-GlcNAc levels sensitizes cells to death, suggesting that O-GlcNAc is a key 
regulator of the cellular stress response (Zachara et al. 2004b). While the exact mechanisms 
by which O-GlcNAc alters protein function leading to cell survival have not been defined, 
O-GlcNAc is known to regulate many signaling events and pathways, and this review will 
specifically focus on 1) the phosphoinositide 3-kinase (PI3K)/Akt pathway, 2) heat shock 
protein (HSP) expression, 3) calcium homeostasis, 4) reactive oxygen species (ROS) 
generation, 5) mitochondrial dynamics, 6) inflammation, and 7) the interplay with other 
PTMs. O-GlcNAc modulates these aspects of the cellular stress response to protect against 
ischemia reperfusion (I/R) injury, trauma hemorrhage, and neurodegeneration. We will 
also discuss the interplay between O-GlcNAc and other PTMs, future directions regarding 
novel technologies for detecting O-GlcNAc, and potential roles for O-GlcNAc in other 
disease mechanisms. 
 
Biosynthesis of O-GlcNAc 
Two enzymes modulate protein O-GlcNAcylation: uridine diphosphate (UDP)-β-
N-acetylglucosamine (GlcNAc):peptide N-acetylglucosaminyl-transferase N-acetyl-β-D-
glucosamine: peptide N-acetylglucosaminyl-transferase (O-GlcNAc transferase, OGT), 
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which catalyzes the addition of O-GlcNAc, and a neutral pH β-N-acetylglucosaminidase 
(O-GlcNAcase, OGA), which is responsible for the removal of O-GlcNAc (Figure 1-1). 
The levels of O-GlcNAc appear to be regulated by five main events: 1) expression and 
activity of OGT; 2) expression and activity of OGA; 3) the concentration of UDP-GlcNAc, 
the sugar nucleotide donor of OGT; 4) the availability of protein substrates; and 5) targeting 
of the enzymes to their substrates.  
The hexosamine biosynthetic pathway 
The synthesis of UDP-GlcNAc occurs via the HBP (Figure 1-1). Upon entering 
cells, glucose is rapidly converted to glucose-6-phosphate by hexokinase (HK), and 
subsequently to fructose-6-phosphate by glucose-6-phosphate isomerase (G6P-I). The first 
step of the HBP is rate limiting, and comprises of the conversion of fructose-6-phosphate 
to glucosamine-6-phosphate by glutamine:fructose-6-phosphate amidotransferase (Gfpt1; 
GFAT). Notably, glutamine is required for this step and can be used to alter cellular O-
GlcNAc levels as well as the levels of other sugar metabolites (Marshall et al. 1991). 
Several subsequent reactions result in the production of UDP-GlcNAc, the sugar nucleotide 
donor substrate used by OGT and other glycosyltransferases. The HBP accounts for ~2-
5% of glucose flux in 3T3-L1 adipocytes (Marshall et al. 1991) These and other 
observations have led some to suggest that O-GlcNAc regulates cellular function in a 
glucose-dependent manner. Although little is known about the regulation of GFAT, it 
appears to be inhibited by high concentrations of UDP-GlcNAc (Traxinger and Marshall 
1991). Interestingly, free radicals promote GFAT activity suggesting one mechanism by 
which cellular stress and high glucose can lead to upregulation of UDP-GlcNAc pools (Du 
et al. 2000). Mutations in genes encoding enzymes that significantly lower O-GlcNAc 
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levels, such as glucosamine-6-phosphate acetyltransferase (EMeg32) and N-
acetylglucosamine-phosphate mutase (Pgm3), are embryonic lethal highlighting the 
importance of O-GlcNAc and other forms of protein glycosylation that rely on UDP-
GlcNAc (Boehmelt et al. 2000a; Boehmelt et al. 2000b; Greig et al. 2007). 
O-GlcNAc transferase 
Unlike many other glycosyltransferases, OGT is a soluble protein that is 
predominantly localized to the nucleus, mitochondria and cytoplasm of all tissues studied 
thus far (Haltiwanger et al. 1992; Kreppel et al. 1997; Lubas et al. 1997; Hanover et al. 
2003; Love et al. 2003). Two functional domains characterize OGT: an N-terminal 
tetratricopeptide repeat (TPR) domain and a C-terminal catalytic domain belonging to the 
glycogen phosphorylase superfamily (Kreppel et al. 1997; Lubas et al. 1997; Wrabl and 
Grishin 2001). Recently the structure of OGT and the TPR domain have been solved (Jinek 
et al. 2004; Martinez-Fleites et al. 2008; Lazarus et al. 2011). The TPR domain forms an 
extended alpha-helix similar to importin-α (Jinek et al. 2004), and is important for 
mediating protein-protein interactions and enzyme activity (Kreppel and Hart 1999; Lubas 
and Hanover 2000). The catalytic domain contains two Rossman folds, separated by an 
intervening sequence. Notably, this linker is missing in the bacterial homologs of OGT that 
do not appear to modify protein substrates (Lazarus et al. 2011).  
The gene for OGT maps to Xq13 on the mammalian X chromosome and encodes 
three well-characterized variants: short OGT, mitochondrial OGT, and 
nuclear/cytoplasmic OGT (Kreppel et al. 1997; Lubas et al. 1997; Hanover et al. 2003; 
Love et al. 2003). Mitochondrial OGT is an alternatively-spliced isoform, which uses 
intron 4 of nuclear/cytoplasmic OGT as an exon to generate a unique N-terminus (Love et 
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al. 2003). Intron 4 encodes an abbreviated TPR domain with an N-terminal mitochondrial 
targeting sequence (Love et al. 2003). Interestingly, overexpression of mitochondrial OGT 
appears to induce apoptosis (Shin et al. 2011). OGT is essential for embryonic stem cell 
viability and somatic cell function (Shafi et al. 2000; O'Donnell et al. 2004). Deletion of 
OGT in Arabidopsis thaliana (Jacobsen et al. 1996), Drosophila melanogaster (Gambetta 
et al. 2009; Sinclair et al. 2009), and mice is lethal (Shafi et al. 2000), and leads to dauer 
phenotypes in Caenorhabditis elegans (Hanover et al. 2005), suggesting that O-GlcNAc is 
essential for cellular homeostasis.  
The mechanism of OGT substrate specificity is not fully understood; however, 
deletions in the TPR domain can affect the ability of OGT to O-GlcNAcylate protein and 
peptide substrates. It is generally thought that protein-protein interactions of OGT form a 
series of OGT complexes with different substrate specificities (Kreppel and Hart 1999). In 
support of this hypothesis, OGT has been found to associate with numerous proteins 
(Cheung et al. 2008) and is targeted to its substrates by p38 mitogen activated protein 
kinase (MAPK) under conditions of nutritional deprivation (Cheung and Hart 2008). 
Moreover, OGT can bind phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which targets 
OGT to the plasma membrane during insulin signaling (Yang et al. 2008). These 
observations may also explain why there is no consensus sequence or motif for the addition 
of O-GlcNAc, although a recent paper has developed a neural network for predicting O-
GlcNAc-modification sites (Wang et al. 2011).  
The activity of OGT appears to be regulated by substrate targeting (discussed 
above), the levels of UDP and UDP-GlcNAc, and potentially by other PTMs. OGT is both 
tyrosine phosphorylated (Kreppel et al. 1997; Kreppel and Hart 1999) and O-GlcNAc-
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modified (Kreppel and Hart 1999; Lubas and Hanover 2000), although the consequence of 
these modifications has not been defined. Interestingly, OGT is phosphorylated and 
activated by active calcium/calmodulin-dependent kinase (CaMK)IV (Song et al. 2008). 
Recently, it has been demonstrated that OGT is S-nitrosylated in resting cells, and its 
denitrosylation following induction of the innate immune response results in increased 
catalytic activity (Ryu and Do 2011). While UDP-GlcNAc levels may alter OGT activity 
by providing more substrate, there is also evidence that UDP-GlcNAc alters the substrate 
specificity of OGT. Thus, OGT may glycosylate one group of proteins at low 
concentrations of UDP-GlcNAc, but at higher concentrations may target a completely 
different panel of proteins (Kreppel and Hart 1999). 
Little is known about how stress affects the activity of OGT, but stress alters 
glucose uptake and the activity of the HBP (discussed above) presumably augmenting 
UDP-GlcNAc pools. During heat stress, the activity of OGT is upregulated 3-fold by 
currently unknown mechanisms (Zachara et al. 2004b) and OGT translocates to the nucleus 
(Kazemi et al. 2010). Suggesting yet another mechanism by which stress alters O-GlcNAc 
levels, stressors such as sodium chloride (NaCl), ethanol, and arsenite appear to alter the 
expression of OGT (Zachara et al. 2004b). During glucose deprivation, the expression of 
OGT is partially dependent on adenosine monophosphate-activated protein kinase 
(AMPK), and OGT is targeted to its substrates by p38 MAPK (Cheung and Hart 2008). 
This results in a dramatic increase in O-GlcNAcylation of the neuronal protein 
neurofilament H, suggesting a possible mechanism by which defective glucose metabolism 
in the brain may directly contribute to the loss of axonal structure and stability (Cheung 
and Hart 2008).  
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Several assays have been used to detect OGT activity. The most common involves 
the addition of a tritiated UDP-GlcNAc (3H-UDP-GlcNAc) to a peptide substrate 
(Haltiwanger et al. 1997). Recently, an effective fluorescence-based substrate analogue 
displacement assay was developed to assess the activity of OGT (Gross et al. 2005). The 
spatiotemporal dynamics of O-GlcNAc have also been characterized using a series of 
genetically-based O-GlcNAc Förster resonance energy transfer (FRET) sensors targeted to 
specific subcellular compartments (Carrillo et al. 2006; Carrillo et al. 2011). For example, 
a study utilizing the O-GlcNAc FRET sensor found that during serum-stimulated signal 
transduction rapid increases in O-GlcNAcylation were observed at the plasma membrane 
and in the nucleus, with a concomitant decrease in O-GlcNAcylation in the cytoplasm 
(Carrillo et al. 2011). 
O-GlcNAcase 
OGA is approximately 103 kDa in size and catalyzes the removal of O-GlcNAc 
from proteins. OGA appears to be predominantly cytoplasmic, and like OGT is 
ubiquitously expressed (Dong and Hart 1994). The gene encoding OGA was identified as 
meningioma expressed antigen 5 (Mgea5) and characterized as a hyaluronidase (Heckel et 
al. 1998). However, further analysis indicated that the product of the Mgea5 gene was 
active at neutral pH, localized to the cytoplasm, and would remove O-GlcNAc from 
peptides suggesting that it was the O-GlcNAcase biochemically characterized by Dong and 
Hart (Comtesse et al. 2001; Gao et al. 2001). OGA exists as two isoforms: the full-length 
isoform with a histone acetyltransferase (HAT)-like domain in its C-terminus and a short 
isoform lacking the C-terminal HAT domain.  
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OGA is serine phosphorylated and O-GlcNAcylated, although the functional 
significance of these modifications has yet to be elucidated (Gao et al. 2001; Wells et al. 
2002a). Like OGT, OGA from bovine brain appears to exist in complexes with other 
proteins including HSP110, heat shock cognate 70 kDa protein (HSC70), amphiphysin, 
and dihydropyriminidase-related protein-2. Finally, OGA is cleaved by caspase-3 during 
apoptosis (Wells et al. 2002a). Notably, the cleavage products appear to remain associated 
with each other and the activity of OGA is unaffected (Butkinaree et al. 2008). Thus far, 
little is known about the regulation of OGA during the cellular stress response. 
While little is known about the regulation of OGA, the activity of OGA can be 
conveniently assayed in vitro with a synthetic substrate p-nitrophenol-β-GlcNAc (Dong 
and Hart 1994). However, care must be taken to exclude the activities of lysosomal 
hexosaminidases A and B in total cell and tissue lysates. Recent studies have shown that 
fluorogenic substrates exhibit higher sensitivity and can be used to study both OGA 
isoforms. Both fluorescein di-GlcNAc (Kim et al. 2006a) and 4-methylumbelliferyl-2-N-
acetyl-2-deoxy-β-D-glucopyranoside have been used successfully (Macauley et al. 2005), 
however the latter is 10-fold less sensitive than fluorescein di-GlcNAc (Kim et al. 2006a).  
 
O-GlcNAc and the cellular stress response 
In response to injury, cells have the ability to modify their metabolic, 
transcriptional, translational, and signaling pathways to promote survival, collectively this 
is known as the “cellular stress response” (Lindquist 1986; Nollen and Morimoto 2002). 
Recent data suggests that O-GlcNAc is one component of the cellular stress response that 
is relevant to a variety of models of injury in several cell and tissue types. O-GlcNAc levels 
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become elevated in response to numerous forms of cell stress and tissue injury including: 
heat stress (Sohn et al. 2004; Zachara et al. 2004b), oxidative stress (Zachara et al. 2004b; 
Jones et al. 2008), ethanolic stress (Zachara et al. 2004b; Ngoh et al. 2009b), genotoxic 
stress (doxorubicin, belocin, ultraviolet B irradiation) (Zachara et al. 2004b; Love et al. 
2010; Zachara et al. 2011a), reductive stress (iodoacetamide) (Zachara et al. 2004b), 
endoplasmic reticulum (ER) stress (dithiothreitol, tunicamycin) (Zachara et al. 2004b; 
Ngoh et al. 2009b), hypoxia-reoxygenation (Ngoh et al. 2008; Ngoh et al. 2009a; Ngoh et 
al. 2011), osmotic stress (NaCl, sorbitol, sucrose) (Zachara et al. 2004b; Zou et al. 2007), 
adenosine triphosphate (ATP) depletion (sodium arsenite) (Zachara et al. 2004b), I/R injury 
(Pang et al. 2002; Liu et al. 2006; Nagy et al. 2006; Champattanachai et al. 2007; Fulop et 
al. 2007a; Fulop et al. 2007b; Liu et al. 2007; Champattanachai et al. 2008; Jones et al. 
2008; Ngoh et al. 2008; Ngoh et al. 2009a; Ngoh et al. 2009b; Zou et al. 2009; Hwang et 
al. 2010; Laczy et al. 2010; Ngoh et al. 2011), and trauma hemorrhage (Yang et al. 2006a; 
Not et al. 2007; Zou et al. 2007; Zou et al. 2009; Not et al. 2010). This response occurs in 
primary and transformed cells, as well as in tissues in vivo and ex vivo. Suggesting that the 
addition of O-GlcNAc to proteins is part of a pro-survival signaling program, elevating O-
GlcNAc levels prior (Zachara et al. 2004b; Chatham et al. 2008; Ngoh et al. 2008) or 
immediately following (Liu et al. 2007) cellular injury dramatically improves survival. 
Conversely, lowering O-GlcNAc levels sensitizes cells and tissues to injury (Zachara et al. 
2004b; Ngoh et al. 2008; Ngoh et al. 2009a; Ngoh et al. 2011). 
Modulating the levels of O-GlcNAc in a manner consistent with improved survival 
regulates a number of biological pathways. Some examples include: 1) increased protein 
solubility during heat stress (Lim and Chang 2006; Cheung and Hart 2008) or Alzheimer’s 
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disease (AD) (Yuzwa et al. 2012); 2) reduced calcium overload (Liu et al. 2006; Liu et al. 
2007); 3) decreased calpain activation (Liu et al. 2007); 4) altered p38 MAPK activation 
in response to I/R injury (Fulop et al. 2007b; Cheung and Hart 2008); 5) modulation of 
pro-inflammatory cytokine expression (Huang et al. 2007; Zou et al. 2009); 6) reduced 
mitochondrial permeability transition pore (mPTP) formation (Jones et al. 2008); 7) 
increased B-cell lymphoma 2 (Bcl-2) expression and translocation (Champattanachai et al. 
2008); and 8) regulation of the expression of a subset of molecular chaperones (Sohn et al. 
2004; Zachara et al. 2004b; Kazemi et al. 2010).  
Numerous reports have suggested that O-GlcNAc regulates many processes in the 
heart and vasculature (Fulop et al. 2007a; Liu et al. 2007; Champattanachai et al. 2008; 
Chatham and Marchase 2010; Ngoh et al. 2011) in models of I/R injury. For example, O-
GlcNAc appears to regulate many of the hallmarks of I/R injury such as calcium overload, 
oxidative damage, ER stress, and mitochondrial aberrations (Chatham and Marchase 
2010). Elevating O-GlcNAc levels with glucosamine, O-(2-acetamido-2-deoxy-d-
glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc), or 2-ethylamino-3aR, 6S, 
7R, 7aR-tetrahydro-5R-hydroxymethyl-5H-pyrano[3, 2-d]thiazole-6, 7-diol (Thiamet-G; 
TMG) leads to improved function and reduced tissue death in both ex vivo and in vivo 
models of I/R injury in the heart (Liu et al. 2006; Fulop et al. 2007b; Liu et al. 2007; Jones 
et al. 2008). Collectively, these data suggest that the stress-induced elevation of the O-
GlcNAc-modification is a pro-survival response of cells and tissues (Champattanachai et 
al. 2007; Champattanachai et al. 2008; Hwang et al. 2010).  
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The PI3K/Akt pathway 
The role of O-GlcNAc in the PI3K/Akt pathway has been extensively studied in 
the context of nutrient sensing, insulin resistance and type II diabetes, and readers are 
directed to pertinent reviews on this topic for more extensive details (Akimoto et al. 2005; 
Buse 2006; Slawson et al. 2010; Hart et al. 2011). In contrast to these data, the interplay 
between O-GlcNAc and Akt signaling has been observed to inhibit apoptosis in a number 
of models including murine pancreatic β-cells (Kang et al. 2008), mouse embryonic 
fibroblasts (Kazemi et al. 2010), and murine liver (Ku et al. 2010), as discussed below.  
Recently, it was demonstrated that O-GlcNAcylation of keratin 18 (K18) is a 
regulator of Akt1 phosphorylation, which promotes downstream anti-apoptotic and 
cytoprotective signaling (Ku et al. 2010). Mouse mutants expressing human K18 
S30/31/49A mutations, which cannot be glycosylated (K18−Gly−), were more susceptible 
to liver and pancreatic injury induced by treatment with either streptozotocin or combined 
OGA inhibition and Fas ligand administration (Ku et al. 2010). It is thought that the pro-
survival mechanism is O-GlcNAcylation of K18, which leads to its interaction with Akt1 
and keratin 8 ultimately promoting the phosphorylation of Akt1 at Thr308. Akt is activated 
by phosphorylation at Thr308 and then phosphorylates substrates such as forkhead box 
protein (Foxo) and glycogen synthase kinase 3β (GSK3β), thereby enhancing cell survival 
(Ku et al. 2010) (Figure 1-2). It is also important to note that Akt itself is dynamically 
modified by O-GlcNAc at Ser473 (Gandy et al. 2006; Kang et al. 2008). While hyper-O-
GlcNAcylation of Akt has deleterious effects in hepatic cell and tissue models of 
euglycemia (Soesanto et al. 2008) and in pancreatic β-cells under hyperglycemic 





Figure 1-2: O-GlcNAc is involved in the cellular stress response. Glucose and glucosamine can enter cells 
via glucose transporters and are directed towards the hexosamine biosynthetic pathway (HBP) for conversion 
to UDP-GlcNAc. O-GlcNAcylation of key proteins is essential for maintaining cellular homeostasis and 
promoting survival during stress and injury. Key survival pathways modulated by O-GlcNAc include: 1) the 
PI3K/Akt pathway, 2) heat shock protein expression, 3) calcium (Ca2+) homeostasis, 4) reactive oxygen 
species (ROS) regulation, 5) mitochondrial dynamics, 6) inflammation, and 7) PTM interplay. Note that 
proteins are shown as light blue squares, O-GlcNAc as green circles, and phosphates as orange circles. 
Arrows denote activation, whereas blunt ends denote inhibition. 
 
Heat shock protein expression 
One mechanism by which O-GlcNAc is thought to regulate cell survival is by 
modulating the expression of HSPs, the sentinels of the cellular stress response. Initial 
reports demonstrated that elevating O-GlcNAc levels augments the heat-induced 
expression of HSP72 and HSP40 (Sohn et al. 2004; Zachara et al. 2004b). Conversely, in 
cells in which O-GlcNAc levels had been lowered, by inhibition of the HBP or deletion of 
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OGT, the expression of HSPs was suppressed (Zachara et al. 2004b; Kazemi et al. 2010). 
Using a real-time polymerase chain reaction array of 84 chaperones, Kazemi and 
colleagues demonstrated that the expression of 18 molecular chaperones was inhibited 
when O-GlcNAc levels were lowered by deletion of OGT (Kazemi et al. 2010). These 
chaperones included HSP72, HSP40 J-domain containing proteins (Dnaja1, Dnaja2, 
Dnaja3, Dnaja4, Dnajb1, Dnajb7), the chaperone regulators Bag2 and Bag3, α-crystallin 
(Cryab, Hspb8), HSP25 (Hspb1), HSP110, HSP90α, and HSP60 (Kazemi et al. 2010). 
Interestingly, the expression of three proteins was upregulated (Dnajb8, Dnajc5b, 
Dnajc5g) (Kazemi et al. 2010).  
The expression of HSPs is regulated by two key transcription factors: heat shock 
factor 1 (HSF1) and Sp1. Several studies have demonstrated that O-GlcNAc regulates both 
of these transcription factors, directly and indirectly, leading to the regulation of chaperone 
expression. One example by which O-GlcNAc is thought to regulate HSP expression is by 
promoting the phosphorylation and inactivation of the kinase GSK3β at Ser9 (Kazemi et 
al. 2010). In cells with reduced O-GlcNAcylation, increased inhibitory phosphorylation of 
HSF1 at Ser303 is observed (Kazemi et al. 2010). Conversely, elevating O-GlcNAc levels 
suppresses the phosphorylation of HSF1 at Ser303, promoting both its activation and 
downstream HSP expression (Kazemi et al. 2010). Recent reports suggest that GSK3β may 
suppress HSF1 activity by phosphorylating serine and threonine residues independent of 
Ser303 (Batista-Nascimento et al. 2011). Nonetheless, consistent with a model in which 
increased GSK3β activity suppresses HSF1 activation in the OGT null, inhibition of 
GSK3β rescues HSP72 expression in these cells (Kazemi et al. 2010). Further supporting 
this model, a reduction of Ser9 inhibitory phosphorylation of nuclear GSK3β was observed 
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in cells with lower O-GlcNAc levels (Kazemi et al. 2010). Notably, unlike the study by 
Gandy and colleagues (Gandy et al. 2006), the stress-induced phosphorylation of Akt was 
unaffected in this model, demonstrating that O-GlcNAc likely regulates numerous points 
upstream of GSK3β.   
Glutamine has been demonstrated to protect cells and tissues from diverse forms of 
cellular stress and tissue injury (Wischmeyer et al. 2001). As glutamine is utilized by the 
HBP in the generation of UDP-GlcNAc (Figure 1-1), it has been postulated that glutamine 
may work in an O-GlcNAc dependent manner. In support of this hypothesis, in vivo 
treatment with glutamine has been shown to elevate O-GlcNAc levels (Singleton and 
Wischmeyer 2008; Hamiel et al. 2009). Moreover, the ability of glutamine to induce 
HSP70 is attenuated in cells in which O-GlcNAc levels have been lowered (Hamiel et al. 
2009). In heat-stressed cells and a septic mouse model, glutamine treatment appears to 
promote the nuclear accumulation of HSF1 and Sp1 in an O-GlcNAc-dependent manner 
(Singleton and Wischmeyer 2008; Hamiel et al. 2009). Although the mechanisms 
underlying the above observations remain unclear, it may be explained in part by the 
observations of Lim and Chang who demonstrated that increased levels of O-GlcNAc are 
associated with a more soluble pool of Sp1 during thermal stress (Lim and Chang 2006). 
This may represent altered localization of Sp1, or that Sp1 exhibits increased thermal 
stability when it is O-GlcNAc-modified (Lim and Chang 2006) similar to Tau (Yuzwa et 
al. 2012). Together the data discussed above suggest that O-GlcNAc can regulate the 
expression of HSPs by regulating both HSF1 and Sp1. 
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Calcium homeostasis 
Another mechanism by which O-GlcNAc may promote cell survival is by 
regulating calcium handling. Angiotensin II, an inositol (3,4,5)-trisphosphate (IP3)-
generating agonist, is a potent stimulator of cardiomyocyte hypertrophy that can elevate 
cytoplasmic calcium during vasoconstriction, increased blood pressure, and hemodynamic 
stress. A number of studies have demonstrated that angiotensin II treatment leads to an 
increase in basal calcium levels in adult and neonatal cardiomyocytes (Kem et al. 1991; 
Shao et al. 1998; Hunton et al. 2004), with sustained exposure affecting numerous cellular 
pathways (Meldrum et al. 1996; Liu et al. 2004b; Zhang et al. 2004) and eventually 
resulting in cell death (Kajstura et al. 1997; Goldenberg et al. 2001). Elevating UDP-
GlcNAc and O-GlcNAc levels through treatment with glucosamine or the OGA inhibitor 
PUGNAc attenuates angiotensin II-induced capacitative calcium entry during I/R injury 
(Nagy et al. 2006). Further suggesting that regulation of calcium homeostasis in the heart 
is modulated by HBP flux and altered O-GlcNAc levels, O-GlcNAc appears to regulate a 
number of pathways downstream of calcium in models of ischemic injury. Consistent with 
decreased calcium influx, CaMKII phosphorylation is reduced, as are downstream events 
such as calpain proteolysis of structural proteins such as α-fodrin (Liu et al. 2007). 
Moreover, augmented O-GlcNAc signaling, via inhibition of OGA or overexpression of 
OGT, has been shown to attenuate oxidative stress and calcium overload in cardiomyocytes 
(Ngoh et al. 2011). Although the mechanism by which this occurs is unknown, it is 
accompanied by a reduction in ROS release and reduced formation of the mPTP (Ngoh et 
al. 2011).  
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While the mechanism by which O-GlcNAc regulates calcium handling in the 
ischemic heart has not been parsed out, recent studies have demonstrated that several IP3 
receptors are O-GlcNAc-modified suggesting a potential molecular mechanism by which 
O-GlcNAc can modulate calcium flux. The IP3 type I receptor is the principle intracellular 
calcium release channel in many cell types including neurons, and it is regulated by 
calcium, ATP and O-GlcNAc. O-GlcNAcylation of the IP3 type I receptor decreased its 
activity, while the removal of O-GlcNAc restored its function (Rengifo et al. 2007). 
Following this study, it was demonstrated that the IP3 type III receptor is functionally 
regulated by O-GlcNAc, except that O-GlcNAcylation enhanced its activity while O-
GlcNAc removal negated its function (Bimboese et al. 2011). Thus, O-GlcNAcylation of 
IP3 type I and III receptors regulates their function(s) in controlling calcium flux and 
ultimately attenuating calcium-dependent apoptosis (Rengifo et al. 2007). 
Reactive oxygen species 
ROS participate in many intracellular signaling pathways that can ultimately lead 
to alterations in gene transcription, protein synthesis, and overall cellular function. 
Stressors such as I/R injury, which induces mitochondrial calcium overload (discussed 
previously) and ROS generation, favor the formation of the mPTP (discussed in the next 
section) and ultimately lead to cell death. Augmenting O-GlcNAc levels by adenoviral 
OGT overexpression or PUGNAc treatment has been shown to attenuate hypoxia and 
oxidative stress-induced ROS production. Conversely, suppression of O-GlcNAcylation 
by adenoviral OGA overexpression exacerbated ROS levels (Ngoh et al. 2011). One 
mechanism by which O-GlcNAc is thought to suppress ROS levels is by promoting the 
expression of antioxidant enzymes by stimulating the activity of Foxo1 and peroxisome 
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proliferator-activated receptor gamma coactivator 1α (PGC1α) (Housley et al. 2009). For 
example, it was demonstrated that induction of PGC1α in response to ROS leads to its O-
GlcNAcylation and activation by OGT. Subsequently, the OGT-PGC1α complex is 
targeted to and hyper-O-GlcNAcylates Foxo1 (Figure 1-2) to promote increased 
transcription of ROS responsive enzymes, such as glutathione peroxidase 1 (GPX1) and 
superoxide dismutase 2 (SOD2), which protect against oxidative damage (St-Pierre et al. 
2006; Housley et al. 2008; Housley et al. 2009). While the above studies were performed 
in hepatocytes, subsequent studies in a model of myocardial damage demonstrated that 
catalase mRNA levels were augmented above baseline following inhibition of OGA 
(PUGNAc), while overexpression of OGA reduced baseline catalase mRNA levels (Ngoh 
et al. 2011). Notably, in contrast to the studies discussed here, O-GlcNAc is thought to 
promote ROS generation in models of hyperglycemia and glucose toxicity (Goldberg et al. 
2011), although the molecular basis for this paradox remains to be defined (Lima et al. 
2012).  
Mitochondrial dynamics 
The mitochondrion is the powerhouse of the cell and is responsible for ATP 
production, maintenance of cellular byproducts, and overall regulation of cellular 
homeostasis. Altered mitochondrial dynamics leads to activation of the mitochondrial 
death pathway, which ultimately results in formation of the mPTP. Pore formation is 
activated by calcium surplus and ROS generation (previously discussed, Figure 1-2), and 
is responsible for non-specifically allowing small molecules (<1.5 kDa) to enter and exit 
the mitochondrial matrix (Crow et al. 2004). One postulated mechanism for the 
cytoprotective nature of O-GlcNAc is through the regulation of mitochondrial function 
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(Jones et al. 2008; Ngoh et al. 2008; Ngoh et al. 2010; Ngoh et al. 2011) by reducing 
calcium overload, dampening ROS production, and preventing mPTP formation (Jones et 
al. 2008; Ngoh et al. 2008; Ngoh et al. 2011). It has been suggested that O-GlcNAc may 
regulate the mPTP directly by modifying and modulating the voltage dependent anion 
channel (VDAC) (Jones et al. 2008; Ngoh et al. 2008) (Figure 1-2). For example, deletion 
of OGT led to reduced O-GlcNAcylation of VDAC, sensitizing cells to mitochondrial 
membrane potential collapse and mPTP formation (Jones et al. 2008; Ngoh et al. 2008). 
Notably, formation of the mPTP is also promoted by active GSK3β (Juhaszova et al. 2004; 
Miura and Miki 2009), which is inhibited in some models by stress-induced O-
GlcNAcylation (Kazemi et al. 2010; Ku et al. 2010).  
In addition to modulating VDAC, O-GlcNAc has been demonstrated to modulate 
Bcl-2 and the electron transport chain. Mitochondrial localization of Bcl-2 has been 
postulated to inhibit mPTP opening (Tsujimoto 2003; Tsujimoto et al. 2006), protect 
against a loss in mitochondrial membrane potential (Tsujimoto 2003; Murphy et al. 2005; 
Tsujimoto et al. 2006), prevent cytochrome c release (Tsujimoto 2003; Murphy et al. 2005; 
Tsujimoto et al. 2006), and attenuate mitochondria-mediated apoptosis (Tsujimoto 2003; 
Murphy et al. 2005; Tsujimoto et al. 2006). One study demonstrated that elevation of O-
GlcNAc levels in hydrogen peroxide treated cells, an ex vivo model of I/R injury, led to 
increased mitochondrial Bcl-2 translocation (Champattanachai et al. 2008). There is some 
debate surrounding this finding, as PUGNAc did not appear to alter I/R-induced increases 
in mitochondrial Bcl-2 levels (Champattanachai et al. 2008). Finally, elevating levels of 
glucose in neonatal cardiomyocytes resulted in augmented O-GlcNAc levels and 
subsequently reduced function of mitochondrial electron transport complexes I, III, and IV 
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(Hu et al. 2005), however, its role in stress has not been studied yet. Interestingly, 
overexpressing OGA to reduce O-GlcNAc levels can reverse the effects of reduced 
mitochondrial function when glucose levels are elevated (Hu et al. 2005).  
Inflammation 
Trauma hemorrhage injury, like infection, induces an acute inflammatory response 
necessary for tissue repair. However, a hyper-inflammatory response can compromise 
healthy tissue, leading to cell and tissue death (Jarrar et al. 1999; Nathan 2002). The 
inflammatory response is driven by secreted tissue-derived cytokines, such as tumor 
necrosis factor-α (TNF-α) and interleukin (IL)-6, that are responsible for inflammation in 
the damaged area. Recent studies have shown that augmenting O-GlcNAc levels prior to 
and following trauma hemorrhage injury improves survival, and this protective phenotype 
is associated with reduced expression of TNF-α and IL-6 and improved recovery of 
multiple tissues and blood pressure (Yang et al. 2006a; Not et al. 2007; Chatham et al. 
2008; Not et al. 2010).  
O-GlcNAc has also been demonstrated to suppress acute inflammation in other 
models of injury presumably promoting cell survival (Not et al. 2007; Xing et al. 2008; 
Pathak et al. 2012). For example, in a rat model of arterial injury elevating O-GlcNAc 
levels by administration of glucosamine or PUGNAc attenuated inflammatory mediator 
expression, leukocyte infiltration, and neointima formation (Xing et al. 2008). Reduced 
inflammation was attributed to decreased TNF-α-induced phosphorylation of the nuclear 
factor κB (NFκB) p65 subunit and subsequent inhibition of NFκB transcriptional activation 
and signaling (Xing et al. 2008). Additionally, augmenting O-GlcNAc levels reduced the 
expression of a number of chemokines (cytokine-induced neutrophil chemoattractant-2β 
 23 
and monocyte chemotactic protein-1) and adhesion molecules (vascular cell adhesion 
molecule-1 and P-selectin) (Xing et al. 2008).  
Pro-inflammatory cytokines, such as TNF-α and IL-1, activate downstream signals 
in a manner mediated by transforming growth factor-β-activated kinase I (TAK-1), also 
known as mitogen-activated protein kinase kinase kinase 7 (Sakurai et al. 2000; Wang et 
al. 2001). A recent study showed that O-GlcNAcylation of TAK-1-binding protein (Tab-
1) modulates TAK-1-mediated cytokine release when induced by IL-1 and osmotic stress 
(Pathak et al. 2012). Utilizing wild type (WT) and O-GlcNAc-deficient mutant Tab-1 
(S395A) in Tab-1-/- mouse embryonic fibroblasts, this study demonstrated that the O-
GlcNAc-modification of Tab-1 at Ser395 is essential for full TAK-1 autophosphorylation 
at Thr187 and activation upon stress, as well as the subsequent downstream activation of 
NFκB and production of IL-6 and TNF-α (Pathak et al. 2012). 
 
Interplay between O-GlcNAc and other PTMs 
One mechanism by which O-GlcNAc is thought to regulate proteins is by directly 
or indirectly regulating other post-translational modifications including phosphorylation, 
nitrosylation, and ubiquitination. 
Phosphorylation 
Phosphate (PO43-) and GlcNAc (C8H15NO6) moieties are both covalently and 
reversibly added in an O-linkage to serine and threonine residues in a manner known as 
phosphorylation and O-GlcNAcylation respectively. There is extensive crosstalk between 
these two modifications, and this dynamic interplay is implicated in regulating numerous 
signaling networks (Wang et al. 2007; Wang et al. 2008; Wang et al. 2010b; Hart et al. 
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2011). For a subset of proteins (Kelly et al. 1993; Cheng and Hart 2001; Comer and Hart 
2001; Du et al. 2001), O-GlcNAc and phosphorylation appear to compete for the same 
serine or threonine residue, such as on the proto-oncogene c-Myc (Chou et al. 1995). 
Alternatively, for numerous proteins O-GlcNAc can sterically hinder nearby 
phosphorylation sites (Yang et al. 2006b; Housley et al. 2008; Dias et al. 2009; Wang et 
al. 2010b; Tarrant et al. 2012), for example in the CK2 protein where O-GlcNAcylation of 
Ser347 prevents its phosphorylation at nearby amino acid Thr344 (Tarrant et al. 2012). The 
idea that these modifications are reciprocal comes from data demonstrating that 
phosphorylation of subsets of proteins is suppressed when global O-GlcNAc levels are 
elevated (Griffith and Schmitz 1999; Lefebvre et al. 2001; Wang et al. 2008). One elegant 
study demonstrated that in vitro O-GlcNAcylation of the C-terminal domain of RNA 
polymerase II blocked its phosphorylation and vice versa (Comer and Hart 2001). 
Suggesting that this interplay also alters protein function in vivo, additional studies have 
demonstrated that tau is hyper-phosphorylated in a brain OGT knockout (O'Donnell et al. 
2004). However, readers should be cautioned as the reciprocal relationship between O-
GlcNAc and phosphorylation exists only for a subset of proteins, while for others there is 
no direct association and proteins can be both phosphorylated and O-GlcNAcylated 
simultaneously, such as insulin receptor substrate-1 (IRS-1) (Ball et al. 2006).  
In addition to cross talk associated with site-occupancy, there is cross talk between 
the enzymes responsible for O-GlcNAcylation and phosphorylation. OGT and OGA are 
known to associate with and modify kinase and phosphatase enzymes (Khidekel et al. 
2004; Wells et al. 2004; Cheung et al. 2008; Slawson et al. 2008; Dias et al. 2009; Wang 
et al. 2010b; Dias et al. 2012). For example, CaMKIV is inhibited by O-GlcNAc-
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modification within its ATP-binding region, and de-O-GlcNAcylation and subsequent 
phosphorylation is required for CaMKIV activation (Dias et al. 2009). Several proteomic 
analyses have been performed to further delineate the interplay between O-GlcNAc and 
phosphorylation in cell cycle progression. One of these studies demonstrated that the kinase 
Aurora B, which regulates mitotic progression, forms a transient complex with OGT and 
OGA in the mitotic phase of the cell cycle and colocalizes with OGT to midbodies during 
telophase and cytokinesis (Slawson et al. 2008). Inhibition of Aurora B leads to diminished 
midbody localization of OGT and an increase in global O-GlcNAc levels (Slawson et al. 
2008). This study also demonstrated that vimentin, a substrate for Aurora B and OGT 
during mitosis, exhibited alterations in its O-GlcNAcylation and phosphorylation patterns 
upon modulation of OGT or OGA activity (Slawson et al. 2008). A second study identified 
141 previously unreported O-GlcNAc sites on proteins that are involved in spindle 
assembly and cytokinesis, many of which are the same site as or are in close proximity to 
sites of phosphorylation (Wang et al. 2010b). Finally, modulation of O-GlcNAc levels was 
found to alter the phosphorylation status of proteins localized to the mitotic spindle and 
midbody, for example upon OGT overexpression, cyclin dependent kinase 1 becomes 
hyper-phosphorylated thereby reducing its activity and subsequently decreasing the 
phosphorylation status of its target proteins (Wang et al. 2010b). 
Endothelial nitric oxide synthase (eNOS) generates nitric oxide and stimulates 
vasodilation by inhibiting smooth muscle contraction and platelet aggregation, with these 
functions reported to be impaired in diabetes-associated erectile dysfunction. One study 
demonstrated that in rats treated with alloxan to induce diabetes, eNOS was hyper-O-
GlcNAcylated and hypo-phosphorylated at Ser1177 (Musicki et al. 2005). Phosphorylation 
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of eNOS at this site is mediated by Akt phosphorylation, and this study demonstrated that 
the phosphorylation of both Akt and eNOS was decreased in the diabetic model, 
implicating that O-GlcNAcylation at Ser1177 is one potential mechanism for eNOS 
inactivation and thereby diminished vasodilation (Musicki et al. 2005).   
Other PTM roles 
There is emerging evidence for the interplay of O-GlcNAc with other post-
translational modifications such as protein ubiquitination and nitrosylation, although it is 
important to note that the exact mechanisms by which these modifications interact are still 
being elucidated.  
A growing body of evidence suggests that O-GlcNAc may be a regulator of protein 
degradation. This evidence includes data demonstrating that enhanced O-GlcNAcylation 
is associated with an extended half-life of proteins, such as with Sp1 (Han and Kudlow 
1997) and the murine β-estrogen receptor (Jiang and Hart 1997; Cheng and Hart 2001). At 
least three mechanisms have been postulated to underlie these observations. Firstly, O-
GlcNAc can block the phosphorylation of PEST (Pro-Glu-Ser-Thr) domains in the murine 
β-estrogen receptor thereby preventing its degradation (Cheng et al. 2000; Cheng and Hart 
2001). Secondly, as discussed below, data suggests that O-GlcNAc may regulate 
ubiquitination. Thirdly, O-GlcNAc is implicated in regulating the proteasome directly, as 
highlighted by studies showing that numerous proteins in the proteasome are O-GlcNAc-
modified and that enhanced O-GlcNAcylation may inhibit proteasome function (Sumegi 
et al. 2003; Zhang et al. 2003). One study demonstrated that both ubiquitination and O-
GlcNAcylation increase upon heat-shock treatment and that these PTMs can occur on some 
proteins concomitantly (Guinez et al. 2008). O-GlcNAc-modified proteins were not 
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observed to be stabilized following proteasome inhibition, and ubiquitination could be 
enhanced or reduced by increasing or decreasing O-GlcNAc levels respectively (Guinez et 
al. 2008). It was speculated that an E1 ubiquitin-activating enzyme interacts with HSP70 
only in its O-GlcNAcylated form (Guinez et al. 2008). An agonistic relationship between 
these two modifications is suggested such that O-GlcNAc may alter the activity of E1 
enzymes to modulate stress-induced ubiquitination (Shimura et al. 2001; Shrikhande et al. 
2010; Fujiki et al. 2011). It has also been shown that O-GlcNAcylation of a protein may 
facilitate its subsequent ubiquitination. For example, O-GlcNAcylation of histone H2B at 
Ser112 facilitates monoubiquitination at Lys120 to regulate transcription (Fujiki et al. 
2011). 
S-nitrosylation is a cysteine modification that is found and maintained on OGT in 
resting cells, and S-nitrosylated OGT has greatly reduced catalytic activity compared to the 
native form of the protein (Ryu and Do 2011). OGT becomes denitrosylated in 
macrophages treated with lipopolysacharides to trigger an innate immune response, which 
leads to increased catalytic activity and hyper-O-GlcNAcylation of proteins (Haberhausen 
et al. 1995). While other PTMs such as acetylation, methylation, sumoylation, and many 
others have pivotal roles in regulating protein function and signal transduction, the 
interplay of these modifications with O-GlcNAcylation has yet to be defined. 
 
Molecular mechanisms of disease 
There are many facets of the cellular stress response whose misregulation can 
contribute to neurodegenerative disease pathophysiology, and O-GlcNAc is implicated in 
the etiology of some of these diseases. Notably, the OGT gene is on the X chromosome at 
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position Xq13.1, the same locus associated with dystonia-parkinsonism syndrome 
(Haberhausen et al. 1995), and OGA maps to chromosome 10 near the locus associated 
with late-onset AD (10q24.1-q24.3) (Bertram et al. 2000). 
Alzheimer’s disease 
AD is a form of dementia that is characterized by reduced brain function and 
cognitive deficits, where both genetic and environmental factors play a role in pathogenesis 
(Hardy and Allsop 1991). AD phenotypes are often the result of unfolded or aggregated 
proteins, aberrant signaling, and oxidative stress. While there are many mechanisms by 
which these events are regulated, the most well studied proteins involved in AD are 
amyloid β precursor protein (APP), amyloid β (Aβ), and tau (Hardy and Allsop 1991). 
Dysregulation of APP, Aβ plaque formation, tau phosphorylation, and tangle formation 
dominate the cascade of events leading to AD and ultimately to neuronal death (Dong et 
al. 2004). 
AD transgenic mouse models are characterized by Aβ plaque formation and this 
leads to decreased cell proliferation and defective contextual memory (Kang et al. 2007). 
APP, the precursor protein to Aβ, is O-GlcNAc-modified although the importance of this 
modification remained elusive for many years (Jacobsen and Iverfeldt 2011). It was later 
demonstrated that inhibiting OGA with PUGNAc or reducing the expression of OGA 
(small interfering RNA) increased the amount of APP O-GlcNAcylation and non-
amyloidogenic α-secretase processing (Jacobsen and Iverfeldt 2011). This has further 
downstream effects such as increasing levels of the neuroprotective soluble APPα cleavage 
fragment, which reduces Aβ secretion and suggests a protective role for O-GlcNAc (Kim 
et al. 2012). Finally, treatment with the OGA inhibitor 1,2-dideoxy-2′-propyl-α-d-
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glucopyranoso-[2,1-d]-Δ2′-thiazoline (NButGT) in a mouse model of AD resulted in 
reduced γ-secretase activity and subsequent attenuation of Aβ plaque production and 
inflammation in vivo, further highlighting the important protective role of O-GlcNAc under 
conditions of stress and neurodegeneration (Rissman et al. 2007; Rissman et al. 2012).  
Tau was demonstrated to be directly O-GlcNAc-modified (Arnold et al. 1996; Liu 
et al. 2004a) and it was later shown that O-GlcNAcylation negatively regulates site-specific 
phosphorylation of tau in the human brain (Liu et al. 2004a). Notably, increased 
phosphorylation of Tau has been implicated in the formation of the toxic tangles associated 
with neurodegeneration. Recent data have demonstrated that inhibition of OGA, which 
leads to an increase in O-GlcNAc levels, in a murine model of AD led to increased O-
GlcNAcylation of tau, decreased tau aggregation, and diminished neuronal cell death. 
Together, these data highlight the protective role of O-GlcNAc and suggest that OGA could 
be a therapeutic target for slowing AD progression (Yuzwa et al. 2012). Interestingly, low 
glucose uptake and metabolism during aging has been postulated to lead to decreased O-
GlcNAcylation of key proteins such as Tau, potentially exacerbating the AD phenotype 
during aging (Yuzwa et al. 2012). 
Parkinson’s disease 
Parkinson’s disease (PD) is a brain disorder characterized by the degeneration of 
midbrain dopaminergic neurons, which is often accompanied by the formation of Lewy 
bodies (abnormal protein aggregates) (Henchcliffe and Beal 2008). Together this leads to 
improper signaling and loss of muscle function. Genetic alterations in the nucleus have 
been linked to disrupted mitochondrial morphology and function that can then modulate 
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protein activity, trigger apoptosis, or lead to accumulation of misfolded or damaged 
proteins in PD pathogenesis (Henchcliffe and Beal 2008).  
Aggregation of the α-synuclein protein or mutations in the α-synuclein gene (A53T) 
which lead to an impairment of mitochondrial dynamics, morphology, and movement have 
been linked to rare inherited forms of PD (Polymeropoulos et al. 1997; Spillantini et al. 
1997; Xie and Chung 2012). One study identified a 22 kDa O-glycosylated form of α-
synuclein in a protein complex with parkin (an E3 ubiquitin ligase) and UbcH7 (an E2 
ubiquitin-conjugating enzyme). These studies suggested that the glycosylated form of α-
synuclein was bound and ubiquitinated by parkin (Shimura et al. 2001). On the contrary, a 
subsequent study postulated that α-synuclein is modified by O-GlcNAc and that its 
nonglycosylated form interacts with parkin in embryonic hippocampal cells, although the 
specific type of glycosylation was never confirmed (Kim et al. 2003). Recently, the O-
GlcNAc-modification status of α-synuclein was mapped to Thr72 (Wang et al. 2010a), 
which has been demonstrated to prevent its aggregation (Marotta et al. 2012). Further data 
(discussed previously) highlights the interplay between O-GlcNAcylation and 
ubiquitination to regulate protein stability and degradation, although a direct link between 
these phenomena and PD has yet to be elucidated.  
 
Methods to study O-GlcNAcomics 
In this section, we will discuss the current methodologies used to modulate O-
GlcNAc levels, enrich O-GlcNAc-modified proteins, and identify sites of O-
GlcNAcylation.  
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In vitro and in vivo modulation of O-GlcNAc levels 
O-GlcNAc levels can be directly or indirectly altered in vitro and in vivo by 
modulating the activity or expression of OGT (Gross et al. 2005; Dorfmueller et al. 2011; 
Gloster et al. 2011), OGA (Beer et al. 1990; Dong and Hart 1994; Haltiwanger et al. 1998; 
Konrad et al. 2002; Liu et al. 2002; Dorfmueller et al. 2006; Knapp et al. 2007; Whitworth 
et al. 2007; Macauley et al. 2008; Yuzwa et al. 2008; Laczy et al. 2010), or other key 
enzymes in the HBP (Marshall et al. 1991; Traxinger and Marshall 1991; Patti et al. 1999; 
Ross et al. 2000; Buse et al. 2002; McClain 2002). Techniques such as overexpression of 
OGT (Zachara et al. 2004b), OGA (Slawson et al. 2005), and GFAT (Chen et al. 1997; 
James et al. 2000; Marshall et al. 2004) by both transient transfection and viral transduction 
have been successful, as has reducing the expression of these enzymes using RNA 
interference (Zachara et al. 2004b; Ngoh et al. 2009a; Hsieh et al. 2012). OGT has also 
been overexpressed using a tetracycline-inducible OGT stably expressed in HeLa human 
cervical cancer cells, although for effective overexpression a histone deacetylase inhibitor 
was included with the tetracycline for appropriate regulation of OGT (Marshall et al. 2003). 
Murine models and the OGTF/Y,mER-Cre-2A-GFP cell line  
Several mouse models and cell lines exist in which the levels of O-GlcNAc can be 
modulated. Notably, in murine models, deletion of Ogt (Shafi et al. 2000; O'Donnell et al. 
2004), EMeg32 (Boehmelt et al. 2000b), or Pgm3 (Greig et al. 2007) leads to embryonic 
lethality, whereas deletion of Mgea5 (OGA) leads to perinatal lethality (Yang et al. 2012). 
A number of hypomorphic alleles of Pgm3 have been characterized, leading to cells and 
mice with different concentrations of UDP-GlcNAc (Greig et al. 2007). Unlike deletion of 
EMeg32, deletion of Ogt is lethal in isolated embryonic fibroblasts (O'Donnell et al. 2004). 
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To overcome this challenge, researchers have immortalized cells in which the first two 
exons of Ogt are flanked by loxP recombination sites (O'Donnell et al. 2004; Kazemi et al. 
2010). These cells (OGTF/Y) have been stably transfected with a Cre recombinase estrogen 
receptor chimera (Cre-ERT2-GFP) that is induced by 4-hydroxytamoxifen (OGTF/Y,mER-
Cre-2A-GFP) (Kazemi et al. 2010). Addition of 4-hydroxytamoxifen activates Cre 
recombinase, resulting in recombination of the LoxP sites and deletion of OGT. 
Modulating O-GlcNAc levels using inhibitors of OGT, OGA, and the HBP 
A large number of inhibitors have been developed for blocking the activity of OGA 
in both cell culture and animal models (Beer et al. 1990; Dong and Hart 1994; Haltiwanger 
et al. 1998; Konrad et al. 2002; Liu et al. 2002; Dorfmueller et al. 2006; Knapp et al. 2007; 
Whitworth et al. 2007; Macauley et al. 2008; Yuzwa et al. 2008), and here we will focus 
on those that are commercially available. PUGNAc was the first OGA inhibitor isolated 
and inhibits OGA at a Ki of 52 nM in vitro (Dong and Hart 1994; Haltiwanger et al. 1998). 
PUGNAc is suitable for use in cells (10-100 µM, 4-18 h) and in animals (50 mg/kg, 4-12 
h) (Jones et al. 2008), however prolonged use (>36 h) can lead to cell cycle defects 
(Slawson et al. 2005). While widely used, recent evidence demonstrates that PUGNAc can 
also inhibit other lysosomal glycosidases including hexosaminidases A and B (Macauley 
et al. 2005; Ficko-Blean et al. 2008), suggesting that PUGNAc may have effects on other 
cellular pathways aside from O-GlcNAcylation. Streptozotocin has also been widely used, 
but only inhibits OGA at very high concentrations (Roos et al. 1998; Gao et al. 2000; 
Okuyama and Yachi 2001; Liu et al. 2002; Toleman et al. 2006). It is important to note that 
streptozotocin is also a DNA-alkylating agent and can release nitric oxide, making it 
difficult to determine whether the observed effects are due to OGA inhibition or 
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streptozotocin toxicity (Kwon et al. 1994). Alloxan has been suggested to inhibit OGA 
(Lee et al. 2006), but has been reported to also inhibit OGT and as such should be used 
with extreme caution (Konrad et al. 2002; Macauley et al. 2005). More recently, TMG has 
been introduced, and unlike PUGNAc, TMG is effective in crossing the blood brain barrier 
and does not appear to inhibit hexosaminidase A or B (Yuzwa et al. 2008). 
Several OGT inhibitors have also been isolated that work well in vitro (Gross et al. 
2005), and thus far these have been useful in isolated neonatal cardiomyocytes (5 µM) 
(Ngoh et al. 2008) and breast cancer cells (200 µM) (Caldwell et al. 2010). A more recent 
study has focused on synthesizing novel OGT inhibitors with structural analogues to UDP-
GlcNAc/UDP (Dorfmueller et al. 2011). While the synthesized compounds inhibit OGT in 
the micromolar range, it should be noted that they are inactive when used on living cells 
(Dorfmueller et al. 2011). Another recent study developed a synthetic carbohydrate 
precursor, 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-5-thio-α-d-glucopyranose (Ac-
5SGlcNAc), which can be successfully converted by the cell to produce UDP-5SGlcNAc 
in cell culture and in vitro models (Gloster et al. 2011). UDP-5SGlcNAc is not an efficient 
substrate for OGT, but excludes binding of UDP-GlcNAc therefore inhibiting OGT 
function (Gloster et al. 2011). It is important to note that these inhibitors are not yet 
commercially available.  
There are numerous commercially available chemicals for suppressing flux through 
the HBP (Marshall et al. 1991; Traxinger and Marshall 1991; Patti et al. 1999; Ross et al. 
2000; Buse et al. 2002; McClain 2002; Ngoh et al. 2010), which reduced UDP-GlcNAc 
levels and thus the O-GlcNAc-modification. Treatment with exogenous glucose, 
glutamine, or glucosamine leads to increased O-GlcNAc levels by increasing flux through 
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the HBP (Traxinger and Marshall 1991), although it is important to note that these 
compounds enter numerous pathways in the cell and observed effects may not be due to 
changes in O-GlcNAcylation. Azaserine and 6-diazo-5-oxo-L-norleucine (DON) are 
GFAT inhibitors, and treatment with these compounds decreases flux through the HBP 
thereby reducing O-GlcNAc levels (Marshall et al. 1991). Despite their common usage, 
both of these GFAT inhibitors do not act specifically on the HBP and may have effects on 
other enzymes and cellular pathways, especially those involved in glutamine metabolism.    
Isolation, purification, and detection of O-GlcNAc and O-GlcNAc-modified 
proteins 
Our understanding of the role of O-GlcNAc has been hampered due to the lack of 
specific and sensitive tools. Many challenges arise as the most commonly used analytical 
protein techniques, including gel electrophoresis, liquid chromatography (LC), and mass 
spectrometry (MS), often fail to detect O-GlcNAc. This is due to a number of factors such 
as 1) the addition of a monosaccharide of O-GlcNAc does not generally affect the 
migration of the glycoprotein during 1- or 2-dimensional gel electrophoresis; 2) the O-
GlcNAc-modification is rapidly hydrolyzed by hexosaminidases during protein isolation 
unless appropriate inhibitors are included; 3) the β-O-glycosidic linkage is chemically 
labile and is rapidly released under conditions of mild acid or base; 4) due to its lability, 
O-GlcNAc is usually lost at the ion source of electrospray ionization (ESI) or during 
ionization by matrix-assisted laser desorption ionization mass spectrometry; and 5) 
ionization of peptides modified by O-GlcNAc is suppressed during mass spectrometry and 
as such need to be enriched. Here, we will review the most robust techniques for the 
 35 
detection and purification of O-GlcNAc-modified proteins, as well as techniques for 
defining sites of O-GlcNAcylation. 
Detecting O-GlcNAc-modified proteins by 3H-galactose labeling 
The gold standard for the detection of O-GlcNAc-modified proteins has been UDP-
galactose:GlcNAc β-1,4-galactosyltransferase (GalT1) labeling, which transfers 3H-
galactose from UDP-3H-galactose to any terminal GlcNAc residue (Torres and Hart 1984; 
Roquemore et al. 1994). One advantage of this technique is the generation of a radiolabeled 
sugar (3H-galactose-R) that can be followed in subsequent analyses. As GalT1 will transfer 
galactose to any terminal GlcNAc reside, it is important to treat samples with peptide N-
glycosidase F to enzymatically remove N-glycans prior to 3H-galactose labeling. Recently 
this technique has also been adapted to incorporate an unnatural tetraacetylated N-
azidoacetylgalactosamine (GalNAz) onto proteins (see section Click-iT). 
Immunopurification with antibodies and lectins 
In contrast to protein phosphorylation where a range of pan- and site-specific 
phospho-antibodies are commercially available, only a few such tools exist for the O-
GlcNAc-modification. These antibodies fall into two classes: those that can be considered 
pan-specific and others that are site-specific (Zachara et al. 2011c). The two most 
commonly used pan-specific antibodies for detecting O-GlcNAc-modified proteins are 
CTD110.6 (Comer and Hart 2001), a mouse immunoglobulin (Ig)M antibody raised 
against the C-terminus of RNA polymerase II, and RL2 (Snow et al. 1987), a mouse IgG 
antibody raised against O-GlcNAc-modified components of the nuclear pore complex. 
Recently, a number of monoclonal IgG antibodies have been introduced for detecting O-
GlcNAc-modified proteins including 1F5.D6(14), 18B10.C7(3) and 9D1.E3(10) (Teo et 
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al. 2010). These antibodies were raised against a three-component immunogen-containing 
epitope regions from the casein kinase II (CKII) α-subunit 15, a mouse major 
histocompatibility complex class II restricted helper T-cell epitope, and a Toll-like receptor 
2 agonist (Teo et al. 2010). Like RL2, these antibodies are mouse IgGs and appear to only 
recognize O-GlcNAc in certain 3-dimensional environments. In addition to the antibodies 
discussed previously, anti-streptococcal monoclonal mouse IgG antibodies have been 
commonly used for detecting proteins containing GlcNAc residues. These antibodies were 
raised against streptococcal group A carbohydrates, which is composed of a polyrhamnose 
backbone with GlcNAc side chains (Turner et al. 1990).  
There has only been a small cohort of studies that have incorporated a top-down 
shotgun proteomics approach for identifying O-GlcNAc-modified proteins using the 
antibodies previously discussed. These studies have been hampered because none of the 
discussed antibodies appear to bind O-GlcNAc-modified peptides. As such, proteins that 
interact with O-GlcNAc-modified proteins are also identified, and in most cases O-
GlcNAc-modified peptides are suppressed in the MS making O-GlcNAc-modification sites 
difficult to map. Nonetheless, a number of studies have been performed highlighting 
proteins that are potentially O-GlcNAc-modified in response to cellular stress and tissue 
injury (Jones et al. 2008; Teo et al. 2010; Zachara et al. 2011c), and the O-GlcNAcylation 
status of a number of proteins has been confirmed by independent techniques (Table 1-1). 
One recent study used 1F5.D6(14), 18B10.C7(3) and 9D1.E3(10) to immunoprecipitate O-
GlcNAc-modified proteins followed by large-scale shotgun proteomics to identify more 
than 200 differentially expressed glycoproteins from human embryonic kidney (HEK)293 
cells and rat livers responding to trauma hemorrhage and resuscitation (Teo et al. 2010). 
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Another recent study relied on Stable Isotopic Labeling of Amino acids in Cell culture 
(SILAC) (Ong et al. 2002; Ong et al. 2003) in combination with CTD110.6 
immunoprecipitation (Zachara et al. 2011a). Here, Cos-7 African green monkey kidney 
cells were isotopically labeled in SILAC media (13C6 L-arginine and 13C615N4 L-arginine) 
and treated with heat shock or an inhibitor of OGA, PUGNAc. Labeled proteins were 
combined in equal ratios, and O-GlcNAc-modified proteins were immunoprecipitated 
using CTD110.6 immobilized to agarose and subsequently identified by LC in conjunction 
with tandem mass spectrometry (MS/MS) (Zachara et al. 2011a). Numerous proteins with 
diverse functions were identified, including nuclear factor 90, RuvB-like 1 (Tip49α), 
RuvB-like 2 (Tip49β), and several COPII vesicle transport proteins. Many of these proteins 
bind double-stranded DNA-dependent protein kinase or double-stranded DNA breaks, 
suggesting a role for O-GlcNAc in regulating DNA damage signaling or repair (Zachara et 
al. 2011a).  
Lectin affinity chromatography 
Wheat germ agglutinin (WGA) is a commonly used plant lectin for enriching and 
detecting O-GlcNAc-modified proteins (Zachara et al. 2004a; Vosseller et al. 2006; 
Zachara et al. 2011b). WGA has weak affinity for single GlcNAc residues, but its affinity 
is dramatically increased for GlcNAc-residues that are clustered (Finlay et al. 1987; Lee 
and Lee 2000; Lundquist and Toone 2002). The drawback of WGA as a tool for O-GlcNAc 
enrichment and detection is its additional recognition of sialic acid (NeuAcα(2-3)) residues 
(Monsigny et al. 1980). Treating samples initially with peptide N-glycosidase F to remove 
N-glycans, and by performing nuclear and cytoplasmic protein extractions (Zachara et al. 
2011b) can resolve these shortcomings. Succinylation of WGA (sWGA) increases its 
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specificity for GlcNAc as it ablates its reactivity to sialic acid (Monsigny et al. 1980). 
However, succinylation reduces the affinity of sWGA for O-GlcNAc and thereby decreases 
its utility for immunoprecipitation. 
Lectin Weak Affinity Chromatography (LWAC) utilizes the affinity of WGA in an 
extended column format (>3 meters in length) with a small diameter (~1 cm) to enrich O-
GlcNAc-modified peptides (Vosseller et al. 2006). This chromatography technique 
employs low flow rates and an isocratic elution buffer containing low concentrations of 
GlcNAc (Vosseller et al. 2006). LWAC has been adapted successfully for shotgun 
characterization of O-GlcNAc-modified proteomes from postsynaptic density preparations 
(Vosseller et al. 2006), A. thaliana (Xu et al. 2012), and mouse embryonic stem cells 
(Myers et al. 2011). 
Table 1-1: A summary of O-GlcNAc-modified proteins, their biological significance, and the methods by which they were detected. This table highlights 
the wide range of techniques and tools for the enrichment and detection of O-GlcNAc-modified proteins, including but not limited to O-GlcNAc antibodies, click-
iT methods, immunoprecipitation, and proteomics tools. Abbreviations include: BEMAD, beta elimination and Michael addition; ETD, electron transfer 
dissociation; GalT1, β-1,4-galactosyltransferase; LC, liquid chromatography; MS, mass spectrometry; MS/MS, tandem mass spectrometry. 
O-GlcNAc-modified 
protein 






Casein kinase II 
(CKII) 
α subunit 
O-GlcNAc antagonizes Thr344 
phosphorylation, promotes proteasomal 






Ion trap ETD MS/MS, 
GalT1, LC-MS/MS 





O-GlcNAcylated Carm1 does not exhibit 
mitotic phosphorylation or proper mitotic 
cellular localization 





Sakabe et al. 
2010),
Forkhead Box O1 
(Foxo1) 
O-GlcNAc regulates activation in 
response to glucose, resulting in 
increased expression of gluconeogenic 








Ion trap ETD MS/MS 
(Housley et al. 
2008; Kuo et al. 
2008; Housley et 
al. 2009) 
Inhibitor of NFκB 
kinase (IKKβ) 
Catalytic activity of IKKβ is enhanced 
through O-GlcNAcylation and loss of p53 




(Kawauchi et al. 
2009) 
NFκB 
Increased O-GlcNAc levels is associated 
with reduced activation of NFκB and 
reduced expression of proinflammatory 
cytokines 
HeLa cells Azide-tag, nano-HPLC/tandem MS
Immunoprecipitation, 
Western blotting
(Nandi et al. 
2006; Golks et 
al. 2007) 
p53 
Modification of p53 with O-GlcNAc 
























Regulation (up or down/ in or out) of 
Ca2+ flux through the ER and Ca2+ 
signaling 
SH-SY5Y and 
DT40 B cells, 
Mouse and Rat 
Cerebella 
Western blotting  
(CTD110.6 & RL2) Immunoprecipitation 




Regulation (up or down/ in or out) of 
calcium flux through the ER and Ca2+ 
signaling 
AR4−2J cells Western blotting (RL2) Immunoprecipitation (Bimboese et al. 2011) 
Tab-1 
O-GlcNAcylation of Tab-1 is required for 
full TAK-1 activation upon stimulation 
by IL-1/osmotic stress, and downstream 
activation of NFκB, and production of IL-









In vitro O-GlcNAc 
assay, GalT1 labeling 
(Pathak et al. 
2012) 
Insulin receptor 
substrate 1 (IRS-1) 
O-GlcNAc contributes to insulin 
resistance by inhibiting phosphorylation 
at the PI3K p85 binding motif in IRS-1 
HEK293T cells BEMAD, Ion trap MS/MS/MS 
Western blotting  
(CTD110.6) 
(Ball et al. 2006; 
Whelan et al. 
2010), 





(Wells et al. 
2002b; Walgren 
et al. 2003; 
Nandi et al. 
2006) 
K18 
Glycosylation of K18 increases upon heat 
stress. In models of liver damage, O-
GlcNAcylated K18 promotes the 








GalT1 activity assays 
(Ku et al. 2010) 
HSF1 
O-GlcNAcylation of HSF1 promotes its 
nuclear translocation and activation 
leading to HSP expression 














dependent Kinase IV 
(CaMKIV) 
O-GlcNAcylation of the CaMKIV active 
site blocks its phosphorylation at Thr200 
and ATP binding, inhibiting its kinase 
activity 




Ion trap MS/MS 







Co-localizes with OGT and targets the 
enzyme to FoxOs, leading to increased 
transcriptional of metabolic enzymes
HEK293T cells Ion trap ETD-MS/MS 




OGT activity assay 





O-GlcNAc–modified VDAC is associated 







(Jones et al. 




Click-iT and other chemically based strategies to detect O-GlcNAc-modified 
proteins 
Click chemistry is a chemoenzymatic strategy for quickly and reliably synthesizing 
compounds of interest. By this method, target substrates are labeled with a probe of interest 
that can be derivatized to detect or enrich proteins and peptides. This technique has been 
adapted for the detection and enrichment of O-GlcNAc-modified proteins and peptides. 
Sugars containing either ketones or azido groups are incorporated into O-GlcNAc-
modified proteins using one of two techniques: 1) a mutant GalT1 (Y289L) with an 
enlarged active site is used to add UDP-GalNAz to terminal GlcNAc residues similar to 
the GalT1 labeling discussed above (Khidekel et al. 2003); and 2) in cells by metabolic 
labeling with a peracetylated azido-GlcNAc substrate (Vocadlo et al. 2003; Sprung et al. 
2005), as many of the enzymes in the HBP will tolerate unnatural sugars. However, the 
kinetics of O-linked tetraacetylated N-azidoacetylglucosamine (GlcNAz) removal from 
proteins by OGA is significantly reduced. These unnatural sugars can be derivatized further 
to incorporate a biotin tag, which facilitates the detection and enrichment of O-GlcNAc-
modified proteins and peptides (Wang et al. 2010a). Alternatively, this method has been 
used to incorporate polyethylene glycol moieties (Rexach et al. 2010), which results in a 
molecular weight shift (~2 kDa) for each GlcNAc residue found on a protein and thus 
makes it possible to estimate the stoichiometry of modification. Additionally, this method 
has been used to incorporate fluorescent tags, allowing researchers to quantitatively 
measure and image intracellular O-GlcNAc-modified proteins in vivo (Clark et al. 2008). 
Although these established methods provided great advancements for the detection of O-
GlcNAc-modified proteins, the weak nature of metabolic labeling with peracetylated 
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GlcNAz has led to the development of better technologies. Subsequent studies have shown 
that GalNAz can be converted to UDP-GalNAz and epimerized to UDP-GlcNAz by 
mammalian biosynthetic enzymes, which can be used as a substrate by OGT (Boyce et al. 
2011). Proof-of-principle experiments highlighting this metabolic labeling demonstrated 
that numerous proteins are O-GlcNAc-modified, laying a solid framework for future 
studies to visualize and characterize dynamic O-GlcNAc-mediated signaling events 
(Boyce et al. 2011).  
Mass spectrometry 
MS-based methods have become widely and successfully employed for studying 
proteins and proteomes as well as PTMs such as phosphorylation and methylation using 
collision-induced dissociation in MS/MS. However, detection and site mapping of O-
GlcNAc-modified peptides by mass spectrometric techniques is challenging. This is 
largely due to the labile nature of the β-linkage in the gas phase, which is lost prior to 
fragmentation of the peptide backbone and often prevents correct peptide identification, 
localization of the O-GlcNAc site, and consequently relative quantification. More 
importantly, distinguishing O-GlcNAc peptides from a complex mixture is problematic 
because ion intensities of O-GlcNAc peptides are often suppressed when compared to 
unmodified peptides. Despite these pitfalls, the generation of diagnostic fragment ions of 
O-GlcNAc-modified peptides, for example [M+H]1+ of m/z 204.1 for GlcNAc oxonium 
ions (Carr et al. 1993; Huddleston et al. 1993), can be used to distinguish O-GlcNAc-
modified peptides from complex mixtures. By optimizing fragmentation energy to release 
O-GlcNAc (m/z 204.1), O-GlcNAc-modified peptides can be detected by ESI-MS, which 
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has been employed in mapping O-GlcNAcylation sites in human cytomegalovirus 
tegument basic phosphoprotein to Ser921 and Ser952 (Greis et al. 1994).  
In contrast to collision-induced dissociation, electron capture dissociation and 
electron transfer dissociation (ETD) are alternative fragmentation methods used to preserve 
more labile modifications such as phosphorylation, methylation, acetylation, glycosylation, 
nitrosylation, and sulfation, and allow for direct mapping of peptide/protein modifications 
(Syka et al. 2004; Mikesh et al. 2006; Udeshi et al. 2007; Wu et al. 2007; Udeshi et al. 
2008; Sobott et al. 2009; Wang et al. 2010a). ETD fragmentation cleaves along the peptide 
backbone between the Cα-N producing c and z ions while still maintaining peptide side 
chains and modifications (Syka et al. 2004; Sobott et al. 2009). ETD-MS has been utilized 
to identify dynamically O-GlcNAcylated proteins and their modification sites in excitatory 
neurons in the brain (Khidekel et al. 2007), the cell adhesion protein paxillin (Kwak et al. 
2010), transcription activation of Foxo1 in response to glucose (Housley et al. 2008), 
examination of the extensive crosstalk between phosphorylation and O-GlcNAcylation 
during cytokinesis (Wang et al. 2010b), and many other processes (Chou et al. 1995). 
Although the emergence of ETD-MS has proven to be a successful technique, again 
enrichment of O-GlcNAcylated peptides is ideal for effective sequencing and identification 
of these peptides by MS. 
 
Future directions 
Phosphorylation and other PTMs have historically been the exclusive focus of 
studies on cellular signal transduction events. As discussed in this review, O-GlcNAc is 
emerging as a PTM that should also be considered as an equally important contributor and 
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regulator of signaling pathways, especially those involved in regulating the cells response 
to stress and injury. Previously, it has proven difficult to detect O-GlcNAc and O-GlcNAc-
modified proteins. The work of numerous groups has resulted in the development of 
alternative approaches that solve many of the caveats associated with studying this labile 
protein modification. The application of these techniques will answer many of the 
remaining questions: Which proteins are O-GlcNAc-modified in response to stress?; Are 
the proteins modified in a stress- and/or tissue-specific manner?; How does the O-GlcNAc-
modification alter the function of these proteins at a molecular level?; How are OGT and 
OGA regulated during stress and injury?; and importantly, how is the O-GlcNAc-mediated 
stress response misregulated in disease?  
 
Acknowledgements 
We apologize to our colleagues whose work was not cited in this review due to 
theme or space restrictions. Natasha E. Zachara, Ph.D., is funded by grants from the 
American Heart Association (SD0930162N) and the National Institutes of Health (NIH) 
National Heart, Lung, and Blood Institute (R21HL108003 and P01HL107153). Albert Lee, 
Ph.D., receives funding as a GCF fellow from the NIH National Heart, Lung and Blood 
Institute PEG Program (P01HL107153). 
 
Disclosures 




1. Akimoto Y, Hart GW, Hirano H, Kawakami H (2005) O-GlcNAc modification of 
nucleocytoplasmic proteins and diabetes. Med Mol Morphol 38 (2):84-91. 
2. Arnold CS, Johnson GV, Cole RN, Dong DL, Lee M, Hart GW (1996) The 
microtubule-associated protein tau is extensively modified with O-linked N-
acetylglucosamine. J Biol Chem 271 (46):28741-28744. 
3. Ball LE, Berkaw MN, Buse MG (2006) Identification of the major site of O-linked 
beta-N-acetylglucosamine modification in the C terminus of insulin receptor 
substrate-1. Mol Cell Proteomics 5 (2):313-323. 
4. Batista-Nascimento L, Neef DW, Liu PC, Rodrigues-Pousada C, Thiele DJ (2011) 
Deciphering human heat shock transcription factor 1 regulation via post-translational 
modification in yeast. PLoS One 6 (1):e15976. 
5. Beer D, Maloisel J-L, Rast DM, Vasella A (1990) Synthesis of 2-Acetamido-2-
deoxy-D-gluconhydroximolactone-and Chitobionhydroximolactone-Derived N-
Phenylcarbamates, Potential Inhibitors of beta-N-Acetylglucosaminidase. Helv 
Chim Acta 73 (7):1918-1922. 
6. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, 
Go RC, Vekrellis K, Selkoe DJ, Saunders AJ, Tanzi RE (2000) Evidence for genetic 
linkage of Alzheimer's disease to chromosome 10q. Science 290 (5500):2302-2303. 
7. Bimboese P, Gibson CJ, Schmidt S, Xiang W, Ehrlich BE (2011) Isoform-specific 
regulation of the inositol 1,4,5-trisphosphate receptor by O-linked glycosylation. J 
Biol Chem 286 (18):15688-15697. 
47 
8. Boehmelt G, Fialka I, Brothers G, McGinley MD, Patterson SD, Mo R, Hui CC, 
Chung S, Huber LA, Mak TW, Iscove NN (2000a) Cloning and characterization of 
the murine glucosamine-6-phosphate acetyltransferase EMeg32. Differential 
expression and intracellular membrane association. J Biol Chem 275 (17):12821-
12832. 
9. Boehmelt G, Wakeham A, Elia A, Sasaki T, Plyte S, Potter J, Yang Y, Tsang E, 
Ruland J, Iscove NN, Dennis JW, Mak TW (2000b) Decreased UDP-GlcNAc levels 
abrogate proliferation control in EMeg32-deficient cells. EMBO J 19 (19):5092-
5104. 
10. Boyce M, Carrico IS, Ganguli AS, Yu SH, Hangauer MJ, Hubbard SC, Kohler JJ, 
Bertozzi CR (2011) Metabolic cross-talk allows labeling of O-linked beta-N-
acetylglucosamine-modified proteins via the N-acetylgalactosamine salvage 
pathway. Proc Natl Acad Sci U S A 108 (8):3141-3146. 
11. Buse MG (2006) Hexosamines, insulin resistance, and the complications of diabetes: 
current status. Am J Physiol Endocrinol Metab 290 (1):E1-E8. 
12. Buse MG, Robinson KA, Marshall BA, Hresko RC, Mueckler MM (2002) Enhanced 
O-GlcNAc protein modification is associated with insulin resistance in GLUT1-
overexpressing muscles. Am J Physiol Endocrinol Metab 283 (2):E241-250. 
13. Butkinaree C, Cheung WD, Park S, Park K, Barber M, Hart GW (2008) 
Characterization of beta-N-acetylglucosaminidase cleavage by caspase-3 during 
apoptosis. J Biol Chem 283 (35):23557-23566. 
14. Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, Walker S, Vosseller K, 
Reginato MJ (2010) Nutrient sensor O-GlcNAc transferase regulates breast cancer 
48 
tumorigenesis through targeting of the oncogenic transcription factor FoxM1. 
Oncogene 29 (19):2831-2842. 
15. Carapito C, Klemm C, Aebersold R, Domon B (2009) Systematic LC-MS analysis 
of labile post-translational modifications in complex mixtures. J Proteome Res 8 
(5):2608-2614. 
16. Carr SA, Huddleston MJ, Bean MF (1993) Selective identification and 
differentiation of N- and O-linked oligosaccharides in glycoproteins by liquid 
chromatography-mass spectrometry. Protein Sci 2 (2):183-196. 
17. Carrillo LD, Froemming JA, Mahal LK (2011) Targeted in Vivo O-GlcNAc Sensors 
Reveal Discrete Compartment-specific Dynamics during Signal Transduction. J Biol 
Chem 286 (8):6650-6658. 
18. Carrillo LD, Krishnamoorthy L, Mahal LK (2006) A cellular FRET-based sensor for 
beta-O-GlcNAc, a dynamic carbohydrate modification involved in signaling. J Am 
Chem Soc 128 (46):14768-14769. 
19. Champattanachai V, Marchase RB, Chatham JC (2007) Glucosamine protects 
neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-
associated O-GlcNAc. Am J Physiol Cell Physiol 292 (1):C178-187. 
20. Champattanachai V, Marchase RB, Chatham JC (2008) Glucosamine protects 
neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein O-
GlcNAc and increased mitochondrial Bcl-2. Am J Physiol Cell Physiol 294 
(6):C1509-C1520. 
49 
21. Chatham JC, Marchase RB (2010) The role of protein O-linked beta-N-
acetylglucosamine in mediating cardiac stress responses. Biochim Biophys Acta 
1800 (2):57-66. 
22. Chatham JC, Not LG, Fulop N, Marchase RB (2008) Hexosamine biosynthesis and 
protein O-glycosylation: the first line of defense against stress, ischemia, and trauma. 
Shock 29 (4):431-440. 
23. Chen H, Ing BL, Robinson KA, Feagin AC, Buse MG, Quon MJ (1997) Effects of 
overexpression of glutamine:fructose-6-phosphate amidotransferase (GFAT) and 
glucosamine treatment on translocation of GLUT4 in rat adipose cells. Mol Cell 
Endocrinol 135 (1):67-77. 
24. Cheng X, Cole RN, Zaia J, Hart GW (2000) Alternative O-glycosylation/O-
phosphorylation of the murine estrogen receptor beta. Biochemistry 39 (38):11609-
11620. 
25. Cheng X, Hart GW (2001) Alternative O-glycosylation/O-phosphorylation of serine-
16 in murine estrogen receptor beta: post-translational regulation of turnover and 
transactivation activity. J Biol Chem 276 (13):10570-10575. 
26. Cheung WD, Hart GW (2008) AMP-activated protein kinase and p38 MAPK 
activate O-GlcNAcylation of neuronal proteins during glucose deprivation. J Biol 
Chem 283 (19):13009-13020. 
27. Cheung WD, Sakabe K, Housley MP, Dias WB, Hart GW (2008) O-linked beta-N-
acetylglucosaminyltransferase substrate specificity is regulated by myosin 
phosphatase targeting and other interacting proteins. J Biol Chem 283 (49):33935-
33941. 
50 
28. Chou T-Y, Hart GW, Dang CV (1995) c-Myc is Glycosylated at Threonine 58, a 
Known Phosphorylation Site and a Mutational Hot Spot in Lymphomas. J Biol Chem 
270(32):18961-18965. 
29. Clark PM, Dweck JF, Mason DE, Hart CR, Buck SB, Peters EC, Agnew BJ, Hsieh-
Wilson LC (2008) Direct in-gel fluorescence detection and cellular imaging of O-
GlcNAc-modified proteins. J Am Chem Soc 130 (35):11576-11577. 
30. Comer FI, Hart GW (1999) O-GlcNAc and the control of gene expression. Biochim 
Biophys Acta 1473 (1):161-171. 
31. Comer FI, Hart GW (2001) Reciprocity between O-GlcNAc and O-phosphate on the 
carboxyl terminal domain of RNA polymerase II. Biochemistry 40 (26):7845-7852. 
32. Comtesse N, Maldener E, Meese E (2001) Identification of a nuclear variant of 
MGEA5, a cytoplasmic hyaluronidase and a beta-N-acetylglucosaminidase. 
Biochem Biophys Res Commun 283 (3):634-640. 
33. Crow MT, Mani K, Nam YJ, Kitsis RN (2004) The mitochondrial death pathway and 
cardiac myocyte apoptosis. Circulation research 95 (10):957-970. 
34. Dias WB, Cheung WD, Hart GW (2012) O-GlcNAcylation of kinases. Biochem 
Biophys Res Commun 422 (2):224-228. 
35. Dias WB, Cheung WD, Wang Z, Hart GW (2009) Regulation of 
calcium/calmodulin-dependent kinase IV by O-GlcNAc modification. J Biol Chem 
284 (32):21327-21337. 
36. Dong DL, Hart GW (1994) Purification and characterization of an O-GlcNAc 
selective N-acetyl-beta-D-glucosaminidase from rat spleen cytosol. J Biol Chem 269 
(30):19321-19330. 
51 
37. Dong H, Goico B, Martin M, Csernansky CA, Bertchume A, Csernansky JG (2004) 
Modulation of hippocampal cell proliferation, memory, and amyloid plaque 
deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience 127 
(3):601-609. 
38. Dorfmueller HC, Borodkin VS, Blair DE, Pathak S, Navratilova I, van Aalten DM 
(2011) Substrate and product analogues as human O-GlcNAc transferase inhibitors. 
Amino Acids 40 (3):781-792. 
39. Dorfmueller HC, Borodkin VS, Schimpl M, Shepherd SM, Shpiro NA, van Aalten 
DM (2006) GlcNAcstatin: a picomolar, selective O-GlcNAcase inhibitor that 
modulates intracellular O-glcNAcylation levels. J Am Chem Soc 128 (51):16484-
16485. 
40. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M (2001) Hyperglycemia 
inhibits endothelial nitric oxide synthase activity by posttranslational modification at 
the Akt site. J Clin Invest 108 (9):1341-1348. 
41. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee 
M (2000) Hyperglycemia-induced mitochondrial superoxide overproduction 
activates the hexosamine pathway and induces plasminogen activator inhibitor-1 
expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 97 
(22):12222-12226. 
42. Dudognon P, Maeder-Garavaglia C, Carpentier JL, Paccaud JP (2004) Regulation of 
a COPII component by cytosolic O-glycosylation during mitosis. FEBS Lett 561 (1-
3):44-50. 
52 
43. Ficko-Blean E, Stubbs KA, Nemirovsky O, Vocadlo DJ, Boraston AB (2008) 
Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB. 
Proceedings of the National Academy of Sciences of the United States of America 
105 (18):6560-6565. 
44. Finlay DR, Newmeyer DD, Price TM, Forbes DJ (1987) Inhibition of in vitro nuclear 
transport by a lectin that binds to nuclear pores. J Cell Biol 104 (2):189-200. 
45. Forsythe ME, Love DC, Lazarus BD, Kim EJ, Prinz WA, Ashwell G, Krause MW, 
Hanover JA (2006) Caenorhabditis elegans ortholog of a diabetes susceptibility 
locus: oga-1 (O-GlcNAcase) knockout impacts O-GlcNAc cycling, metabolism, and 
dauer. Proc Natl Acad Sci U S A 103 (32):11952-11957. 
46. Fujiki R, Hashiba W, Sekine H, Yokoyama A, Chikanishi T, Ito S, Imai Y, Kim J, 
He HH, Igarashi K, Kanno J, Ohtake F, Kitagawa H, Roeder RG, Brown M, Kato S 
(2011) GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature 480 
(7378):557-560. 
47. Fulop N, Marchase RB, Chatham JC (2007a) Role of protein O-linked N-acetyl-
glucosamine in mediating cell function and survival in the cardiovascular system. 
Cardiovasc Res 73 (2):288-297. 
48. Fulop N, Zhang Z, Marchase RB, Chatham JC (2007b) Glucosamine 
cardioprotection in perfused rat hearts associated with increased O-linked N-
acetylglucosamine protein modification and altered p38 activation. Am J Physiol 
Heart Circ Physiol 292 (5):H2227-2236. 
49. Gambetta MC, Oktaba K, Muller J (2009) Essential role of the glycosyltransferase 
sxc/Ogt in polycomb repression. Science 325 (5936):93-96. 
53 
50. Gandy JC, Rountree AE, Bijur GN (2006) Akt1 is dynamically modified with O-
GlcNAc following treatments with PUGNAc and insulin-like growth factor-1. FEBS 
Lett 580 (13):3051-3058. 
51. Gao Y, Miyazaki J, Hart GW (2003) The transcription factor PDX-1 is post-
translationally modified by O-linked N-acetylglucosamine and this modification is 
correlated with its DNA binding activity and insulin secretion in min6 beta-cells. 
Arch Biochem Biophys 415 (2):155-163. 
52. Gao Y, Parker GJ, Hart GW (2000) Streptozotocin-induced beta-cell death is 
independent of its inhibition of O-GlcNAcase in pancreatic Min6 cells. Arch 
Biochem Biophys 383 (2):296-302. 
53. Gao Y, Wells L, Comer FI, Parker GJ, Hart GW (2001) Dynamic O-glycosylation of 
nuclear and cytosolic proteins - Cloning and characterization of a neutral, cytosolic 
beta-N-acetylglucosam inidase from human brain. J Biol Chem 276 (13):9838-9845. 
54. Gloster TM, Zandberg WF, Heinonen JE, Shen DL, Deng L, Vocadlo DJ (2011) 
Hijacking a biosynthetic pathway yields a glycosyltransferase inhibitor within cells. 
Nat Chem Biol 7 (3):174-181. 
55. Goldberg H, Whiteside C, Fantus IG (2011) O-linked beta-N-acetylglucosamine 
supports p38 MAPK activation by high glucose in glomerular mesangial cells. Am J 
Physiol Endocrinol Metab 301 (4):E713-726. 
56. Goldenberg I, Grossman E, Jacobson KA, Shneyvays V, Shainberg A (2001) 
Angiotensin II-induced apoptosis in rat cardiomyocyte culture: a possible role of 
AT1 and AT2 receptors. J Hypertens 19 (9):1681-1689. 
54 
57. Golks A, Tran TT, Goetschy JF, Guerini D (2007) Requirement for O-linked N-
acetylglucosaminyltransferase in lymphocytes activation. EMBO J 26 (20):4368-
4379. 
58. Greig KT, Antonchuk J, Metcalf D, Morgan PO, Krebs DL, Zhang JG, Hacking DF, 
Bode L, Robb L, Kranz C, de Graaf C, Bahlo M, Nicola NA, Nutt SL, Freeze HH, 
Alexander WS, Hilton DJ, Kile BT (2007) Agm1/Pgm3-mediated sugar nucleotide 
synthesis is essential for hematopoiesis and development. Mol Cell Biol 27 
(16):5849-5859. 
59. Greis KD, Gibson W, Hart GW (1994) Site-specific glycosylation of the human 
cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 
952. J Virol 68 (12):8339-8349. 
60. Griffith LS, Schmitz B (1999) O-linked N-acetylglucosamine levels in cerebellar 
neurons respond reciprocally to pertubations of phosphorylation. Eur J Biochem 262 
(3):824-831. 
61. Gross BJ, Kraybill BC, Walker S (2005) Discovery of O-GlcNAc transferase 
inhibitors. J Am Chem Soc 127 (42):14588-14589. 
62. Guinez C, Losfeld ME, Cacan R, Michalski JC, Lefebvre T (2006) Modulation of 
HSP70 GlcNAc-directed lectin activity by glucose availability and utilization. 
Glycobiology 16 (1):22-28. 
63. Guinez C, Mir AM, Dehennaut V, Cacan R, Harduin-Lepers A, Michalski JC, 
Lefebvre T (2008) Protein ubiquitination is modulated by O-GlcNAc glycosylation. 
FASEB J 22 (8):2901-2911. 
55 
64. Guinez C, Mir AM, Leroy Y, Cacan R, Michalski JC, Lefebvre T (2007) Hsp70-
GlcNAc-binding activity is released by stress, proteasome inhibition, and protein 
misfolding. Biochemical and biophysical research communications 361 (2):414-420. 
65. Guinez C, Mir AM, Martin N, Leprince D, Michalski JC, Vergoten G, Lefebvre T 
(2010) Arginine 469 is a pivotal residue for the Hsc70-GlcNAc-binding property. 
Biochemical and biophysical research communications 400 (4):537-542. 
66. Gurcel C, Vercoutter-Edouart AS, Fonbonne C, Mortuaire M, Salvador A, Michalski 
JC, Lemoine J (2008) Identification of new O-GlcNAc modified proteins using a 
click-chemistry-based tagging. Anal Bioanal Chem 390 (8):2089-2097. 
67. Haberhausen G, Schmitt I, Kohler A, Peters U, Rider S, Chelly J, Terwilliger JD, 
Monaco AP, Muller U (1995) Assignment of the dystonia-parkinsonism syndrome 
locus, DYT3, to a small region within a 1.8-Mb YAC contig of Xq13.1. Am J Hum 
Genet 57 (3):644-650. 
68. Haltiwanger RS, Blomberg MA, Hart GW (1992) Glycosylation of nuclear and 
cytoplasmic proteins. Purification and characterization of a uridine diphospho-N-
acetylglucosamine:polypeptide beta-N-acetylglucosaminyltransferase. J Biol Chem 
267 (13):9005-9013. 
69. Haltiwanger RS, Busby S, Grove K, Li S, Mason D, Medina L, Moloney D, 
Philipsberg G, Scartozzi R (1997) O-glycosylation of nuclear and cytoplasmic 
proteins: Regulation analogous to phosphorylation? BiochemBiophysResCommun 
231:237-242. 
70. Haltiwanger RS, Grove K, Philipsberg GA (1998) Modulation of O-linked N-
acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the 
56 
peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-
deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate. J Biol Chem 273 
(6):3611-3617. 
71. Hamiel CR, Pinto S, Hau A, Wischmeyer PE (2009) Glutamine enhances heat shock 
protein 70 expression via increased hexosamine biosynthetic pathway activity. Am J 
Physiol Cell Physiol 297 (6):C1509-1519. 
72. Han I, Kudlow JE (1997) Reduced O glycosylation of Sp1 is associated with 
increased proteasome susceptibility. Mol Cell Biol 17 (5):2550-2558. 
73. Hanover JA, Forsythe ME, Hennessey PT, Brodigan TM, Love DC, Ashwell G, 
Krause M (2005) A Caenorhabditis elegans model of insulin resistance: altered 
macronutrient storage and dauer formation in an OGT-1 knockout. Proc Natl Acad 
Sci U S A 102 (32):11266-11271. 
74. Hanover JA, Yu S, Lubas WB, Shin SH, Ragano-Caracciola M, Kochran J, Love DC 
(2003) Mitochondrial and nucleocytoplasmic isoforms of O-linked GlcNAc 
transferase encoded by a single mammalian gene. Archives of biochemistry and 
biophysics 409 (2):287-297. 
75. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of 
Alzheimer's disease. Trends Pharmacol Sci 12 (10):383-388. 
76. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O (2011) Cross Talk Between O-
GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription, and Chronic 
Disease. Annu Rev Biochem 80:825-858. 
57 
77. Heckel D, Comtesse N, Brass N, Blin N, Zang KD, Meese E (1998) Novel 
immunogenic antigen homologous to hyaluronidase in meningioma. Hum Mol Genet 
7 (12):1859-1872. 
78. Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in 
Parkinson disease pathogenesis. Nat Clin Pract Neurol 4 (11):600-609. 
79. Housley MP, Rodgers JT, Udeshi ND, Kelly TJ, Shabanowitz J, Hunt DF, Puigserver 
P, Hart GW (2008) O-GlcNAc regulates FoxO activation in response to glucose. J 
Biol Chem 283 (24):16283-16292. 
80. Housley MP, Udeshi ND, Rodgers JT, Shabanowitz J, Puigserver P, Hunt DF, Hart 
GW (2009) A PGC-1alpha-O-GlcNAc transferase complex regulates FoxO 
transcription factor activity in response to glucose. J Biol Chem 284 (8):5148-5157. 
81. Hsieh TJ, Lin T, Hsieh PC, Liao MC, Shin SJ (2012) Suppression of 
Glutamine:fructose-6-phosphate amidotransferase-1 inhibits adipogenesis in 3T3-L1 
adipocytes. J Cell Physiol 227 (1):108-115. 
82. Hu Y, Belke D, Suarez J, Swanson E, Clark R, Hoshijima M, Dillmann WH (2005) 
Adenovirus-mediated overexpression of O-GlcNAcase improves contractile 
function in the diabetic heart. Circ Res 96 (9):1006-1013. 
83. Huang JB, Clark AJ, Petty HR (2007) The hexosamine biosynthesis pathway 
negatively regulates IL-2 production by Jurkat T cells. Cell Immunol 245 (1):1-6. 
84. Huddleston MJ, Bean MF, Carr SA (1993) Collisional fragmentation of 
glycopeptides by electrospray ionization LC/MS and LC/MS/MS: methods for 
selective detection of glycopeptides in protein digests. Anal Chem 65 (7):877-884. 
58 
85. Hunton DL, Zou L, Pang Y, Marchase RB (2004) Adult rat cardiomyocytes exhibit 
capacitative calcium entry. Am J Physiol Heart Circ Physiol 286 (3):H1124-1132. 
86. Hwang SY, Shin JH, Hwang JS, Kim SY, Shin JA, Oh ES, Oh S, Kim JB, Lee JK, 
Han IO (2010) Glucosamine exerts a neuroprotective effect via suppression of 
inflammation in rat brain ischemia/reperfusion injury. Glia 58 (15):1881-1892. 
87. Ise H, Kobayashi S, Goto M, Sato T, Kawakubo M, Takahashi M, Ikeda U, Akaike 
T (2010) Vimentin and desmin possess GlcNAc-binding lectin-like properties on cell 
surfaces. Glycobiology 20 (7):843-864. 
88. Jackson SP, Tjian R (1989) Purification and analysis of RNA polymerase II 
transcription factors by using wheat germ agglutinin affinity chromatography. Proc 
Natl Acad Sci U S A 86 (6):1781-1785. 
89. Jacobsen KT, Iverfeldt K (2011) O-GlcNAcylation increases non-amyloidogenic 
processing of the amyloid-beta precursor protein (APP). Biochem Biophys Res 
Commun 404 (3):882-886. 
90. Jacobsen SE, Binkowski KA, Olszewski NE (1996) SPINDLY, a tetratricopeptide 
repeat protein involved in gibberellin signal transduction Arabidopsis. Proc Natl 
Acad Sci U S A 93 (17):9292-9296. 
91. James LR, Fantus IG, Goldberg H, Ly H, Scholey JW (2000) Overexpression of 
GFAT activates PAI-1 promoter in mesangial cells. Am J Physiol Renal Physiol 279 
(4):F718-727. 
92. Jarrar D, Chaudry IH, Wang P (1999) Organ dysfunction following hemorrhage and 
sepsis: mechanisms and therapeutic approaches. Int J Mol Med 4 (6):575-583. 
59 
93. Jiang M-S, Hart GW (1997) A Subpopulation of Estrogen Receptors Are Modified 
by O-Linked N-Acetylglucosamine. JBiolChem 272:2421-2498. 
94. Jinek M, Rehwinkel J, Lazarus BD, Izaurralde E, Hanover JA, Conti E (2004) The 
superhelical TPR-repeat domain of O-linked GlcNAc transferase exhibits structural 
similarities to importin alpha. Nat Struct Mol Biol 11 (10):1001-1007. 
95. Jones SP, Zachara NE, Ngoh GA, Hill BG, Teshima Y, Bhatnagar A, Hart GW, 
Marban E (2008) Cardioprotection by N-acetylglucosamine linkage to cellular 
proteins. Circulation 117 (9):1172-1182. 
96. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang 
S, Ytrehus K, Antos CL, Olson EN, Sollott SJ (2004) Glycogen synthase kinase-
3beta mediates convergence of protection signaling to inhibit the mitochondrial 
permeability transition pore. J Clin Invest 113 (11):1535-1549. 
97. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, Anversa P (1997) 
Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell 
Cardiol 29 (3):859-870. 
98. Kang ES, Han D, Park J, Kwak TK, Oh MA, Lee SA, Choi S, Park ZY, Kim Y, Lee 
JW (2008) O-GlcNAc modulation at Akt1 Ser473 correlates with apoptosis of 
murine pancreatic beta cells. Exp Cell Res 314 (11-12):2238-2248. 
99. Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM (2007) Acute stress 
increases interstitial fluid amyloid-beta via corticotropin-releasing factor and 
neuronal activity. Proc Natl Acad Sci U S A 104 (25):10673-10678. 
60 
100. Kawauchi K, Araki K, Tobiume K, Tanaka N (2009) Loss of p53 enhances catalytic 
activity of IKKbeta through O-linked beta-N-acetyl glucosamine modification. Proc 
Natl Acad Sci U S A 106 (9):3431-3436. 
101. Kazemi Z, Chang H, Haserodt S, McKen C, Zachara NE (2010) O-linked beta-N-
acetylglucosamine (O-GlcNAc) regulates stress-induced heat shock protein 
expression in a GSK-3beta-dependent manner. J Biol Chem 285 (50):39096-39107. 
102. Kearse KP, Hart GW (1991) Lymphocyte activation induces rapid changes in nuclear 
and cytoplasmic glycoproteins. Proc Natl Acad Sci U S A 88 (5):1701-1705. 
103. Kelly WG, Dahmus ME, Hart GW (1993) RNA polymerase II is a glycoprotein. 
Modification of the COOH-terminal domain by O-GlcNAc. J Biol Chem 268 
(14):10416-10424. 
104. Kem DC, Johnson EI, Capponi AM, Chardonnens D, Lang U, Blondel B, Koshida 
H, Vallotton MB (1991) Effect of angiotensin II on cytosolic free calcium in neonatal 
rat cardiomyocytes. Am J Physiol 261 (1 Pt 1):C77-85. 
105. Khidekel N, Arndt S, Lamarre-Vincent N, Lippert A, Poulin-Kerstien KG, 
Ramakrishnan B, Qasba PK, Hsieh-Wilson LC (2003) A chemoenzymatic approach 
toward the rapid and sensitive detection of O-GlcNAc posttranslational 
modifications. J Am Chem Soc 125 (52):16162-16163. 
106. Khidekel N, Ficarro SB, Clark PM, Bryan MC, Swaney DL, Rexach JE, Sun YE, 
Coon JJ, Peters EC, Hsieh-Wilson LC (2007) Probing the dynamics of O-GlcNAc 
glycosylation in the brain using quantitative proteomics. Nat Chem Biol 3 (6):339-
348. 
61 
107. Khidekel N, Ficarro SB, Peters EC, Hsieh-Wilson LC (2004) Exploring the O-
GlcNAc proteome: direct identification of O-GlcNAc-modified proteins from the 
brain. Proc Natl Acad Sci U S A 101 (36):13132-13137. 
108. Kim C, Nam DW, Park SY, Song H, Hong HS, Boo JH, Jung ES, Kim Y, Baek JY, 
Kim KS, Cho JW, Mook-Jung I (2012) O-linked beta-N-acetylglucosaminidase 
inhibitor attenuates beta-amyloid plaque and rescues memory impairment. Neurobiol 
Aging 34 (1):275–285. 
109. Kim EJ, Kang DO, Love DC, Hanover JA (2006a) Enzymatic characterization of O-
GlcNAcase isoforms using a fluorogenic GlcNAc substrate. Carbohydr Res 341 
(8):971-982. 
110. Kim SJ, Sung JY, Um JW, Hattori N, Mizuno Y, Tanaka K, Paik SR, Kim J, Chung 
KC (2003) Parkin cleaves intracellular alpha-synuclein inclusions via the activation 
of calpain. J Biol Chem 278 (43):41890-41899. 
111. Kim YH, Song M, Oh YS, Heo K, Choi JW, Park JM, Kim SH, Lim S, Kwon HM, 
Ryu SH, Suh PG (2006b) Inhibition of phospholipase C-beta1-mediated signaling by 
O-GlcNAc modification. J Cell Physiol 207 (3):689-696. 
112. Knapp S, Abdo M, Ajayi K, Huhn RA, Emge TJ, Kim EJ, Hanover JA (2007) 
Tautomeric modification of GlcNAc-thiazoline. Org Lett 9 (12):2321-2324. 
113. Konrad RJ, Zhang F, Hale JE, Knierman MD, Becker GW, Kudlow JE (2002) 
Alloxan is an inhibitor of the enzyme O-linked N-acetylglucosamine transferase. 
Biochem Biophys Res Commun 293 (1):207-212. 
62 
114. Kreppel LK, Blomberg MA, Hart GW (1997) Dynamic glycosylation of nuclear and 
cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase 
with multiple tetratricopeptide repeats. J Biol Chem 272 (14):9308-9315. 
115. Kreppel LK, Hart GW (1999) Regulation of a cytosolic and nuclear O-GlcNAc 
transferase. Role of the tetratricopeptide repeats. J Biol Chem 274 (45):32015-32022. 
116. Ku NO, Toivola DM, Strnad P, Omary MB (2010) Cytoskeletal keratin glycosylation 
protects epithelial tissue from injury. Nat Cell Biol 12 (9):876-885. 
117. Kuo M, Zilberfarb V, Gangneux N, Christeff N, Issad T (2008) O-GlcNAc 
modification of FoxO1 increases its transcriptional activity: a role in the 
glucotoxicity phenomenon? Biochimie 90 (5):679-685. 
118. Kwak TK, Kim H, Jung O, Lee SA, Kang M, Kim HJ, Park JM, Kim SH, Lee JW 
(2010) Glucosamine treatment-mediated O-GlcNAc modification of paxillin 
depends on adhesion state of rat insulinoma INS-1 cells. J Biol Chem 285 
(46):36021-36031. 
119. Kwon NS, Lee SH, Choi CS, Kho T, Lee HS (1994) Nitric oxide generation from 
streptozotocin. FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology 8 (8):529-533. 
120. Laczy B, Marsh SA, Brocks CA, Wittmann I, Chatham JC (2010) Inhibition of O-
GlcNAcase in perfused rat hearts by NAG-thiazolines at the time of reperfusion is 
cardioprotective in an O-GlcNAc dependent manner. Am J Physiol Heart Circ 
Physiol 299 (5):H1715-H1727. 
121. Lazarus MB, Nam Y, Jiang J, Sliz P, Walker S (2011) Structure of human O-GlcNAc 
transferase and its complex with a peptide substrate. Nature 469 (7331):564-567. 
63 
122. Lee RT, Lee YC (2000) Affinity enhancement by multivalent lectin-carbohydrate 
interaction. Glycoconjugate journal 17 (7-9):543-551. 
123. Lee TN, Alborn WE, Knierman MD, Konrad RJ (2006) Alloxan is an inhibitor of O-
GlcNAc-selective N-acetyl-beta-D-glucosaminidase. Biochem Biophys Res 
Commun 350 (4):1038-1043. 
124. Lefebvre T, Cieniewski C, Lemoine J, Guerardel Y, Leroy Y, Zanetta JP, Michalski 
JC (2001) Identification of N-acetyl-d-glucosamine-specific lectins from rat liver 
cytosolic and nuclear compartments as heat-shock proteins. Biochem J 360 (Pt 
1):179-188. 
125. Lim K, Chang HI (2010) O-GlcNAc inhibits interaction between Sp1 and sterol 
regulatory element binding protein 2. Biochemical and biophysical research 
communications 393 (2):314-318. 
126. Lim KH, Chang HI (2006) O-linked N-acetylglucosamine suppresses thermal 
aggregation of Sp1. FEBS Lett 580 (19):4645-4652. 
127. Lima VV, Spitler K, Choi H, Webb RC, Tostes RC (2012) O-GlcNAcylation and 
oxidation of proteins: is signalling in the cardiovascular system becoming sweeter? 
Clin Sci (Lond) 123 (8):473-486. 
128. Lindquist S (1986) The heat-shock response. Annu Rev Biochem 55:1151-1191. 
129. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX (2004a) O-GlcNAcylation 
regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc 
Natl Acad Sci U S A 101 (29):10804-10809. 
64 
130. Liu HR, Gao F, Tao L, Yan WL, Gao E, Christopher TA, Lopez BL, Hu A, Ma XL 
(2004b) Antiapoptotic mechanisms of benidipine in the ischemic/reperfused heart. 
Br J Pharmacol 142 (4):627-634. 
131. Liu J, Marchase RB, Chatham JC (2007) Increased O-GlcNAc levels during 
reperfusion lead to improved functional recovery and reduced calpain proteolysis. 
Am J Physiol Heart Circ Physiol 293 (3):H1391-1399. 
132. Liu J, Pang Y, Chang T, Bounelis P, Chatham JC, Marchase RB (2006) Increased 
hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial 
protection against calcium paradox and ischemia. J Mol Cell Cardiol 40 (2):303-312. 
133. Liu K, Paterson AJ, Konrad RJ, Parlow AF, Jimi S, Roh M, Chin E, Jr., Kudlow JE 
(2002) Streptozotocin, an O-GlcNAcase inhibitor, blunts insulin and growth 
hormone secretion. Mol Cell Endocrinol 194 (1-2):135-146. 
134. Love DC, Ghosh S, Mondoux MA, Fukushige T, Wang P, Wilson MA, Iser WB, 
Wolkow CA, Krause MW, Hanover JA (2010) Dynamic O-GlcNAc cycling at 
promoters of Caenorhabditis elegans genes regulating longevity, stress, and 
immunity. Proc Natl Acad Sci U S A 107 (16):7413-7418. 
135. Love DC, Kochan J, Cathey RL, Shin SH, Hanover JA (2003) Mitochondrial and 
nucleocytoplasmic targeting of O-linked GlcNAc transferase. Journal of cell science 
116 (Pt 4):647-654. 
136. Lubas WA, Frank DW, Krause M, Hanover JA (1997) O-Linked GlcNAc transferase 
is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J Biol 
Chem 272 (14):9316-9324. 
65 
137. Lubas WA, Hanover JA (2000) Functional expression of O-linked GlcNAc 
transferase. Domain structure and substrate specificity. J Biol Chem 275 (15):10983-
10988. 
138. Lundquist JJ, Toone EJ (2002) The cluster glycoside effect. Chemical reviews 102 
(2):555-578. 
139. Macauley MS, Bubb AK, Martinez-Fleites C, Davies GJ, Vocadlo DJ (2008) 
Elevation of Global O-GlcNAc Levels in 3T3-L1 Adipocytes by Selective Inhibition 
of O-GlcNAcase Does Not Induce Insulin Resistance. J Biol Chem 283 (50):34687-
34695. 
140. Macauley MS, Whitworth GE, Debowski AW, Chin D, Vocadlo DJ (2005) O-
GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of 
highly selective mechanism-inspired inhibitors. J Biol Chem 280 (27):25313-25322. 
141. Machida M, Jigami Y (1994) Glycosylated DNA-binding proteins from filamentous 
fungus, Aspergillus oryzae: Modification with N-acetylglucosamine 
monosaccharide through an O-glycosidic linkage. BiosciBiotechnolBiochem 
58:344-348. 
142. Marotta NP, Cherwien CA, Abeywardana T, Pratt MR (2012) O-GlcNAc 
modification prevents peptide-dependent acceleration of alpha-synuclein 
aggregation. ChemBioChem 13 (18):2665-2670. 
143. Marshall S, Bacote V, Traxinger RR (1991) Discovery of a metabolic pathway 
mediating glucose-induced desensitization of the glucose transport system. Role of 
hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 266 
(8):4706-4712. 
66 
144. Marshall S, Duong T, Wu T, Hering MA, Yada J, Higgins S, Orbus RJ, Yan ZH, 
Rumberger JM (2003) Enhanced expression of uridine diphosphate-N-
acetylglucosaminyl transferase (OGT) in a stable, tetracycline-inducible HeLa cell 
line using histone deacetylase inhibitors: kinetics of cytosolic OGT accumulation 
and nuclear translocation. Anal Biochem 319 (2):304-313. 
145. Marshall S, Nadeau O, Yamasaki K (2004) Dynamic actions of glucose and 
glucosamine on hexosamine biosynthesis in isolated adipocytes: differential effects 
on glucosamine 6-phosphate, UDP-N-acetylglucosamine, and ATP levels. J Biol 
Chem 279 (34):35313-35319. 
146. Martinez-Fleites C, Macauley MS, He Y, Shen DL, Vocadlo DJ, Davies GJ (2008) 
Structure of an O-GlcNAc transferase homolog provides insight into intracellular 
glycosylation. Nat Struct Mol Biol 15 (7):764-765. 
147. McClain DA (2002) Hexosamines as mediators of nutrient sensing and regulation in 
diabetes. J Diabetes Complications 16 (1):72-80. 
148. Meldrum DR, Cleveland JC, Jr., Mitchell MB, Sheridan BC, Gamboni-Robertson F, 
Harken AH, Banerjee A (1996) Protein kinase C mediates Ca2(+)-induced 
cardioadaptation to ischemia-reperfusion injury. Am J Physiol 271 (3 Pt 2):R718-
726. 
149. Mikesh LM, Ueberheide B, Chi A, Coon JJ, Syka JE, Shabanowitz J, Hunt DF (2006) 
The utility of ETD mass spectrometry in proteomic analysis. Biochim Biophys Acta 
1764 (12):1811-1822. 
67 
150. Mio T, Yamada-Okabe T, Arisawa M, Yamada-Okabe H (1999) Saccharomyces 
cerevisiae GNA1, an essential gene encoding a novel acetyltransferase involved in 
UDP-N-acetylglucosamine synthesis. J Biol Chem 274 (1):424-429. 
151. Miura T, Miki T (2009) GSK-3beta, a therapeutic target for cardiomyocyte 
protection. Circ J 73 (7):1184-1192. 
152. Monsigny M, Roche AC, Sene C, Maget-Dana R, Delmotte F (1980) Sugar-lectin 
interactions: how does wheat-germ agglutinin bind sialoglycoconjugates? European 
journal of biochemistry / FEBS 104 (1):147-153. 
153. Murphy E, Imahashi K, Steenbergen C (2005) Bcl-2 regulation of mitochondrial 
energetics. Trends Cardiovasc Med 15 (8):283-290. 
154. Musicki B, Kramer MF, Becker RE, Burnett AL (2005) Inactivation of 
phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in 
diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A 102 (33):11870-
11875. 
155. Myers SA, Panning B, Burlingame AL (2011) Polycomb repressive complex 2 is 
necessary for the normal site-specific O-GlcNAc distribution in mouse embryonic 
stem cells. Proc Natl Acad Sci U S A 108 (23):9490-9495. 
156. Nagy T, Champattanachai V, Marchase RB, Chatham JC (2006) Glucosamine 
inhibits angiotensin II-induced cytoplasmic Ca2+ elevation in neonatal 
cardiomyocytes via protein-associated O-linked N-acetylglucosamine. Am J Physiol 
Cell Physiol 290 (1):C57-65. 
157. Nandi A, Sprung R, Barma DK, Zhao Y, Kim SC, Falck JR (2006) Global 
identification of O-GlcNAc-modified proteins. Anal Chem 78 (2):452-458. 
68 
158. Nathan C (2002) Points of control in inflammation. Nature 420 (6917):846-852. 
159. Ngoh GA, Facundo HT, Hamid T, Dillmann W, Zachara NE, Jones SP (2009a) 
Unique hexosaminidase reduces metabolic survival signal and sensitizes cardiac 
myocytes to hypoxia/reoxygenation injury. Circ Res 104 (1):41-49. 
160. Ngoh GA, Facundo HT, Zafir A, Jones SP (2010) O-GlcNAc signaling in the 
cardiovascular system. Circ Res 107 (2):171-185. 
161. Ngoh GA, Hamid T, Prabhu SD, Jones SP (2009b) O-GlcNAc signaling attenuates 
ER stress-induced cardiomyocyte death. Am J Physiol Heart Circ Physiol 297 
(5):H1711-1719. 
162. Ngoh GA, Watson LJ, Facundo HT, Dillmann W, Jones SP (2008) Non-canonical 
glycosyltransferase modulates post-hypoxic cardiac myocyte death and 
mitochondrial permeability transition. J Mol Cell Cardiol 45 (2):313-325. 
163. Ngoh GA, Watson LJ, Facundo HT, Jones SP (2011) Augmented O-GlcNAc 
signaling attenuates oxidative stress and calcium overload in cardiomyocytes. Amino 
Acids 40 (3):895-911. 
164. Nollen EA, Morimoto RI (2002) Chaperoning signaling pathways: molecular 
chaperones as stress-sensing 'heat shock' proteins. J Cell Sci 115 (Pt 14):2809-2816. 
165. Not LG, Brocks CA, Vamhidy L, Marchase RB, Chatham JC (2010) Increased O-
linked beta-N-acetylglucosamine levels on proteins improves survival, reduces 
inflammation and organ damage 24 hours after trauma-hemorrhage in rats. Crit Care 
Med 38 (2):562-571. 
69 
166. Not LG, Marchase RB, Fulop N, Brocks CA, Chatham JC (2007) Glucosamine 
Administration Improves Survival Rate after Severe Hemorrhagic Shock Combined 
with Trauma in Rats. Shock 28 (3):345-352. 
167. O'Donnell N, Zachara NE, Hart GW, Marth JD (2004) Ogt-dependent X-
chromosome-linked protein glycosylation is a requisite modification in somatic cell 
function and embryo viability. Mol Cell Biol 24 (4):1680-1690. 
168. Okuyama R, Yachi M (2001) Cytosolic O-GlcNAc accumulation is not involved in 
beta-cell death in HIT-T15 or Min6. Biochem Biophys Res Commun 287 (2):366-
371. 
169. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M 
(2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and 
accurate approach to expression proteomics. Mol Cell Proteomics 1 (5):376-386. 
170. Ong SE, Kratchmarova I, Mann M (2003) Properties of 13C-substituted arginine in 
stable isotope labeling by amino acids in cell culture (SILAC). J Proteome Res 2 
(2):173-181. 
171. Ozcan S, Andrali SS, Cantrell JE (2010) Modulation of transcription factor function 
by O-GlcNAc modification. Biochim Biophys Acta 1799 (5-6):353-364. 
172. Pang Y, Hunton DL, Bounelis P, Marchase RB (2002) Hyperglycemia inhibits 
capacitative calcium entry and hypertrophy in neonatal cardiomyocytes. Diabetes 51 
(12):3461-3467. 
173. Pathak S, Borodkin VS, Albarbarawi O, Campbell DG, Ibrahim A, van Aalten DM 
(2012) O-GlcNAcylation of TAB1 modulates TAK1-mediated cytokine release. 
EMBO J 31 (6):1394-1404. 
70 
174. Patti ME, Virkamaki A, Landaker EJ, Kahn CR, Yki-Jarvinen H (1999) Activation 
of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early 
postreceptor insulin signaling events in skeletal muscle. Diabetes 48 (8):1562-1571. 
175. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root 
H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, 
Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe 
LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families 
with Parkinson's disease. Science 276 (5321):2045-2047. 
176. Rengifo J, Gibson CJ, Winkler E, Collin T, Ehrlich BE (2007) Regulation of the 
inositol 1,4,5-trisphosphate receptor type I by O-GlcNAc glycosylation. J Neurosci  
27 (50):13813-13821. 
177. Rexach JE, Clark PM, Hsieh-Wilson LC (2008) Chemical approaches to 
understanding O-GlcNAc glycosylation in the brain. Nat Chem Biol 4 (2):97-106. 
178. Rexach JE, Rogers CJ, Yu SH, Tao J, Sun YE, Hsieh-Wilson LC (2010) 
Quantification of O-glycosylation stoichiometry and dynamics using resolvable 
mass tags. Nat Chem Biol 6 (9):645-651. 
179. Rissman RA, Lee KF, Vale W, Sawchenko PE (2007) Corticotropin-releasing factor 
receptors differentially regulate stress-induced tau phosphorylation. J neurosci 27 
(24):6552-6562. 
180. Rissman RA, Staup MA, Lee AR, Justice NJ, Rice KC, Vale W, Sawchenko PE 
(2012) Corticotropin-releasing factor receptor-dependent effects of repeated stress 
on tau phosphorylation, solubility, and aggregation. Proc Natl Acad Sci U S A 109 
(16):6277-6282. 
71 
181. Roos MD, Xie W, Su K, Clark JA, Yang X, Chin E, Paterson AJ, Kudlow JE (1998) 
Streptozotocin, an analog of N-acetylglucosamine, blocks the removal of O-GlcNAc 
from intracellular proteins. Proc Assoc Am Physicians 110 (5):422-432. 
182. Roquemore EP, Chou TY, Hart GW (1994) Detection of O-linked N-
acetylglucosamine (O-GlcNAc) on cytoplasmic and nuclear proteins. Methods 
Enzymol 230:443-460. 
183. Ross SA, Chen X, Hope HR, Sun S, McMahon EG, Broschat K, Gulve EA (2000) 
Development and comparison of two 3T3-L1 adipocyte models of insulin resistance: 
increased glucose flux vs glucosamine treatment. Biochem Biophys Res Commun 
273 (3):1033-1041. 
184. Ryu IH, Do SI (2011) Denitrosylation of S-nitrosylated OGT is triggered in LPS-
stimulated innate immune response. Biochem Biophys Res Commun 408 (1):52-57. 
185. Sakabe K, Wang Z, Hart GW (2010) Beta-N-acetylglucosamine (O-GlcNAc) is part 
of the histone code. Proc Natl Acad Sci U S A 107 (46):19915-19920. 
186. Sakurai H, Miyoshi H, Mizukami J, Sugita T (2000) Phosphorylation-dependent 
activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1. FEBS 
Lett 474 (2-3):141-145. 
187. Sayat R, Leber B, Grubac V, Wiltshire L, Persad S (2008) O-GlcNAc-glycosylation 
of beta-catenin regulates its nuclear localization and transcriptional activity. Exp Cell 
Res 314 (15):2774-2787. 
188. Shafi R, Lyer SPN, Ellies LG, O'Donnell N, Marek KW, Chui D, Hart GW, Marth 
JD (2000) The O-GlcNAc transferase gene resides on the X chromosome and is 
72 
essential for embryonic stem cell viability and mouse ontogeny. Proc Natl Acad Sci 
USA 97 (11):5735-5739. 
189. Shao Q, Saward L, Zahradka P, Dhalla NS (1998) Ca2+ mobilization in adult rat 
cardiomyocytes by angiotensin type 1 and 2 receptors. Biochem Pharmacol 55 
(9):1413-1418. 
190. Shen A, Kamp HD, Grundling A, Higgins DE (2006) A bifunctional O-GlcNAc 
transferase governs flagellar motility through anti-repression. Genes Dev 20 
(23):3283-3295. 
191. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider 
R, Mizuno Y, Kosik KS, Selkoe DJ (2001) Ubiquitination of a new form of alpha-
synuclein by parkin from human brain: implications for Parkinson's disease. Science 
293 (5528):263-269. 
192. Shin SH, Love DC, Hanover JA (2011) Elevated O-GlcNAc-dependent signaling 
through inducible mOGT expression selectively triggers apoptosis. Amino Acids 40 
(3):885-893. 
193. Shrikhande GV, Scali ST, da Silva CG, Damrauer SM, Csizmadia E, Putheti P, 
Matthey M, Arjoon R, Patel R, Siracuse JJ, Maccariello ER, Andersen ND, Monahan 
T, Peterson C, Essayagh S, Studer P, Guedes RP, Kocher O, Usheva A, Veves A, 
Kaczmarek E, Ferran C (2010) O-glycosylation regulates ubiquitination and 
degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in 
diabetic ApoE-null mice. PLoS One 5 (12):e14240. 
194. Sinclair DA, Syrzycka M, Macauley MS, Rastgardani T, Komljenovic I, Vocadlo 
DJ, Brock HW, Honda BM (2009) Drosophila O-GlcNAc transferase (OGT) is 
73 
encoded by the Polycomb group (PcG) gene, super sex combs (sxc). Proc Natl Acad 
Sci U S A 106 (32):13427-13432. 
195. Singleton KD, Wischmeyer PE (2008) Glutamine induces heat shock protein 
expression via O-glycosylation and phosphorylation of HSF-1 and Sp1. JPEN J 
Parenter Enteral Nutr 32 (4):371-376. 
196. Slawson C, Copeland RJ, Hart GW (2010) O-GlcNAc signaling: a metabolic link 
between diabetes and cancer? Trends Biochem Sci 35 (10):547-555. 
197. Slawson C, Lakshmanan T, Knapp S, Hart GW (2008) A mitotic 
GlcNAcylation/phosphorylation signaling complex alters the posttranslational state 
of the cytoskeletal protein vimentin. Mol Biol Cell 19 (10):4130-4140. 
198. Slawson C, Zachara NE, Vosseller K, Cheung WD, Lane MD, Hart GW (2005) 
Perturbations in O-linked beta-N-acetylglucosamine protein modification cause 
severe defects in mitotic progression and cytokinesis. J Biol Chem 280 (38):32944-
32956. 
199. Snow CM, Senior A, Gerace L (1987) Monoclonal antibodies identify a group of 
nuclear pore complex glycoproteins. J Cell Biol 104 (5):1143-1156. 
200. Sobott F, Watt SJ, Smith J, Edelmann MJ, Kramer HB, Kessler BM (2009) 
Comparison of CID versus ETD based MS/MS fragmentation for the analysis of 
protein ubiquitination. J Am Soc Mass Spectrom 20 (9):1652-1659. 
201. Soesanto YA, Luo B, Jones D, Taylor R, Gabrielsen JS, Parker G, McClain DA 
(2008) Regulation of Akt signaling by O-GlcNAc in euglycemia. Am J Physiol 
Endocrinol Metab 295 (4):E974-E980. 
74 
202. Sohn KC, Lee KY, Park JE, Do SI (2004) OGT functions as a catalytic chaperone 
under heat stress response: a unique defense role of OGT in hyperthermia. Biochem 
Biophys Res Commun 322 (3):1045-1051. 
203. Song M, Kim HS, Park JM, Kim SH, Kim IH, Ryu SH, Suh PG (2008) o-GlcNAc 
transferase is activated by CaMKIV-dependent phosphorylation under potassium 
chloride-induced depolarization in NG-108-15 cells. Cell Signal 20 (1):94-104. 
204. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) 
Alpha-synuclein in Lewy bodies. Nature 388 (6645):839-840. 
205. Sprung R, Nandi A, Chen Y, Kim SC, Barma D, Falck JR, Zhao Y (2005) Tagging-
via-substrate strategy for probing O-GlcNAc modified proteins. J Proteome Res 4 
(3):950-957. 
206. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, 
Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM (2006) Suppression of 
reactive oxygen species and neurodegeneration by the PGC-1 transcriptional 
coactivators. Cell 127 (2):397-408. 
207. Sumegi M, Hunyadi-Gulyas E, Medzihradszky KF, Udvardy A (2003) 26S 
proteasome subunits are O-linked N-acetylglucosamine-modified in Drosophila 
melanogaster. Biochemical and biophysical research communications 312 (4):1284-
1289. 
208. Syka JE, Coon JJ, Schroeder MJ, Shabanowitz J, Hunt DF (2004) Peptide and protein 
sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl 
Acad Sci U S A 101 (26):9528-9533. 
75 
209. Tarrant MK, Rho HS, Xie Z, Jiang YL, Gross C, Culhane JC, Yan G, Qian J, 
Ichikawa Y, Matsuoka T, Zachara N, Etzkorn FA, Hart GW, Jeong JS, Blackshaw 
S, Zhu H, Cole PA (2012) Regulation of CK2 by phosphorylation and O-
GlcNAcylation revealed by semisynthesis. Nat Chem Biol 8 (3):262-269. 
210. Teo CF, Ingale S, Wolfert MA, Elsayed GA, Not LG, Chatham JC, Wells L, Boons 
GJ (2010) Glycopeptide-specific monoclonal antibodies suggest new roles for O-
GlcNAc. Nat Chem Biol 6 (5):338-343. 
211. Toleman C, Paterson AJ, Shin R, Kudlow JE (2006) Streptozotocin inhibits O-
GlcNAcase via the production of a transition state analog. Biochem Biophys Res 
Commun 340 (2):526-534. 
212. Torres CR, Hart GW (1984) Topography and polypeptide distribution of terminal N-
acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-
linked GlcNAc. J Biol Chem 259 (5):3308-3317. 
213. Traxinger RR, Marshall S (1991) Coordinated Regulation of Glutamine:Fructose-6-
Phosphate Amidotransferase Activity by Insulin, Glucose, and Glutamine.  Role of 
Hexosamine Biosynthesis in Enzyme Regulation. J Biol Chem 266(16):10148-
10154. 
214. Tsujimoto Y (2003) Cell death regulation by the Bcl-2 protein family in the 
mitochondria. J Cell Physiol 195 (2):158-167. 
215. Tsujimoto Y, Nakagawa T, Shimizu S (2006) Mitochondrial membrane permeability 
transition and cell death. Biochim Biophys Acta 1757 (9-10):1297-1300. 
76 
216. Turner JR, Tartakoff AM, Greenspan NS (1990) Cytologic assessment of nuclear 
and cytoplasmic O-linked N-acetylglucosamine distribution by using anti-
streptococcal monoclonal antibodies. Proc Natl Acad Sci U S A 87 (15):5608-5612. 
217. Udeshi ND, Compton PD, Shabanowitz J, Hunt DF, Rose KL (2008) Methods for 
analyzing peptides and proteins on a chromatographic timescale by electron-transfer 
dissociation mass spectrometry. Nat protoc 3 (11):1709-1717. 
218. Udeshi ND, Shabanowitz J, Hunt DF, Rose KL (2007) Analysis of proteins and 
peptides on a chromatographic timescale by electron-transfer dissociation MS. FEBS 
J 274 (24):6269-6276. 
219. Vocadlo DJ, Hang HC, Kim EJ, Hanover JA, Bertozzi CR (2003) A chemical 
approach for identifying O-GlcNAc-modified proteins in cells. Proc Natl Acad Sci 
U S A 100 (16):9116-9121. 
220. Vosseller K, Trinidad JC, Chalkley RJ, Specht CG, Thalhammer A, Lynn AJ, 
Snedecor JO, Guan S, Medzihradszky KF, Maltby DA, Schoepfer R, Burlingame AL 
(2006) O-Linked N-Acetylglucosamine Proteomics of Postsynaptic Density 
Preparations Using Lectin Weak Affinity Chromatography and Mass Spectrometry. 
Mol Cell Proteomics 5 (5):923-934. 
221. Walgren JL, Vincent TS, Schey KL, Buse MG (2003) High glucose and insulin 
promote O-GlcNAc modification of proteins, including alpha-tubulin. Am J Physiol 
Endocrinol Metab 284 (2):E424-434. 
222. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ (2001) TAK1 is a 
ubiquitin-dependent kinase of MKK and IKK. Nature 412 (6844):346-351. 
77 
223. Wang J, Torii M, Liu H, Hart GW, Hu ZZ (2011) dbOGAP - an integrated 
bioinformatics resource for protein O-GlcNAcylation. BMC Bioinformatics 12:91. 
224. Wang Z, Gucek M, Hart GW (2008) Cross-talk between GlcNAcylation and 
phosphorylation: site-specific phosphorylation dynamics in response to globally 
elevated O-GlcNAc. Proc Natl Acad Sci U S A 105 (37):13793-13798. 
225. Wang Z, Pandey A, Hart GW (2007) Dynamic interplay between O-linked N-
acetylglucosaminylation and glycogen synthase kinase-3-dependent 
phosphorylation. Mol Cell Proteomics 6 (8):1365-1379. 
226. Wang Z, Udeshi ND, O'Malley M, Shabanowitz J, Hunt DF, Hart GW (2010a) 
Enrichment and site mapping of O-linked N-acetylglucosamine by a combination of 
chemical/enzymatic tagging, photochemical cleavage, and electron transfer 
dissociation mass spectrometry. Mol Cell Proteomics 9 (1):153-160. 
227. Wang Z, Udeshi ND, Slawson C, Compton PD, Sakabe K, Cheung WD, 
Shabanowitz J, Hunt DF, Hart GW (2010b) Extensive crosstalk between O-
GlcNAcylation and phosphorylation regulates cytokinesis. Sci Signal 3 (104):ra2. 
228. Wells L, Gao Y, Mahoney JA, Vosseller K, Chen C, Rosen A, Hart GW (2002a) 
Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization 
of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase. J Biol 
Chem 277 (3):1755-1761. 
229. Wells L, Kreppel LK, Comer FI, Wadzinski BE, Hart GW (2004) O-GlcNAc 
transferase is in a functional complex with protein phosphatase 1 catalytic subunits. 
J Biol Chem 279 (37):38466-38470. 
78 
230. Wells L, Vosseller K, Cole RN, Cronshaw JM, Matunis MJ, Hart GW (2002b) 
Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine 
post-translational modifications. Mol Cell Proteomics 1 (10):791-804. 
231. Whelan SA, Dias WB, Thiruneelakantapillai L, Lane MD, Hart GW (2010) 
Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin 
signaling by O-Linked beta-N-acetylglucosamine in 3T3-L1 adipocytes. J Biol Chem 
285 (8):5204-5211. 
232. Whelan SA, Lane MD, Hart GW (2008) Regulation of the O-linked beta-N-
acetylglucosamine transferase by insulin signaling. J Biol Chem 283 (31):21411-
21417. 
233. Whitworth GE, Macauley MS, Stubbs KA, Dennis RJ, Taylor EJ, Davies GJ, Greig 
IR, Vocadlo DJ (2007) Analysis of PUGNAc and NAG-thiazoline as transition state 
analogues for human O-GlcNAcase: mechanistic and structural insights into 
inhibitor selectivity and transition state poise. J Am Chem Soc 129 (3):635-644. 
234. Wischmeyer PE, Kahana M, Wolfson R, Ren H, Musch MM, Chang EB (2001) 
Glutamine reduces cytokine release, organ damage, and mortality in a rat model of 
endotoxemia. Shock 16 (5):398-402. 
235. Wrabl JO, Grishin NV (2001) Homology between O-linked GlcNAc transferases and 
proteins of the glycogen phosphorylase superfamily. J Mol Biol 314 (3):365-374. 
236. Wu SL, Huhmer AF, Hao Z, Karger BL (2007) On-line LC-MS approach combining 
collision-induced dissociation (CID), electron-transfer dissociation (ETD), and CID 
of an isolated charge-reduced species for the trace-level characterization of proteins 
with post-translational modifications. J Proteome Res 6 (11):4230-4244. 
79 
237. Xie W, Chung KK (2012) Alpha-synuclein impairs normal dynamics of 
mitochondria in cell and animal models of Parkinson's disease. J Neurochem 122 
(3):404-414. 
238. Xing D, Feng W, Not LG, Miller AP, Zhang Y, Chen YF, Majid-Hassan E, Chatham 
JC, Oparil S (2008) Increased protein O-GlcNAc modification inhibits inflammatory 
and neointimal responses to acute endoluminal arterial injury. Am J Physiol Heart 
Circ Physiol 295 (1):H335-H342. 
239. Xu SL, Chalkley RJ, Wang ZY, Burlingame AL (2012) Identification of O-linked 
beta-D-N-acetylglucosamine-modified proteins from Arabidopsis. Methods Mol 
Biol 876:33-45. 
240. Yang S, Zou LY, Bounelis P, Chaudry I, Chatham JC, Marchase RB (2006a) 
Glucosamine administration during resuscitation improves organ function after 
trauma hemorrhage. Shock 25 (6):600-607. 
241. Yang WH, Kim JE, Nam HW, Ju JW, Kim HS, Kim YS, Cho JW (2006b) 
Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and 
stability. Nat Cell Biol 8 (10):1074-1083. 
242. Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, So WV, Kudlow JE, Michell 
RH, Olefsky JM, Field SJ, Evans RM (2008) Phosphoinositide signalling links O-
GlcNAc transferase to insulin resistance. Nature 451 (7181):964-969. 
243. Yang YR, Song M, Lee H, Jeon Y, Choi EJ, Jang HJ, Moon HY, Byun HY, Kim EK, 
Kim DH, Lee MN, Koh A, Ghim J, Choi JH, Lee-Kwon W, Kim KT, Ryu SH, Suh 
PG (2012) O-GlcNAcase is essential for embryonic development and maintenance 
of genomic stability. Aging cell 11 (3):439-448. 
80 
244. Yuzwa SA, Macauley MS, Heinonen JE, Shan X, Dennis RJ, He Y, Whitworth GE, 
Stubbs KA, McEachern EJ, Davies GJ, Vocadlo DJ (2008) A potent mechanism-
inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem 
Biol 4 (8):483-490. 
245. Yuzwa SA, Shan X, Macauley MS, Clark T, Skorobogatko Y, Vosseller K, Vocadlo 
DJ (2012) Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against 
aggregation. Nat Chem Biol 8 (4):393-399. 
246. Zachara NE, Cheung WD, Hart GW (2004a) Nucleocytoplasmic glycosylation, O-
GlcNAc: identification and site mapping. Methods Mol Biol 284:175-194. 
247. Zachara NE, Molina H, Wong KY, Pandey A, Hart GW (2011a) The dynamic stress-
induced "O-GlcNAc-ome" highlights functions for O-GlcNAc in regulating DNA 
damage/repair and other cellular pathways. Amino Acids 40 (3):793-808. 
248. Zachara NE, O'Donnell N, Cheung WD, Mercer JJ, Marth JD, Hart GW (2004b) 
Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to 
stress. A survival response of mammalian cells. J Biol Chem 279 (29):30133-30142. 
249. Zachara NE, Vosseller K, Hart GW (2011b) Detection and analysis of proteins 
modified by O-linked N-acetylglucosamine. Curr Protoc Mol Biol Chapter 17:Unit 
17 16. 
250. Zachara NE, Vosseller K, Hart GW (2011c) Detection and analysis of proteins 
modified by O-linked N-acetylglucosamine. Curr Protoc Mol Biol Chapter 12:Unit 
8. 
251. Zhang F, Su K, Yang X, Bowe DB, Paterson AJ, Kudlow JE (2003) O-GlcNAc 
modification is an endogenous inhibitor of the proteasome. Cell 115 (6):715-725. 
81 
252. Zhang T, Miyamoto S, Brown JH (2004) Cardiomyocyte calcium and 
calcium/calmodulin-dependent protein kinase II: friends or foes? Recent Prog Horm 
Res 59:141-168. 
253. Zou L, Yang S, Champattanachai V, Hu S, Chaudry IH, Marchase RB, Chatham JC 
(2009) Glucosamine improves cardiac function following trauma-hemorrhage by 
increased protein O-GlcNAcylation and attenuation of NF-{kappa}B signaling. Am 
J PHysiol Heart Circ Physiol 296 (2):H515-H523. 
254. Zou L, Yang S, Hu S, Chaudry IH, Marchase RB, Chatham JC (2007) The protective 
effects of PUGNAc on cardiac function after trauma-hemorrhage are mediated via 









Characterization of tools to detect and enrich human and 
mouse O-GlcNAcase 











Originally published in Glycobiology. 2017 June 8. doi: 10.1093/glycob/cwx051. 
Format adapted for dissertation 
83 
Summary 
O-linked β-N-acetylglucosamine (O-GlcNAc) is an essential regulatory post-
translational modification of thousands of nuclear, cytoplasmic, and mitochondrial 
proteins. O-GlcNAc is dynamically added and removed from proteins by the O-GlcNAc 
transferase and the O-GlcNAcase (OGA), respectively. Dysregulation of O-GlcNAc-
cycling is implicated in the etiology of numerous diseases including tumorigenesis, 
metabolic dysfunction, and neurodegeneration. To facilitate studies focused on the role of 
O-GlcNAc and OGA in disease, we sought to identify commercially available antibodies 
that enable the enrichment of full-length OGA from lysates of mouse and human origin. 
Here, we report that antibodies from Abcam and Bethyl Laboratories can be used to 
immunoprecipitate OGA to near-saturation from human and mouse cell lysates. However, 
Western blotting analysis indicates that both antibodies, as well as three non-commercially 
available antibodies (OGA-345, OGA-346, OGA-352), detect full-length OGA and 
numerous cross-reacting proteins. These non-specific signals migrate similarly to full-
length OGA and are detected robustly, suggesting that the use of appropriate controls is 





O-linked b-N-acetylglucosamine (O-GlcNAc) is a regulatory post-translational 
modification (PTM) of nuclear, cytoplasmic, and mitochondrial proteins that plays key 
roles in cellular physiology and disease progression such as metabolic dysfunction, 
tumorigenesis, and neurodegeneration (Hart et al. 2011; Groves et al. 2013; Bond and 
Hanover 2015; Martinez et al. 2017). Underpinning these observations are thousands of O-
GlcNAc-modified proteins that regulate a broad range of cellular processes including 
epigenetics, transcription, translation, the cell cycle, and survival signaling (Hart et al. 
2011; Groves et al. 2013; Bond and Hanover 2015; Martinez et al. 2017). The dynamic 
cycling of O-GlcNAc on proteins is regulated by the concerted actions of enzymes encoded 
by just two genes: the O-GlcNAc transferase (OGT) (Haltiwanger et al. 1992; Kreppel et 
al. 1997; Lubas et al. 1997) and the O-GlcNAcase (OGA) (Dong and Hart 1994; Gao et al. 
2001; Wells et al. 2002), which add and remove O-GlcNAc, respectively. Highlighting 
their importance, OGT and OGA are essential for the viability of mice (Shafi et al. 2000; 
O'Donnell et al. 2004; Yang et al. 2012; Keembiyehetty et al. 2015).  
OGA is a neutral pH N-acetylglucosaminidase (Comtesse et al. 2001; Gao et al. 
2001; Wells et al. 2002) encoded by the meningioma expressed antigen 5 (Mgea5) gene. 
To date, five splice variants of OGA have been reported (Heckel et al. 1998; Comtesse et 
al. 2001; Gao et al. 2001; Schultz and Pils 2002; Wells et al. 2002; Toleman et al. 2004; Li 
et al. 2010; Keembiyehetty et al. 2011). Full-length OGA (fOGA; 916 amino acids; Figure 
2-1A), the most abundant isoform, contains an N-terminal 350 amino acid catalytic domain 
and a C-terminal histone acetyltransferase (HAT)-like domain that are separated by a linker 
region (Comtesse et al. 2001; Schultz and Pils 2002; Rao et al. 2013). The 677 amino acid 
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variant of OGA contains the same N-terminus as fOGA, but lacks the HAT-like domain 
and has an alternative C-terminal sequence (Comtesse et al. 2001; Schultz and Pils 2002; 
Kim et al. 2006; Li et al. 2010; Keembiyehetty et al. 2011). Additional isoforms include 
short OGA (Li et al. 2010), which contains only the catalytic domain, and two splice 
variants of rat origin that lack amino acids 250-345/398 (Toleman et al. 2004). 
Since the discovery of O-GlcNAc in 1984, the development of tools to probe O-
GlcNAc-signaling has been critical for understanding its role in regulating cellular 
physiology. While a cohort of antibodies has been developed for detecting and enriching 
O-GlcNAc and OGT, specific antibodies for probing OGA in a broad range of sample 
types/sources have lagged behind. The majority of OGA antibodies generated to date were 
raised against sequences from human OGA. Despite ~97% sequence identity between the 
human and mouse homologs of OGA, existing antibodies preferentially recognize human 
OGA and do not efficiently enrich mouse OGA. Thus, the goal of this study was to identify 
commercially available antibodies that enrich OGA to saturation from both human and 
mouse sources. These studies focused on antibodies from Abcam and Bethyl Laboratories, 
herein referred to as OGA-A and OGA-B, respectively. OGA-A was raised against a 
synthetic N-terminal peptide derived from human OGA (proprietary; Figure 2-1A), and is 
reported to react with both human and mouse OGA for Western blotting and 
immunoprecipitation applications. OGA-B, which was raised against amino acids 500-550 
(Figure 2-1A), is reported to react with only human OGA and is recommended for 
immunoprecipitation and Western blot detection of enriched OGA. This study also utilized 
non-commercially available antibodies (OGA-345, OGA-346, OGA-352) (Butkinaree et 
al. 2008), and the antigens used to generate these antibodies are outlined in Figure 2-1A. 
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Our studies demonstrate that all of the antibodies tested recognize fOGA by Western blot 
and that both commercially available antibodies enrich fOGA from human and mouse 
lysates. However, the presence of cross-reacting bands with a similar migration pattern to 
fOGA, especially in mouse cell lysates, suggests that careful antibody selection and data 




Figure 2-1: Detection of OGA with commercial and non-commercial antibodies. (A) Antigens in human 
OGA used to generate the antibodies used in this study. The N-terminal catalytic domain and C-terminal 
histone acetyltransferase (HAT)-like domain of full-length OGA are indicated. The yellow circle defines the 
Caspase-3 cleavage site (Asp413). The asterisk (*) denotes that the antibody from Abcam (OGA-A) was 
raised against a proprietary peptide within the first 50 amino acids of the N-terminus of OGA. OGA-B 
represents the antibody purchased from Bethyl Laboratories. (B) Equal amounts of protein (15 µg) from OGT 
wild type (WT) and null (D) mouse embryonic fibroblasts (MEFs), OGA WT and null MEFs, mouse liver 
tissue, U2OS human osteosarcoma cells, and HEPG2 human hepatocellular carcinoma cells were separated 
by SDS-PAGE. Western blots (WB) were performed for OGA (OGA-A, OGA-B, OGA-352, OGA-345, 
OGA-346), O-GlcNAc, and OGT (positive control). OGA-345 was used at high (0.33 µg/mL) and low (0.033 
µg/mL) concentrations. Protein load was assessed by Western blotting for HSC70 and by Sypro Ruby total 
protein staining. The blue star indicates full-length OGA (fOGA).   
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Results and discussion 
Detection of OGA by Western blotting 
To verify the specificity of OGA antibodies for Western blotting, we utilized lysates 
(15 µg) of human and mouse origin that included: U2OS human osteosarcoma cells, 
HEPG2 human hepatocellular carcinoma cells, mouse liver tissue, OGA wild type (WT) 
and null mouse embryonic fibroblasts (MEFs) (Keembiyehetty et al. 2015; Olivier-Van 
Stichelen et al. 2017), and OGT WT and null MEFs (Kazemi et al. 2010). Notably, OGA 
expression is tightly regulated by O-GlcNAc levels (Slawson et al. 2005; Kazemi et al. 
2010; Ghosh et al. 2014; Zhang et al. 2014), and we have previously demonstrated that 
OGA protein levels are significantly reduced in OGT null cells (Kazemi et al. 2010). As 
such, lysates from OGT null MEFs are a negative control for the detection of both OGT 
and OGA. OGA was detected by Western blot using the following antibodies: OGA-A, 
OGA-B, OGA-352, OGA-345, and OGA-346 (Figure 2-1B). Western blots were also 
performed using antibodies raised against O-GlcNAc, OGT, and heat shock cognate 70 
kDa protein (HSC70; loading control), and membranes were stained with Sypro Ruby as 
an additional loading control (Figure 2-1B).  
As expected, we observe a band at ~130 kDa using each OGA antibody that is not 
present in the OGT and OGA null MEFs (Figure 2-1B, blue star), suggesting that this band 
represents fOGA. OGA-A also detects strong signals at ~150 kDa and ~75 kDa in WT 
MEF lysates that are not reduced in the OGT and OGA nulls (Figure 2-1B). These data 
suggest that the only signal specific to OGA is that at ~130 kDa. OGA-B recognizes 
numerous bands, only one of which is significantly decreased by deletion of OGA and 
which migrates at ~130 kDa (fOGA). In U2OS cells, but not HEPG2 cells, OGA-B also 
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detects a doublet at ~130 kDa (Figure 2-1B). The presence of these additional bands likely 
underpins the application note from Bethyl Laboratories stating that this antibody does not 
perform satisfactorily for Western blots in crude lysates. Each of the non-commercial OGA 
antibodies (352, 345, 346) recognizes fOGA in the human and mouse samples tested, 
although cross-reactivity is observed (Figure 2-1B). OGA-352 and OGA-346 detect a 
strong signal at ~115 kDa, particularly in the MEFs (Figure 2-1B), and the identity of this 
protein is unknown. OGA-346 also reacts with a strong cross-reacting band just above 150 
kDa similar to OGA-A and OGA-B (Figure 2-1B). OGA-345 demonstrates the least cross-
reactivity (Figure 2-1B). Overall, all of the antibodies tested recognize fOGA in human 
and mouse cells, although cross-reacting bands warrant appropriate controls, such as 
deletion of OGA, to confirm specificity. 
Enrichment of OGA by immunoprecipitation 
We next assessed the utility of OGA-A and OGA-B for enriching fOGA from 
human and mouse lysates (Figure 2-2). These studies did not use the non-commercially 
available antibodies, as we have previously demonstrated that OGA-345 does not enrich 
fOGA to saturation and that there is significant background in the chicken immunoglobulin 
(Ig)Y isotype control immunoprecipitate (data not shown). Enriched OGA was detected by 
Western blot using OGA-A, OGA-B, and OGA-345. Western blotting using OGA-345 
reveals a band at ~130 kDa in the inputs and immunoprecipitates (Figure 2-2, left panel) 
representing fOGA (blue star), which is nearly absent in the unbound fractions (Figure 2-2, 
right panel) of the OGA but not IgG immunoprecipitates. These data suggest that OGA-A 
(0.5 µg per 100 µg lysate) and OGA-B (0.75 µg per 100 µg lysate) enrich endogenous 
fOGA to near-saturation from MEFs and U2OS cells. Western blotting using OGA-A and 
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OGA-B demonstrated that these antibodies detect a cross-reacting band at ~150 kDa in the 
MEFs (Figure 2-2). Importantly, OGA-A does not enrich this band (Figure 2-2), suggesting 
that this antibody is suitable for immunoprecipitating fOGA from both human and mouse 
sources. However, the ~150 kDa protein is enriched to saturation by OGA-B in the mouse 
cell lysates (Figure 2-2). Finally, following immunoprecipitation, OGA-A detects a greater 
amount of overall non-specific staining compared to OGA-B.  
Cross-reacting species detected by OGA-A, OGA-B, and OGA-346 near 150 kDa 
(Figure 2-1B) led us to initially consider the possibility of uncharacterized OGA isoforms. 
However, the presence of these signals in both the OGT and OGA null lysates does not 
support this hypothesis. Moreover, if the majority of the antibodies utilized in this study 
were detecting the same “uncharacterized isoform”, we would expect OGA-A to also 
recognize the ~150 kDa protein in the OGA-B MEF immunoprecipitates. As shown in 











Figure 2-2: Enrichment of human and mouse OGA by immunoprecipitation. Anti-OGA antibodies from 
Abcam (OGA-A) and Bethyl Laboratories (OGA-B), or a rabbit isotype control IgG, were used to enrich 
endogenous OGA from U2OS, MEF OGT WT, and MEF OGT null (D) lysates (400 µg). Incubation of 
antibody in buffer was used as a control. The inputs (2.5%), immunoprecipitates (IP; 25%; left panel), and 
unbound fractions (UB; 2.5%; right panel) were analyzed by SDS-PAGE. Western blots (WB) were 






The goal of this study was to identify commercial antibodies recognizing OGA that 
are useful for Western blotting and immunoprecipitation. Our studies highlight two 
commercially available antibodies (OGA-A, OGA-B) and three non-commercial 
antibodies (OGA-345, OGA-346, OGA-352) that recognize fOGA in both human and 
mouse lysates (Figure 2-1B). However, each antibody recognizes additional bands in the 
OGT and OGA null MEFs, indicating reactivity with proteins containing similar epitopes. 
Notably, these cross-reacting proteins often give a stronger signal than fOGA and are close 
in molecular weight to fOGA (Figure 2-1B, Figure 2-2). As such, use of ≤10% gels that 
provide adequate separation in this molecular weight range are ideal, as are controls in 
which OGA expression has been suppressed. Both OGA-A and OGA-B immunoprecipitate 
fOGA from human and mouse lysates to near-saturation, however, enrichment of a ~150 
kDa protein by OGA-B limits the utility of this antibody in lysates of mouse origin. While 
not addressed in this study, cross-reacting proteins will likely impede the use of OGA 
antibodies for immunofluorescence unless antibody specificity is robustly demonstrated. 
Collectively, our data characterize useful antibodies for immunoprecipitation and Western 
blotting of OGA from mouse and human sources, and highlight technical challenges that 




Materials and methods 
Antibodies 
The following antibodies were purchased: anti-OGA-A (ab124807; Abcam); anti-
OGA-B (A304-345A), anti-chicken IgY-horseradish peroxidase (HRP; A30-206P), rabbit 
isotype control IgG (P120-101; Bethyl Laboratories); anti-OGT (O6264), anti-mouse IgM-
HRP (A8786; Sigma-Aldrich); anti-HSC70 (sc-7298; Santa Cruz Biotechnology); and 
anti-rabbit IgG-HRP (NA934V) and anti-mouse IgG-HRP (NA931V; GE Healthcare). The 
following previously characterized antigen-purified antibodies were gifts: anti-OGA-345, 
anti-OGA-346, anti-OGA-352, and anti-O-GlcNAc (CTD110.6) (Comer and Hart 2000; 
Butkinaree et al. 2008). 
Cell and tissue preparation and extraction 
Cells were cultured in DMEM (Corning) containing 4.5 g/L (U2OS, HEPG2; 
American Type Culture Collection) or 1 g/L (OGT WT/null MEFs) glucose, 10% (v/v) 
heat inactivated fetal bovine serum (Thermo Fisher Scientific), and 1% (v/v) 
penicillin/streptomycin (Corning) as previously described (Kazemi et al. 2010; Groves et 
al. 2017). Deletion of OGT was induced with 4-hydroxytamoxifen 4-OHT or vehicle 
control (100% ethanol) for 40-44 h as previously reported (Kazemi et al. 2010). OGA WT 
and null MEF pellets (Keembiyehetty et al. 2015; Olivier-Van Stichelen et al. 2017) were 
a kind gift from the laboratory of John Hanover, Ph.D (National Institutes of Health (NIH)).  
Mouse care, procedures, and liver collections were performed as described (Groves 
et al. 2017). Cells and livers were lysed in NETN buffer and the protein concentrations 
were determined as reported (Groves et al. 2017). 
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Immunoprecipitation 
Endogenous OGA was enriched by incubating cell lysates or buffer with OGA-A, 
OGA-B, or rabbit isotype control IgG (16-20 h, 4°C, with rotation). Antibody-protein 
complexes were captured using protein G or A/G magnetic beads pre-blocked with bovine 
serum albumin, washed with NETN buffer, and eluted in Laemmli sample buffer 
containing dithiothreitol as described (Groves et al. 2017).   
Electrophoresis and Western blotting 
These procedures have been reported (Groves et al. 2017). Briefly, sodium dodecyl 
sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) was performed using 7.5% or 
10% Tris-Glycine eXtended polyacrylamide gels (Bio-Rad), and then proteins were 
electroblotted to nitrocellulose. Equal protein loading was assessed prior to blocking using 
the Sypro Ruby total protein membrane stain according to the manufacturer’s instructions. 
Membranes were blocked in 3% (w/v) non-fat milk in Tris-buffered saline with 0.05% 
(v/v) TWEEN-20 (1 h, 25°C), and then incubated with primary (16-20 h, 4°C) and HRP-
conjugated secondary (1 h, 25°C) antibodies. Western blots were developed using 
Immobilon Western Chemiluminescent Substrate (EMD Millipore) and captured on 
autoradiography film or the Amersham Imager 600 RGB (GE Healthcare). Membranes 
were stripped and re-probed as described (Groves et al. 2017).  
Reproducibility 
Four biological replicates were independently analyzed for Figure 2-1B, with the 
exception of OGA WT and null cells in which one biological replicate was used due to 




Antibodies for OGA (345, 346, 352) (Butkinaree et al. 2008) and O-GlcNAc 
(CTD110.6) (Comer and Hart 2000) were a kind gift from the O-GlcNAc resources Core 
C4 (Gerald Hart, Ph.D. and Natasha Zachara, Ph.D., Department of Biological Chemistry, 
The Johns Hopkins University School of Medicine). OGA WT and null cell pellets were 
provided by John Hanover, Ph.D. and Michelle Bond, Ph.D. (NIH) (Keembiyehetty et al. 
2015; Olivier-Van Stichelen et al. 2017), and OGT WT and null cell pellets were provided 
by Marissa Martinez, Ph.D. (Zachara laboratory, Department of Biological Chemistry, The 
Johns Hopkins University School of Medicine). This work was supported by grants from 
the NIH National Heart, Lung, and Blood Institute (P01HL107153 to NEZ) and the NIH 
National Institute on Aging (F31AG047724 to JAG). 
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Summary 
The dynamic post-translational modification O-linked-β-N-acetylglucosamine (O-
GlcNAc) regulates thousands of nuclear, cytoplasmic, and mitochondrial proteins. Cellular 
stress, including oxidative stress, results in increased O-GlcNAcylation of numerous 
proteins and this increase is thought to promote cell survival. The mechanisms by which 
the O-GlcNAc transferase (OGT) and the O-GlcNAcase (OGA), the enzymes that add and 
remove O-GlcNAc respectively, are regulated during oxidative stress to alter O-
GlcNAcylation are not fully characterized. Here, we demonstrate that oxidative stress leads 
to elevated O-GlcNAc levels in U2OS cells, but has little impact on the activity of OGT. 
In contrast, the expression and activity of OGA are enhanced. We hypothesized that this 
seeming paradox could be explained by proteins that bind to and control the local activity 
or substrate targeting of OGA, thereby resulting in the observed stress-induced elevations 
of O-GlcNAc. To identify potential protein partners, we utilized BioID proximity 
biotinylation in combination with Stable Isotopic Labeling of Amino acids in Cell culture 
(SILAC). This analysis revealed 90 OGA-interacting partners, many of which exhibited 
increased binding to OGA upon stress. The associations of OGA with fatty acid synthase 
(FAS), filamin-A, heat shock cognate 70 kDa protein, and OGT were confirmed by co-
immunoprecipitation. The pool of OGA bound to FAS demonstrated a substantial (~85%) 
reduction in specific activity, suggesting that FAS inhibits OGA. Consistent with this 
observation, FAS overexpression augmented stress-induced O-GlcNAcylation. While the 
mechanism by which FAS sequesters OGA remains unknown, these data suggest that FAS 
fine-tunes the cell’s response to stress and injury by remodeling cellular O-GlcNAcylation. 
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Introduction 
The modification of intracellular proteins by monosaccharides of O-linked β-N-
acetylglucosamine (O-GlcNAc) has emerged as an essential and dynamic post-
translational modification (PTM) of metazoans (Hart et al. 2011; Groves et al. 2013; Bond 
and Hanover 2015). O-GlcNAcylation is regulated by two enzymes, the O-GlcNAc 
transferase (OGT) (Kreppel et al. 1997; Lubas et al. 1997) and the O-GlcNAcase (OGA) 
(Gao et al. 2001; Wells et al. 2002), which catalyze the addition and removal of O-GlcNAc, 
respectively. OGT utilizes the nucleotide sugar uridine diphosphate (UDP)-GlcNAc 
(Haltiwanger et al. 1992; Bond and Hanover 2015), which is synthesized by the 
hexosamine biosynthetic pathway (HBP) (Hart et al. 2011; Groves et al. 2013; Bond and 
Hanover 2015). Highlighting the importance of O-GlcNAcylation in the maintenance of 
cellular homeostasis, Ogt, Mgea5 (OGA), and Pgm3, a key enzyme in the HBP, are 
essential for the viability of cells, tissues, and organisms (Shafi et al. 2000; O'Donnell et 
al. 2004; Greig et al. 2007; Yang et al. 2012). 
O-GlcNAcylation of cellular proteins is implicated in the regulation of diverse 
cellular pathways and processes such as development, aging, inflammation, cell cycle 
regulation, metabolic sensing, and the cellular stress response, the focus of this study 
(Zachara et al. 2004; Hart et al. 2011; Groves et al. 2013; Bond and Hanover 2015). O-
GlcNAc levels are dynamically elevated in response to many forms of cellular stress 
(Zachara et al. 2004; Jones et al. 2008), including oxidative stress (Zachara et al. 2004; 
Jones et al. 2008) and ischemia reperfusion (I/R) injury (Liu et al. 2006; Fülöp et al. 2007; 
Champattanachai et al. 2008; Jones et al. 2008; Ngoh et al. 2011; Vibjerg Jensen et al. 
2013). Elevating O-GlcNAc levels prior to (Zachara et al. 2004; Liu et al. 2006; Nagy et 
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al. 2006; Champattanachai et al. 2007; Fülöp et al. 2007; Champattanachai et al. 2008; 
Jones et al. 2008; Ngoh et al. 2008; 2009a; 2009b; Hwang et al. 2010; Laczy et al. 2010; 
Ngoh et al. 2011) or immediately after (Yang et al. 2006; Liu et al. 2007; Nöt et al. 2007; 
Zou et al. 2007; Nöt et al. 2010) injury significantly improves survival. In contrast, 
decreasing O-GlcNAc levels sensitizes cells and tissues to apoptosis and necrosis (Zachara 
et al. 2004; Ngoh et al. 2008; 2009a; 2009b; 2011). Together, these studies suggest that 
stress-induced changes in protein O-GlcNAcylation promote survival signaling.  
Alterations in the expression, activity, localization, and targeting of OGT and OGA, 
as well as increased flux through the HBP, have been correlated with stress-induced 
changes in O-GlcNAcylation. For example, various cell culture models of stress result in 
enhanced O-GlcNAcylation that has been correlated with increases in the expression 
(Zachara et al. 2004; Cheung and Hart 2008), activity (Zachara et al. 2004; Ryu and Do 
2011), and targeting (Cheung and Hart 2008) of OGT. In both ex vivo (Fülöp et al. 2007) 
and in vivo (Wang et al. 2014) rodent models of cardiac I/R injury, O-GlcNAc levels are 
elevated concomitant with UDP-GlcNAc levels. Furthermore, increased O-GlcNAc levels 
have been correlated with elevated OGT expression (Vibjerg Jensen et al. 2013) and 
activity (Jensen et al. 2013; Vibjerg Jensen et al. 2013), as well as decreased OGA activity 
(Jensen et al. 2013), in models of ischemic preconditioning. The mechanisms controlling 
the activity and substrate specificity of OGT and OGA in models of cellular injury remain 
unknown. However, it is generally accepted that these enzymes, like RNA polymerase II 
(Seither et al. 1998), exist as holoenzymes; that is, the proteins they interact with regulate 
their specificity and activity (Wells et al. 2003; Hart et al. 2011).  
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To identify protein candidates that regulate O-GlcNAc during oxidative stress, we 
have focused on the regulation of the full-length and predominant isoform of OGA 
(Comtesse et al. 2001; Gao et al. 2001; Wells et al. 2002; Hart et al. 2011; Groves et al. 
2013; Bond and Hanover 2015). We have identified the basal and oxidative stress-
dependent protein-protein interactions of OGA using proximity biotinylation (Roux et al. 
2012) coupled with Stable Isotopic Labeling of Amino acids in Cell culture (SILAC)-based 
proteomics (Ong et al. 2002; Amanchy et al. 2005; Zachara et al. 2011). A total of 90 
interaction partners of OGA were identified, many of which exhibit increased association 
with oxidative stress, including fatty acid synthase (FAS), filamin-A (FLNA), heat shock 
cognate 70 kDa protein (HSC70), and OGT. The pool of OGA bound to FAS exhibited a 
significant reduction (~85%) in catalytic activity. Consistent with the stress-induced 
inhibition of OGA by FAS, we observed elevated O-GlcNAcylation on a subset of proteins 
during oxidative stress in FAS-overexpressing cells. These results suggest a novel 
mechanism by which the components of two metabolic-sensing pathways, O-GlcNAc 






Oxidative stress increases OGT and OGA expression, OGA activity, and O-
GlcNAc levels 
To characterize the mechanisms that cells use to modulate O-GlcNAc levels in 
response to oxidative stress, we first assessed the activity and expression of OGT and OGA 
in U2OS human osteosarcoma cells exposed to the oxidant hydrogen peroxide (H2O2; 2.5 
mM, 1-3 h). Normalization was performed against the housekeeping protein actin, whose 
expression is not affected by H2O2 treatment (Figure 3-1A, B). Consistent with our 
previous data (Zachara et al. 2004; Jones et al. 2008), there is a time-dependent increase in 
O-GlcNAc levels upon the induction of oxidative stress that is significant at 3 h (Figure 
3-1A, C; repeated measures one-way analysis of variance (RM-1ANOVA)/Dunnett’s 
multiple comparison test (MCT), p≤0.01). The increase in O-GlcNAc levels is 
accompanied by an elevation in the expression of OGT at 3 h (Figure 3-1A, D; RM-
1ANOVA/Dunnett’s MCT, p≤0.0001). While we did not observe a statistically significant 
increase in OGT activity (Figure 3-1E), the fold change increase in OGT expression at 2 h 
and 3 h parallels that of OGT activity. Interestingly, we detected a modest but significant 
augmentation of OGA expression (Figure 3-1A, F; RM-1ANOVA/ Dunnett’s MCT, 
p≤0.01) and activity (Figure 3-1G; RM-1ANOVA/Dunnett’s MCT, p≤0.05 (2 h), p≤0.0001 
(3 h)) after 2 h and 3 h of oxidative stress. These data suggest that increased O-
GlcNAcylation during oxidative stress cannot be attributed solely to global changes in the 
expression and activity of OGT or OGA. Together, these findings suggest that the substrate 
specificity of OGA may be modulated during oxidative stress, likely resulting from 
changes in its targeting or local activity. As protein-protein interactions are integral to the 
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targeting of many enzymes including OGT (Cheung and Hart 2008; Cheung et al. 2008; 
Hart et al. 2011; Groves et al. 2013; Bond and Hanover 2015), we hypothesized that OGA 
may be regulated in a similar manner. 
 
Figure 3-1: Oxidative stress increases OGT and OGA expression, OGA activity, and O-GlcNAc levels. 
U2OS cells were treated with vehicle (V) or H2O2 (2.5 mM, 1-3 h). N=10, unless otherwise indicated. (A) 
The expression of OGT, OGA, and actin, as well as O-GlcNAc levels, was assessed in NETN lysates (5 µg) 
by Western blot (WB). Protein load was assessed by total protein stain (colloidal Coomassie G-250) and by 
Western blot (actin). Molecular weight (MW) markers are indicated. (B) Quantitation of actin normalized to 
total protein (G-250). (C) Quantitation of O-GlcNAc levels normalized to actin. (D) Quantitation of OGT 
expression normalized to actin. (E) NETN lysates (5 µg) were assayed for OGT activity using 3H-UDP-
GlcNAc (0.5 µCi) and CKII acceptor peptide (1 mM). N=4, 3 technical replicates per assay. (F) Quantitation 
of OGA expression normalized to actin. (G) NETN lysates (5 µg) were assayed for OGA activity using 4MU-
GlcNAc (1 mM). N=6, 2 technical replicates per assay. (B-G) Data are presented as the mean ± SEM. 
Significance was determined by RM-1ANOVA followed by Dunnett’s multiple comparison test and 
differences were considered statistically significant at p≤0.05 (*), p≤0.01 (**), and p≤0.0001 (****). 
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The OGA-mBirA fusion proteins express, maintain catalytic activity, and 
biotinylate proteins in vivo 
In order to identify the proteins that bind to and regulate OGA, we utilized the 
BioID proximity biotinylation methodology (Roux et al. 2012; 2013; Varnaitė and 
MacNeill 2016). This technique relies on the Escherichia coli biotin ligase BirA, which 
contains a single point mutation (R118G; herein referred to as mBirA) enabling it to release 
activated biotin and this results in the biotinylation of proteins within a ~10 nm radius 
(Kwon and Beckett 2000; Choi-Rhee et al. 2004; Cronan 2005; Kim et al. 2014; Varnaitė 
and MacNeill 2016). OGA is a large protein (916 amino acids) containing two domains, 
an N-terminal catalytic domain (β-N-acetylglucosaminidase; CD; amino acids 1-350) and 
a C-terminal histone acetyltransferase (HAT)-like domain (amino acids 583-916), which 
are separated by a linker (Figure 3-2A) (Gao et al. 2001; Schultz and Pils 2002; Wells et 
al. 2002). As such, full-length OGA was cloned in-frame on the N-terminus of mBirA-HA 
(OGA-mBirA-HA) or the C-terminus of Myc-mBirA (Myc-mBirA-OGA) to provide 
greater coverage of the OGA interactome (Figure 3-2A). The fusion constructs and a 
control vector (pcDNA3.1) were transiently transfected into U2OS cells and treated with 
or without biotin. Western blot analysis demonstrates that OGA-mBirA-HA and Myc-
mBirA-OGA are overexpressed (Figure 3-2B). Of note, Myc-mBirA-OGA appears to be 
modestly stabilized by the addition of exogenous biotin, which is consistent with previous 
observations (Figure 3-2B; (Roux et al. 2012; Coyaud et al. 2015)). To determine if the 
fusion proteins maintain β-N-acetylglucosaminidase activity, desalted total cell lysates 
(TCL) were incubated with the small fluorescent small molecule substrate 4-
methylumbelliferyl (4MU)-GlcNAc. Both fusion proteins maintain catalytic activity, 
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which is enhanced by the addition of exogenous biotin (Figure 3-2C). Interestingly, 
endogenous OGA activity is significantly elevated in pcDNA3.1-transfected cells treated 
with biotin (ratio-paired t-test (RPT), p≤0.05, N=3). 
 
Figure 3-2: The OGA-mBirA fusion proteins express, maintain catalytic activity, and biotinylate 
proteins in vivo. (A) Schematic of the OGA-mBirA fusion proteins. CD and HATL represent the catalytic 
(β-N-acetylglucosaminidase) domain and histone acetyltransferase-like domain of OGA, respectively. (B-D) 
U2OS cells were transfected with pcDNA3.1, OGA-mBirA-HA, or Myc-mBirA-OGA, and treated with or 
without biotin (25 µM, 16 h) or TMG (100 nM, 20 h) as indicated. Proteins were extracted in TCL buffer. 
(B) Equal amounts of protein (10 µg) were separated by SDS-PAGE and the following were detected by 
Western blot (WB): OGA, HA, Myc, and actin. N=3. (C) Desalted lysates were assayed for OGA activity 
using 4MU-GlcNAc (1 mM). N=3, representative data from one experiment is shown. Error bars indicate the 
intra-assay standard deviation from two technical replicates. (D) Equal amounts of protein (4.5 µg) were 
separated by SDS-PAGE and the following were detected by Western blot: biotin, O-GlcNAc, OGA, HA, 
Myc, and actin. N=2. Migration of endogenous OGA (e), mBirA-tagged OGA (b), and the molecular weight 
(MW) markers are indicated. 
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To determine if the fusion proteins biotinylate proximal proteins in vivo, cell lysate 
was separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis 
(PAGE) and biotinylated proteins were detected with NeutrAvidin-horseradish peroxidase 
(HRP). Of note, two signals were observed in the pcDNA3.1 transfected cells at ~130 kDa 
and ~80 kDa (Figure 3-2D). These molecular weights are consistent with the endogenously 
biotinylated mammalian carboxylases (acetyl-CoA carboxylase, pyruvate carboxylase, 3-
methylcrotonyl-CoA carboxylase, propionyl-CoA carboxylase) (Moss and Lane 1971; 
Tong 2013) and have been previously reported (Roux et al. 2012; 2013). Overexpression 
of OGA-mBirA-HA and Myc-mBirA-OGA in the presence of exogenous biotin leads to 
the appearance of numerous biotinylated proteins (Figure 3-2D). The biotinylation patterns 
of OGA-mBirA-HA and Myc-mBirA-OGA are different, suggesting that our dual-tagging 
strategy provides greater coverage of the OGA interactome (Figure 3-2D). One potential 
control for our studies is overexpression of mBirA alone. However, mBirA-HA and Myc-
mBirA biotinylate proteins in a promiscuous manner when compared to their OGA-mBirA 
counterparts (Figure 3-3). As such, mBirA was not used as a control for subsequent 
experiments and this is in accordance with previous BioID studies (Roux et al. 2012; 2013; 
Varnaitė and MacNeill 2016).  
To determine whether interacting partners of OGA are predominantly substrates, 
cells were treated with the OGA inhibitor 2-ethylamino-3aR, 6S, 7R, 7aR-tetrahydro-5R-
hydroxymethyl-5H-pyrano[3, 2-d]thiazole-6, 7-diol (Thiamet-G; TMG) (Yuzwa et al. 
2008). Interestingly, there is not a dramatic change in the biotinylation pattern for either 
fusion protein with the addition of TMG. These data suggest that the biotinylated proteins 
are not predominantly substrates of OGA (Figure 3-2D).  
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Figure 3-3: The biotinylation pattern produced by OGA-mBirA-HA and Myc-mBirA-OGA is different 
to that of mBirA alone. Cells were transfected with mBirA-HA, OGA-mBirA-HA, Myc-mBirA, or Myc-
mBirA-OGA, and treated with or without H2O2 (2.5 mM, 2 h). Non-transfected wild type (WT) U2OS cells 
were treated with vehicle. All cells were treated with biotin (25 µM, 16 h). Equal amounts of protein (5 µg; 
TCL lysates) were separated by SDS-PAGE and the following were detected by Western blot (WB): biotin, 
OGA, HA, Myc, and actin. The migration of endogenous OGA (e), mBirA-tagged OGA (b), and the 





The localization and in vivo biotinylation of the OGA-mBirA fusion proteins was 
confirmed by indirect immunofluorescence. As a control, we first determined the 
localization of endogenous OGA in U2OS cells. Our data demonstrate that OGA staining 
is detected in the nucleus and cytoplasm of U2OS cells under basal conditions (Figure 3-4), 
which is consistent with previous reports describing the subcellular localization of 
endogenous full-length OGA (Comtesse et al. 2001; Gao et al. 2001). OGA has recently 
been demonstrated to exist in mitochondria of neonatal rat cardiomyocytes (Banerjee et al. 
2015), and the orange signal in the merged images (Figure 3-4; white triangles) may 
represent co-localization of OGA (green) and MitoTracker (red). Upon oxidative stress, 
we observe an increase in OGA staining that is consistent with the Western blot analysis 
(Figure 3-1A, F), but the overall pattern of localization remains unchanged.  
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Figure 3-4: Endogenous OGA localizes to the nucleus, cytoplasm, and mitochondria of U2OS cells. 
U2OS cells were fixed, permeabilized, and stained for OGA. Nuclei and mitochondria were stained with 
Hoechst 33342 and MitoTracker Orange CMTMRos, respectively. White triangles indicate co-localization 
(orange) of MitoTracker and OGA. Images were acquired at 63x magnification on a Zeiss Axio Examiner 
710NLO-Meta multiphoton microscope. N=3. The scale bar represents 15 µm. (A) Cells were treated with 
vehicle. (B) Cells were treated with H2O2 (2.5 mM, 2 h). 
 
Like endogenous OGA, OGA-mBirA-HA (Figure 3-5B, C) and Myc-mBirA-OGA 
(Figure 3-5E, F) are present in the nucleus and cytoplasm. However, the overexpressed 
protein appears to have a more cytosolic distribution than the endogenous protein (Figure 
3-4). Similar to the staining pattern of endogenous OGA, the orange signal in the merged 
images (Figure 3-5B, E; white triangles) may represent co-localization of the OGA-mBirA 
fusion proteins with MitoTracker. Biotinylation, which is stimulated by the addition of 
exogenous biotin, is observed in cells overexpressing OGA-mBirA-HA (Figure 3-5C) and 
Myc-mBirA-OGA (Figure 3-5F). Faint staining for biotin in control cells (pcDNA3.1; 
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Figure 3-5A) can be attributed to the endogenously biotinylated mammalian carboxylases 
described above. Finally, the localization and biotinylation of OGA-mBirA-HA (Figure 
3-5D) and Myc-mBirA-OGA (Figure 3-5G) are not altered by oxidative stress. 
OGA-mBirA-HA and Myc-mBirA-OGA biotinylate proximal proteins 
differentially in response to oxidative stress 
To determine if oxidative stress alters the interactome of OGA, cells were 
transfected with the OGA-mBirA constructs and treated with biotin and H2O2 (2 h). 
Western blotting for biotin demonstrates that OGA-mBirA-HA and Myc-mBirA-OGA 
each exhibit a markedly altered biotinylation pattern in response to oxidative stress (Figure 
3-6A). These data suggest that oxidative stress induces a change in the proteins associating 
with OGA, wherein some interactions appear to be augmented while others are decreased 
(Figure 3-6A). Similar to the results described above, OGA-mBirA-HA and Myc-mBirA-
OGA have distinct biotinylation patterns. These results are further illustrated in the 
densitometric total lane profiling of the biotin signal (Figure 3-6B). Importantly, 
endogenous biotinylation and biotinylation by mBirA-HA and Myc-mBirA are not altered 
by oxidative stress (Figure 3-3). These data suggest that changes in the biotinylation pattern 
are not a result of changes in mBirA activity, but rather are due to specific changes in 




Figure 3-5: The OGA-mBirA fusion proteins localize to and biotinylate proteins in the nucleus, 
cytoplasm, and mitochondria of U2OS cells. U2OS cells were transfected with pcDNA3.1 (A), OGA-
mBirA-HA (B-D), or Myc-mBirA-OGA (E-G), treated with (A, C, D, F, G) or without (B, E) biotin (25 µM, 
16 h), and treated with (D, G) or without (A, B, C, E, F) H2O2 (2.5 mM, 2 h). Cells were fixed, permeabilized, 
and stained for BirA and biotin. Nuclei and mitochondria were stained with Hoechst 33342 and MitoTracker 
Orange CMTMRos, respectively. White triangles indicate co-localization (orange) of MitoTracker and OGA 
(B, E). Images were acquired at 63x magnification on a Zeiss Axio Examiner 710NLO-Meta multiphoton 
microscope. N=3. The scale bar represents 15 µm. 
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Figure 3-6: OGA-mBirA-HA and Myc-mBirA-OGA biotinylate proximal proteins differentially in 
response to oxidative stress. U2OS cells were transfected with pcDNA3.1, OGA-mBirA-HA, or Myc-
mBirA-OGA and treated with biotin (25 µM, 16 h) in the presence or absence of H2O2 (2.5 mM, 2 h). (A) 
Equal amounts of protein (5 µg; denaturing TCL lysis) were separated by SDS-PAGE and the following were 
detected by Western blot (WB): biotin, O-GlcNAc, OGA, HA, Myc, and actin. N=4. (B) Densitometric total 
lane profiles for each lane from the biotin signal in (A). Asterisks are used to highlight a subset of the 
biotinylated signals that are altered by oxidative stress. Migration of endogenous OGA (e), mBirA-tagged 
OGA (b), and the molecular weight (MW) markers are indicated. 
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SILAC-BioID-MS/MS reveals numerous basal and stress-induced OGA-
interacting proteins 
To identify the proteins bound by OGA in basal and oxidatively stressed cells, we 
performed two SILAC-based proteomic experiments (Figure 3-7). In all cases, the heavy 
(H) SILAC-labeled cells were transfected with pcDNA3.1, and the light (L) and medium 
(M) labeled cells were transfected with OGA-mBirA-HA (Experiment 1) or Myc-mBirA-
OGA (Experiment 2) (Figure 3-7A). Following transient transfection, biotinylation was 
stimulated and the cells were treated with vehicle (V; medium SILAC label) or 2 h H2O2 
(light SILAC label) prior to harvesting (Figure 3-7A). SILAC-labeled proteins were 
extracted in denaturing TCL buffer and combined in equal amounts (Figure 3-7A, B). 
Biotinylated proteins in the 1:1:1 extract mixture were enriched using NeutrAvidin-
agarose, eluted with SDS (95°C), and precipitated twice with acetone to remove free SDS. 
Peptides were generated by digestion with trypsin and LysC, and the resulting peptides 
were subjected to offline basic reversed phase (bRP) fractionation followed by reversed 
phase (RP) liquid chromatography (LC)-electrospray ionization (ESI)-tandem mass 
spectrometry (MS/MS) (Figure 3-7A). The mass spectrometry (MS) proteomics data have 
been deposited to the ProteomeXchange Consortium (http://proteomecentral. 
proteomexchange.org) via the PRIDE partner repository (Martens et al. 2005; Côté et al. 
2012; Vizcaíno et al. 2014; Perez-Riverol et al. 2016; Vizcaíno et al. 2016) with the dataset 
identifier PXD005039.  
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Figure 3-7: SILAC-BioID-MS/MS strategy used to identify the basal and oxidative stress-dependent 
interactome of OGA. (A) U2OS cells were labeled with light, medium, or heavy isotopes of arginine and 
lysine for 6 generations. In experiment 1, cells were transfected with pcDNA3.1 (heavy) or OGA-mBirA-
HA (light, medium), treated with biotin (25 µM, 16 h), and treated with vehicle (medium, heavy) or H2O2 
(light; 2.5 mM, 2 h, N=1). In experiment 2, Myc-mBirA-OGA was transfected in replacement of OGA-
mBirA-HA. For each experiment, proteins were extracted in denaturing TCL buffer and combined in equal 
amounts. The biotinylated proteins were isolated on NeutrAvidin-agarose in denaturing conditions, eluted in 
2% (w/v) SDS (95oC), and precipitated with acetone. Peptides were generated by trypsin and LysC digestion, 
separated by basic reversed phase (bRP) fractionation, and identified by liquid chromatography-tandem mass 
spectrometry (LC-ESI-MS/MS). Subsequently, protein-protein interactions were validated by co-
immunoprecipitation (IP) and Western blot (WB). (B) For the SILAC experiments (N=1, each), equal 
amounts of protein (10 µg; denaturing TCL lysis) were separated by SDS-PAGE and the following were 
detected by Western blot: biotin, OGA, HA, Myc, and actin. Protein load was assessed by total protein stain 
(Sypro Ruby) and by Western blot (actin). Migration of endogenous OGA (e), mBirA-tagged OGA (b), and 





Raw MS protein and peptide identifications are reported in Supplemental Tables 3-
1 through 3-6, and processing of the raw MS data, as described below, is outlined in Figure 
3-8. LC-MS/MS identified 126 proteins in the OGA-mBirA-HA pulldown (Supplemental 
Table 3-7) and 157 proteins in the Myc-mBirA-OGA pulldown (Supplemental Table 3-8) 
after application of the following inclusion criteria in Proteome Discover 1.4: a peptide 
rank of 1 (filter 1), a 5% false discovery rate (FDR; filter 1), as well as >1 unique peptide, 
>2 total peptides, and >3 peptide spectral matches (PSMs) per identification (filter 2). Next, 
the variability in the endogenously biotinylated carboxylases was used to set a threshold 
for excluding non-specific interactors (Figure 3-8 (exclusion criteria 2), Figure 3-9; 
Supplemental Table 3-9), yielding 44 proteins and 41 proteins enriched above background 
for the HA (Figure 3-10A; Supplemental Table 3-10) and Myc (Figure 3-10B; 
Supplemental Table 3-11) screens, respectively. To determine the interactors that are 
induced upon oxidative stress, we set a threshold of a 25% increase in protein abundance 
in stressed cells compared to control cells (Supplemental Table 3-12). For the OGA-
mBirA-HA pulldown, 48 proteins were identified as stress-induced interactors, of which 
19 were present above background in only the stressed sample (Figure 3-10A; 
Supplemental Table 3-10). For the Myc-mBirA-OGA fusion protein, 28 proteins were 
identified as stress-induced interactors. Of these proteins, 12 were identified above 
background in only the stressed sample (Figure 3-10B; Supplemental Table 3-11). 
Highlighting the utility of our dual-tagging strategy for maximizing coverage of the OGA 
interactome, there were only 21 basal interactors (Figure 3-10C) and 15 stress-induced 
interactors (Figure 3-10D) that were present in both the HA and Myc datasets. MS protein 
identifications are summarized in Supplemental Table 3-13. In total, 90 proteins were 
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identified as potential OGA-interactors using SILAC-BioID-MS/MS (Table 3-1). Of these 
interactors, we identified 21 proteins above background in the basal and stressed samples 
(regardless of fold change upon stress) from both datasets (Figure 3-10E), and consider 
these proteins to be high-confidence binding partners of OGA (bold, Table 3-1). Finally, 
gene list analysis using the Protein Analysis Through Evolutionary Relationships 
(PANTHER) (Thomas et al. 2003; Mi et al. 2005) classification system revealed that the 
identified proteins have diverse functions, belonging to classes of chaperones, cytoskeletal 




Figure 3-8: Flowchart for mass spectrometry dataset processing to generate the protein lists in the 
supplemental tables and table 3-1. 
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Figure 3-9: Determination of the threshold for non-specific interactors using Log2 SILAC ratios and 
frequency histograms of the endogenously biotinylated carboxylases. Frequency histograms were 
generated from: (A) Log2(M/H) SILAC ratios for the carboxylases (HA dataset; Supplemental Table 3-9); 
(B) Log2(M/H) SILAC ratios for raw interactors (HA dataset; Supplemental Table 3-7); (C) Log2(L/H) 
SILAC ratios for the carboxylases (HA dataset; Supplemental Table 3-9); (D) Log2(L/H) SILAC ratios for 
raw interactors (HA dataset; Supplemental Table 3-7); (E) Log2(M/H) SILAC ratios for the carboxylases 
(Myc dataset; Supplemental Table 3-9); (F) Log2(M/H) SILAC ratios for raw interactors (Myc dataset; 
Supplemental Table 3-8); (G) Log2(L/H) SILAC ratios for the carboxylases (Myc dataset; Supplemental 
Table 3-9); and (H) Log2(L/H) SILAC ratios for raw interactors (Myc dataset; Supplemental Table 3-8). (A-






Figure 3-10: SILAC-BioID-MS/MS reveals numerous basal and stress-induced OGA-interacting 
proteins. Venn diagrams illustrate: (A) basal and stress-induced interactors identified in the OGA-mBirA-
HA screen; (B) basal and stress-induced interactors identified in the Myc-mBirA-OGA screen; (C) basal 
interactors identified in the HA and Myc datasets; (D) stress-induced interactors identified in the HA and 
Myc datasets; and (E) interactors identified above background in the basal and stressed samples (regardless 
of fold change upon stress) in the HA and Myc datasets. (F) PANTHER gene list analysis indicating the 
protein classes represented in the OGA interactome. 
Table 3-1: Interacting partners of OGA. Bold proteins are high confidence interactors that were identified in the basal and stressed samples in the HA and Myc 
datasets. 
   HA Dataset Myc Dataset 












1 25777602 26S proteasome non-ATPase regulatory subunit 2 isoform 1    ü á 2.410 
2 16507237 78 kDa glucose-regulated protein precursor ü á 1.627 ü á 1.709 
3 546231404 actin-binding protein anillin isoform 3 ü á 1.719    
4 156071459 ADP/ATP translocase 2 ü  1.042    
5 194097352 alpha-actinin-1 isoform c  á 4.834  á 6.123 
6 224809474 ankycorbin isoform b ü  1.310    
7 50845386 annexin A2 isoform 2  á 2.000  á 1.719 
8 21264575 AT-rich interactive domain-containing protein 1A isoform b ü  1.012    
9 528281421 band 4.1-like protein 3 isoform 3 ü  1.222 ü  1.389 
10 62241042 bifunctional glutamate/proline--tRNA ligase ü á 1.621 ü  1.328 
11 11024698 bifunctional protein NCOAT isoform a ü  1.057 ü  1.308 
12 58218968 calmodulin     á 2.772 
13 24432106 cell cycle and apoptosis regulator protein 2 ü á 1.756    
14 5031635 cofilin-1     á 2.083 
15 65787364 coronin-1B ü  0.934 ü â 0.791 
16 451172106 coronin-1C isoform b    ü â 0.777 
17 126032350 DNA-dependent protein kinase catalytic subunit isoform 2  á 1.715    
18 4503471 elongation factor 1-alpha 1  á 2.418    
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19 4503483 elongation factor 2     á 3.899 
20 4758256 eukaryotic translation initiation factor 2 subunit 1 ü á 2.141    
21 302699239 eukaryotic translation initiation factor 4 gamma 1 isoform 4 ü 1.598
22 41872631 fatty acid synthase ü á 1.357 ü  1.353 
23 388490223 FERM domain-containing protein 6 isoform 3 ü  0.933    
24 116063573 filamin-A isoform 1 ü á 1.325 ü  1.335 
25 256222415 filamin-B isoform 4 ü á 2.155 ü á 1.901 
26 4504981 galectin-1 á 1.714
27 356461016 gem-associated protein 5 isoform 2    ü  1.572 
28 66932975 gephyrin isoform 2 ü á 1.863    
29 194248072 heat shock 70 kDa protein 1A/1B ü á 1.516    
30 34419635 heat shock 70 kDa protein 6    ü á 1.877 
31 24234686 heat shock cognate 71 kDa protein isoform 2 ü á 1.689 ü á 2.019
32 4504517 heat shock protein beta-1  á 12.816 ü á 7.830 
33 154146191 heat shock protein HSP 90-alpha isoform 2 ü á 1.835    
34 431822406 heat shock protein HSP 90-beta isoform b ü á 2.061    
35 431822408 heat shock protein HSP 90-beta isoform c     á 2.152 
36 10645195 histone H2A type 1-B/E á 3.832
37 10800140 histone H2B type 1-B  á 3.598    
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38 4504301 histone H4  á 3.731    
39 5032027 histone-binding protein RBBP4 isoform a    ü  1.616 
40 98986457 host cell factor 1 ü 1.453
41 4557888 keratin, type I cytoskeletal 18 ü  1.240 ü  1.208 
42 372466577 keratin, type II cytoskeletal 8 isoform 2 ü  1.204 ü  1.251 
43 12383062 kinesin light chain 2 isoform 1 ü á 1.633 ü á 2.418 
44 216548085 leucine zipper protein 1 ü á 2.504 ü á 2.497 
45 41350320 melanoma-associated antigen D2 ü á 2.096 á 2.407
46 262073007 monocarboxylate transporter 1  á 1.325    
47 38176300 nestin ü  0.880    
48 140972063 neurabin-2    ü á 1.638 
49 114155142 nucleoprotein TPR    ü  1.162 
50 170932516 paxillin isoform 1 ü á 3.692
51 196162711 PDZ and LIM domain protein 4 isoform 2    ü  1.397 
52 33356174 pinin ü  1.273    
53 41322910 plectin isoform 1d  á 1.408  á 1.657 
54 601984520 polyubiquitin-C ü á 3.919 ü á 2.781 
55 530394628 PREDICTED: BAG family molecular chaperone regulator 3 isoform X1 ü á 2.677    
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56 578812465 PREDICTED: band 4.1-like protein 2 isoform X12 ü á 1.881    
57 578812459 PREDICTED: band 4.1-like protein 2 isoform X9    ü  1.046 
58 578822562 PREDICTED: chromodomain-helicase-DNA-binding protein 4 isoform X6 ü á 1.447    
59 578815876 PREDICTED: elongation factor 1-delta isoform X14    ü  1.353 
60 530388831 PREDICTED: elongation factor 1-delta isoform X7    ü  1.411 
61 578814066 PREDICTED: filamin-C isoform X1 ü á 3.169 ü á 2.390 
62 530381927 PREDICTED: heat shock 70 kDa protein 1-like isoform X4 ü á 1.585 ü á 1.935 
63 578824891 PREDICTED: LIM domain only protein 7 isoform X39     á 2.027 
64 530379305 PREDICTED: microtubule-associated protein 1B isoform X1 ü á 1.399 ü  1.359 
65 530397279 PREDICTED: neuroblast differentiation-associated protein AHNAK isoform X1 ü  1.125 ü  1.288 
66 578821456 PREDICTED: nuclear mitotic apparatus protein 1 isoform X9    ü â 0.799 
67 530381066 PREDICTED: nucleophosmin isoform X2  á 2.499    
68 578811124 PREDICTED: nucleophosmin isoform X3     á 2.141 
69 530403029 PREDICTED: protein AHNAK2 isoform X1 ü á 1.556 ü á 1.640 
70 578805886 PREDICTED: raftlin isoform X7 ü â 0.772    
71 530407875 PREDICTED: RNA-binding protein FUS isoform X3 ü  0.857    
72 530411381 PREDICTED: septin-9 isoform X3    ü  1.278 
73 530390127 PREDICTED: tropomyosin beta chain isoform X7  á 2.926    
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74 530383156 PREDICTED: unconventional myosin-VI isoform X8  á 2.696    
75 578818565 PREDICTED: vimentin isoform X1 ü  1.162 ü  1.288 
76 530365709 PREDICTED: zinc finger CCCH domain-containing protein 11A isoform X5 ü á 1.818    
77 5454064 RNA-binding protein 14 isoform 1     á 2.047 
78 55741709 RNA-binding protein 25 ü á 1.649    
79 148352331 septin-7 isoform 1    ü  1.392 
80 112382252 spectrin beta chain, non-erythrocytic 1 isoform 2  á 1.365    
81 24234688 stress-70 protein, mitochondrial precursor ü á 1.578    
82 150417971 supervillin isoform 1  á 2.454    
83 325651836 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5  á 1.553    
84 544711041 T-complex protein 1 subunit theta isoform 2    ü  1.329 
85 116875765 tight junction protein ZO-1 isoform b ü á 1.750    
86 98986464 transmembrane emp24 domain-containing protein 10 precursor     á 2.674 
87 393715095 tubulin alpha-1A chain isoform 2  á 1.918    
88 29788785 tubulin beta chain isoform b  á 3.379    
89 557129022 ubiquitin carboxyl-terminal hydrolase 7 isoform 3    ü á 2.354 
90 296010977 zinc finger protein 185 isoform 7 ü á 2.983 ü á 2.027 
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Oxidative stress induces the association of OGA with FAS, FLNA, HSC70, 
and OGT 
To validate a subset of the identified protein-protein interactions, endogenous OGA 
was enriched using the anti-OGA-Bethyl antibody from NETN U2OS cell lysates treated 
with H2O2 (1-3 h), and Western blots were performed for interacting partners-of-interest 
(Figure 3-11A). In addition to a subset of proteins identified in the screen, we also probed 
for OGT, a known binding partner of OGA (Whisenhunt et al. 2006). The interaction of 
OGA with FAS, FLNA, HSC70, and OGT is clearly induced in response to oxidative stress 
(Figure 3-11A). Actin is shown as both a loading and negative control. 
Further validation of these protein-protein interactions was performed by 
immunoprecipitation (IP) of endogenous FAS and V5-tagged FAS using an anti-FAS 
antibody and an anti-V5 antibody, respectively. Endogenous FAS or transiently 
overexpressed pCMV-SPORT6 V5-FAS was enriched from NETN U2OS cell lysates 
treated with H2O2 (1-3 h), and Western blots were performed for interacting partners-of-
interest (Figure 3-11B, C). Consistent with previous results (Figure 3-11A), the interaction 
between OGA and endogenous FAS is induced in response to oxidative stress (Figure 
3-11B, C). Interestingly, we also observe that OGT and HSC70 exhibit increased binding 
to endogenous FAS and V5-FAS upon oxidative stress (Figure 3-11B, C).  
To determine if these protein-protein interactions are conserved in other cell types 
in addition to U2OS cells, we enriched endogenous OGA and endogenous FAS from 
HEPG2 human hepatocellular carcinoma cells (Figure 3-12). We chose HEPG2 cells as a 
recent publication has indicated an interaction between OGT and FAS in the liver (Baldini 
et al. 2016). Western blots for the proteins-of-interest reveal that FAS and HSC70 co-IP 
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with OGA in HEPG2 cells under basal conditions (Figure 3-12A). We also observe that 
OGA and HSC70 co-IP with FAS basally in HEPG2 cells (Figure 3-12B). Unlike U2OS 
cells, the interactions in HEPG2 cells are not induced in response to oxidative stress (data 
not shown). Furthermore, we assessed these interactions in murine liver tissue by enriching 
endogenous OGA and endogenous FAS. We have demonstrated that HSC70 co-IPs with 
OGA (Figure 3-12C), and that OGA and HSC70 co-IP with FAS in normal liver tissue 
(Figure 3-12D). Overall, these data suggest that the aforementioned protein-protein 
interactions are not specific to only U2OS cells, but that the interactions also occur in 
normal tissue and that the pathways regulating OGT and OGA may be cell/tissue-type 
specific.   
An immunoprecipitation with a rabbit isotype control immunoglobulin (Ig)G was 
used as an indicator of non-specific binding for the endogenous OGA and endogenous FAS 
IPs (Figure 3-11A, B; Figure 3-12), and pcDNA3.1-overexpressing cells were used to 
control for non-specific binding in the V5-FAS IPs (Figure 3-11C). Of note, a band at the 
apparent molecular weight of actin is observed in the control IgG IP (Figure 3-11B). 
Analysis of control IgG alone in buffer indicates that this signal arises from the anti-actin 





Figure 3-11: Oxidative stress induces the association of OGA with FAS, FLNA, HSC70, and OGT. 
U2OS cells were treated with vehicle (V) or H2O2 (2.5 mM, 1-3 h). N=3. (A) An anti-OGA antibody (IP: 
OGA; top panel) or a rabbit isotype control immunoglobulin (IP: IgG; middle panel) were used to enrich 
endogenous OGA from NETN cell lysates (500 µg), of which 1.5-2% (input) and 30-40% 
(immunoprecipitate) were analyzed by SDS-PAGE. OGA, FAS, FLNA, HSC70, OGT (positive control), and 
actin (loading/negative control) were detected by Western blot (WB). (B) An anti-FAS antibody (IP: FAS; 
top panel) or a rabbit isotype control immunoglobulin (IP: IgG; middle panel) were used to enrich 
endogenous FAS from NETN cell lysates (250 µg), of which 3% (input) and 60% (immunoprecipitate) were 
analyzed by SDS-PAGE. FAS, OGA, HSC70, OGT, and actin (loading/negative control) were detected by 
Western blot. (C) U2OS cells were transfected with pcDNA3.1 (control) or pCMV-SPORT6 V5-FAS (test). 
An anti-V5 antibody was used to enrich V5-FAS from control and test NETN cell lysates (300 µg), of which 
1.7% (input) and 33.3% (immunoprecipitate) were analyzed by SDS-PAGE. V5, OGA, HSC70, OGT, and 
actin (loading/negative control) were detected by Western blot. (A-C) FAS (CST) and FAS (NB) represent 
anti-FAS antibody from Cell Signaling Technology and Novus Biologicals, respectively. To ensure that 
images were in the linear range, Western blot exposures from the input and immunoprecipitated fractions are 
often different. The exposure lengths for the test and control isotype antibody immunoprecipitates are always 
identical. The migration of molecular weight (MW) markers is indicated. 
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Figure 3-12: FAS, OGA, and HSC70 interact basally in human hepatocytes and murine liver tissue. 
Cells and tissue were lysed in NETN buffer and pre-cleared. Immunoprecipitations were performed with the 
anti-OGA-Bethyl antibody (IP: OGA; A, C), an anti-FAS antibody (IP: FAS; B, D), or a rabbit isotype control 
immunoglobulin (IP: IgG; A-D). (A) Endogenous OGA was enriched from HEPG2 cell lysate (500 µg), of 
which 2% (input) and 50% (immunoprecipitate) were analyzed by SDS-PAGE. OGA, FAS, and HSC70 were 
detected by Western blot (WB). N=4, except for WB: FAS (N=2). (B) Endogenous FAS was enriched from 
HEPG2 cell lysate (250-600 µg), of which 1.7-4% (input) and 33-80% (immunoprecipitate) were analyzed 
by SDS-PAGE. FAS, OGA, and HSC70 were detected by Western blot. N=4. (C) Endogenous OGA was 
enriched from normal murine liver tissue lysate (400 µg), of which 3.8% (input) and 63% 
(immunoprecipitate) were analyzed by SDS-PAGE. OGA and HSC70 were detected by Western blot. N=3. 
(D) Endogenous FAS was enriched from normal murine liver tissue lysate (400 µg), of which 3.8% (input) 
and 63% (immunoprecipitate) were analyzed by SDS-PAGE. FAS, OGA, and HSC70 were detected by 
Western blot. N=3. (A-D) FAS (CST) and FAS (NB) represent anti-FAS antibody from Cell Signaling 
Technology and Novus Biologicals, respectively. To ensure that images were in the linear range, Western 
blot exposures from the input and immunoprecipitated fractions are often different. The exposure lengths for 
the test and control isotype antibody immunoprecipitates are always identical. The migration of molecular 







OGA exhibits reduced catalytic activity when bound to FAS 
Next, we sought to determine if FAS alters the catalytic activity of OGA. As the 
mechanism controlling the stress-induced association of OGA and FAS is currently 
unknown, we assessed the activity of OGA in cells stably overexpressing pcDNA3.1 or 
V5-FAS and treated with or without 2 h H2O2 (Figure 3-13). The immunoprecipitation 
technique utilized in Figure 3-11C was coupled with a downstream OGA activity assay. 
This allowed us to measure the activity of OGA in total cell lysates (Figure 3-13A, C) and 
the pool of OGA bound to FAS (Figure 3-13B, D). In total cell lysates (Figure 3-13A), 
overexpression of V5-FAS did not alter OGA activity (Figure 3-13C), and we attribute this 
observation to the small percentage of OGA that associates with FAS (<5%). To overcome 
the stoichiometry of this interaction, we enriched V5-FAS using an anti-V5 antibody and 
assessed the activity of OGA on the protein A/G magnetic beads (Figure 3-13B, D).  
Consistent with previous results (Figure 3-11C), the interaction of V5-FAS with 
OGA was induced in response to oxidative stress (Figure 3-13B). To assess the specific 
activity of OGA bound to FAS (on-bead) and compare it to the specific activity of OGA in 
the unbound and input lysates, we determined the amount of OGA on the beads using 
Western blot quantitation of the bound fractions and a dilution series of the inputs. The 
fraction of OGA bound to V5-FAS during oxidative stress exhibited an ~85% reduction in 
specific activity (Figure 3-13D; RM-1ANOVA/Tukey’s MCT, p≤0.0001) when compared 
to its activity in the unbound fraction. Importantly, we did not detect on-bead OGA activity 
above the baseline in the pcDNA3.1 controls or the vehicle-treated V5-FAS sample. 
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Figure 3-13: OGA exhibits reduced catalytic activity when bound to FAS. U2OS cells stably 
overexpressing pcDNA3.1 (control) or pcDNA3.1 V5-FAS (test) were treated with vehicle (V) or H2O2 (2.5 
mM, 2 h). An anti-V5 antibody was used to enrich V5-FAS from control and test NETN cell lysates (1.6 
mg). N=3. (A, B) V5, OGA, and actin (loading/negative control) were detected by Western blot (WB). 
Western blots for each antibody were exposed for equal lengths of time. (A) Analysis of the inputs and 
unbound fractions. (B) Analysis of the bound fractions (31.25%). (C) OGA activity was measured in the 
inputs and unbound fractions using 4MU-GlcNAc (1 mM). N=3, 2 technical replicates per assay. 
Fluorescence values were converted to pmoles/min and then normalized to the pcDNA3.1 vehicle-treated 
sample. (D) OGA activity was assessed in the input, bound (on-bead, 31.25%), and unbound fractions using 
4MU-GlcNAc (1 mM). N=3, 2 technical replicates per assay. Fluorescence values were converted to 
pmoles/min/µg using densitometric analysis of OGA in the input serial dilutions and the bound fractions, and 
then normalized to the pcDNA3.1 vehicle-treated sample. Only the data from FAS-overexpressing cells 
treated with H2O2 are shown, as OGA protein and activity was absent in the bound fraction of the other 
samples. Data are presented as the mean ± SEM. Significance was determined by RM-1ANOVA followed 
by Tukey’s multiple comparison test, and differences were considered statistically significant at p≤0.0001 




FAS overexpression increases O-GlcNAcylation during oxidative stress 
As the pool of OGA bound to FAS is inhibited, we hypothesized that 
overexpression of FAS would result in a stress-dependent increase in O-GlcNAcylation on 
a subset of proteins. To test this hypothesis, cells stably overexpressing pcDNA3.1 or V5-
FAS were treated with vehicle or H2O2 (1-3 h). Proteins from NETN lysates were separated 
by SDS-PAGE and Western blots for OGT, OGA, and O-GlcNAc were performed. O-
GlcNAc levels are significantly higher in FAS-overexpressing cells compared to control 
cells at 3 h H2O2 (Figure 3-14A, B; repeated measures two-way analysis of variance (RM-
2ANOVA)/Sidak’s MCT, p≤0.01). Of note, we observe variable changes in the expression 
of OGT and OGA basally upon V5-FAS overexpression that only reach statistical 
significance for OGT (Figure 3-14A, C, D; RM-2ANOVA/Sidak’s MCT, p≤0.001). 
However, the expression of OGA and OGT remain unchanged in FAS-overexpressing cells 
during the hydrogen peroxide time course. Overall, these data suggest that FAS binds to 
and sequesters OGA preventing it from de-glycosylating a subset of proteins during 
oxidative stress, thereby augmenting cellular O-GlcNAcylation (Figure 3-15). 
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Figure 3-14: FAS overexpression increases O-GlcNAcylation during oxidative stress. U2OS cells stably 
overexpressing pcDNA3.1 or pcDNA3.1 V5-FAS were treated with vehicle (V) or H2O2 (2.5 mM, 1-3 h). 
N=5. (A) NETN lysates (~7.5 µg) were analyzed by SDS-PAGE. O-GlcNAc, OGA, OGT, V5, and actin 
were detected by Western blot (WB). Total protein stain (colloidal coomassie G-250) was used to assess 
protein load. The migration of molecular weight (MW) markers is indicated. (B) Quantitation of O-GlcNAc 
levels normalized to G-250. (C) Quantitation of OGA expression normalized to G-250. (D) Quantitation of 
OGT expression normalized to G-250. (B-D) Data are presented as the mean ± SEM. Significance was 
determined by RM-2ANOVA followed by Sidak’s multiple comparison test, and differences were considered 
statistically significant at p≤0.05 (*), p≤0.01 (**), and p≤0.001 (***). 
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Figure 3-15: Proposed model for the regulation of OGA during oxidative stress resulting in elevated 
levels of O-GlcNAc. O-GlcNAc levels become elevated during oxidative stress, and this is associated with 
cytoprotection. Counterintuitively, in U2OS cells exposed to oxidative stress, OGT activity remains constant 
while OGA activity and expression are elevated. Our data supports a model in which OGA forms complexes 







Dynamic O-GlcNAcylation is a critical regulator of many cellular processes 
including the cellular stress response and survival signaling (Zachara et al. 2004; Hart et 
al. 2011; Groves et al. 2013; Bond and Hanover 2015). The molecular mechanisms by 
which cells communicate with OGT and OGA to glycosylate and de-glycosylate the correct 
substrates in response to stimuli, including cell stress and injury, are not well understood. 
The goal of this study was to determine which mechanisms the cell utilizes to regulate O-
GlcNAc levels during oxidative stress, and to provide insight into the proteins that interact 
with and regulate OGA. We have demonstrated that both OGA and OGT appear to be 
targeted during oxidative stress, resulting in an increase in the expression of both enzymes 
and elevated OGA activity (Figure 3-1). An increase in the expression and activity of OGA 
cannot be reconciled with the observed increase in O-GlcNAc (Figure 3-1), suggesting that 
OGA is targeted to substrates or that specific pools of OGA are inhibited. Several lines of 
evidence support this rationale. First, in glucose deprived Neuro2A cells, O-GlcNAc levels 
are robustly elevated. However, only modest changes in OGT expression, but not specific 
activity, are observed. Contrary to expectations, there is a decrease in UDP-GlcNAc levels 
and an increase in OGA activity (Cheung and Hart 2008). Second, OGT interacts with p38 
mitogen-activated protein kinase during glucose starvation, resulting in the targeting of 
OGT to glycosylate substrates such as neurofilament H (Cheung and Hart 2008). Third, we 
have recently reported that a subset of proteins exhibit decreased O-GlcNAcylation during 
oxidative stress, even when global O-GlcNAc levels are elevated (Lee et al. 2016). To 
define the regulation of OGA during oxidative stress, we have identified a subset of its 
interaction partners and determined how these interactions change with oxidative stress. 
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Collectively, we have identified 90 binding partners and validated the interaction of OGA 
with FAS, FLNA, HSC70, and OGT. Notably, FAS was demonstrated to inhibit OGA 
activity, and consistent with this observation cellular O-GlcNAcylation was augmented in 
FAS-overexpressing cells upon oxidative stress.  
In this study, we utilized BioID (Roux et al. 2012) to identify the interaction 
partners of OGA. BioID offers many advantages when compared to other methodologies 
(Roux et al. 2012; Mehta and Trinkle-Mulcahy 2016; Varnaitė and MacNeill 2016), such 
as identifying low affinity and transient interactors, as well as obviating the need for an 
antibody-based enrichment. One disadvantage of this technique, when combined with 
SILAC quantification, is that the fold change reported for signal-induced interactions can 
be diluted out by the long biotin-labeling step (16 h). This dilution effect is highlighted by 
our data, in which proteins such as FAS and FLNA demonstrate clear stress-induced 
associations with OGA by co-immunoprecipitation, but are only enriched ~25% over OGA 
in the BioID screen. We speculate that the interactions of OGA with FAS and FLNA exist 
with a low affinity basally, but are stabilized and enhanced during oxidative stress. In 
addition, BioID may be capturing stress-induced interactions between these proteins that 
occur as a result of natural fluctuations in reactive oxygen species levels that occur in 
growing cells. The recent development of spatially and temporally restricted enzymatic 
biotinylation has resolved this issue (Martell et al. 2012; Rhee et al. 2013). However, this 
second-generation approach relies on biotinylation that is activated by hydrogen peroxide 
(Martell et al. 2012; Rhee et al. 2013), a technique which is not compatible with our 
oxidative stress model. One additional caveat of the BioID approach is that the long biotin-
labeling step reduces the chance of identifying interactions that dissociate upon stress. This 
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is further exacerbated by our analysis approach, which excluded proteins if mass 
spectrometric quantification was present in only one channel.     
Our study, using SILAC-BioID-MS/MS, has discovered candidate regulatory 
proteins of OGA during injury through the global identification of OGA’s binding partners. 
Collectively, our screen identified 90 interacting proteins of OGA, which fall into diverse 
groups but were enriched in chaperones, cytoskeletal proteins, and nucleic acid binding 
proteins (Figure 3-10F). Of these proteins, 21 were present in the basal and stressed 
samples from both datasets (bold, Table 3-1) suggesting that these proteins are robust, high 
confidence interactors of OGA. Of note, 6 proteins were identified to co-purify with OGA 
during its initial cloning and characterization (Gao et al. 2001), and one of these proteins 
(HSC70) was confirmed in our BioID screen. Recently, OGA was also identified to bind 
chromodomain helicase DNA-binding protein 4 (Mi2β), erythroid transcription factor 
(GATA-1), and Friend of GATA-1 at the Aγ-globin promoter using co-
immunoprecipitation (Zhang et al. 2016), although none of these nuclear interactors were 
identified in our study. Interestingly, our BioID screen revealed mitochondrial OGA-
interacting proteins such as adenosine disphosphate (ADP)/adenosine triphosphate (ATP) 
translocase 2, of which isoform 1 of this protein has previously been reported to be O-
GlcNAcylated in cardiac mitochondria (Ma et al. 2015). While these results require further 
validation, our data are consistent with the co-localization of OGA(-mBirA) and 
MitoTracker in U2OS cells, as well as recent work demonstrating the mitochondrial 
localization of OGA (Banerjee et al. 2015). 
As our goal is to understand the regulation of OGA during cellular injury, we 
focused our validation efforts on proteins whose association with OGA was augmented 
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during oxidative stress (61 total proteins; Figure 3-10D). A number of proteins were of 
particular interest including FAS, FLNA, and HSC70, as they are known to be involved in 
the cellular stress response. Furthermore, confirmation of FAS and FLNA allowed us to 
test the arbitrary threshold of 25% set for stress-induced interactions. FAS is most 
commonly known as the enzyme that performs de novo lipogenesis, synthesizing 16-
carbon chain fatty acids (palmitate) from acetyl-CoA and malony-CoA (Semenkovich 
1997). Recently, FAS has been implicated as a metabolic oncogene and a biomarker for 
cancer detection and prognosis (Kuhajda et al. 1994; Pizer et al. 1996; Hamada et al. 2014; 
Ito et al. 2014; Wakamiya et al. 2014; Mullen and Yet 2015). Suggesting that FAS is a pro-
survival signaling molecule, its inhibition has been demonstrated to induce tumor cell 
apoptosis through various mechanisms including cell cycle arrest (Zhou et al. 2003), 
reduced cellular growth and proliferation (Kuhajda et al. 1994; Carvalho et al. 2008; Lee 
et al. 2009; Veigel et al. 2015; Ventura et al. 2015), decreased phospholipid biosynthesis 
(Ventura et al. 2015), disruption of lipid raft architecture (Ventura et al. 2015), and 
blockage of the β-catenin and phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of 
rapamycin (mTOR) signal transduction pathways (Ventura et al. 2015). Importantly for 
our studies, FAS is also implicated in protecting the heart and has been demonstrated to be 
upregulated in cardiomyocytes during heart failure (van der Vusse et al. 1992; Abdalla et 
al. 2011; Razani et al. 2011). Interestingly, heart-specific FAS knockout mice exhibit 
upregulated calcium/calmodulin-dependent protein kinase (CaMK)II signaling upon an 
acute transaortic constriction mechanical stress, leading to rapid cardiac dysfunction and 
arrhythmias (Razani et al. 2011). Supporting this model, CaMKII is O-GlcNAc-modified 
at Ser279 during acute hyperglycemia, resulting in its activation and cardiac dysfunction 
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(Erickson et al. 2013). These data suggest that FAS induction in the stressed heart may be 
a protective compensatory response to pathological calcium flux (Razani et al. 2011), and 
may at least in part be under the control of O-GlcNAc cycling. In accordance with this 
hypothesis, we have demonstrated that FAS interacts with OGA in a stress-induced manner 
in U2OS cells (Figure 3-11), and that this results in the inhibition of OGA (Figure 3-13) 
and increased cellular O-GlcNAcylation (Figure 3-14). Collectively, these data lead to a 
novel and attractive model in which FAS binds to and inhibits OGA upon oxidative stress 
to promote cell survival (Figure 3-15).  
In addition to FAS, we identified and validated the interactions of OGA with 
FLNA, HSC70, and OGT in U2OS cells (Figure 3-11A). While OGT and OGA have 
previously been reported to interact (Whisenhunt et al. 2006), the physiological 
significance of the stress-dependent association remains uncertain and suggests reciprocal 
regulation between the two enzymes. Interestingly, HSC70 and OGT were also 
demonstrated to interact with FAS in response to oxidative stress (Figure 3-11B, C), raising 
the possibility of a large stress-induced multi-protein complex containing FAS, OGT, 
OGA, and HSC70. These interactions are maintained basally in HEPG2 liver cancer cells 
and normal murine liver tissue (Figure 3-12), suggesting that the interactions are not 
specific to U2OS cells. These data are in concordance with a recent study by Baldini and 
colleagues demonstrating that FAS binds OGT in the liver of ob/ob mice (Baldini et al. 
2016). Collectively, our data suggest that the cell/tissue type may regulate the interactions 
and thus the regulation of OGT and OGA. 
Our study, utilizing proximity biotinylation and SILAC-based MS, has revealed a 
host of novel basal and oxidative stress-dependent binding partners of OGA (Figure 3-10; 
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Table 3-1). Our data provides evidence for a model in which the interactors of OGA, such 
as FAS, regulate its local activity in a manner consistent with cell survival (Figure 3-15). 
Such results will provide a framework for understanding the regulation of OGA during 
injury and in other models in which O-GlcNAc is misregulated, such as cancer, 






All chemicals and reagents were of the highest grade and supplied by Sigma-
Aldrich (St. Louis, MO) or Thermo Fisher Scientific (Waltham, MA), unless otherwise 
indicated. TMG (Yuzwa et al. 2008) was synthesized by SD ChemMolecules LLC (Owings 
Mills, MD) to a purity of 99.1%, as determined by high-performance liquid 
chromatography. The chemical structure of TMG was verified by 1H nuclear magnetic 
resonance and ESI-MS. 
Antibodies 
The following antibodies were used for Western blot analysis: anti-OGA (345), 
anti-O-GlcNAc (CTD110.6) (gift, The Johns Hopkins University School of Medicine 
(JHUSOM) Core C4); anti-FLNA (A301-135A; Bethyl Laboratories); anti-HA (H6908), 
anti-Actin (A5060), anti-OGT (DM17, O6264), anti-mouse IgM-HRP (A8786; Sigma-
Aldrich); NeutrAvidin-HRP (31030), anti-V5 (461157; Thermo Fisher Scientific); anti-
Myc (9E10, CRL-1729; American Type Culture Collection, Manassas, VA); anti-FAS 
(3180; Cell Signaling Technology, Danvers, MA); anti-FAS (H00002194-M01; Novus 
Biologicals, Littleton, CO); anti-HSC70 (sc-7298), anti-chicken IgY-HRP (sc-2428; Santa 
Cruz Biotechnology, Dallas, TX); anti-rabbit IgG-HRP (NA934V), anti-mouse IgG-HRP 
(NA931V; GE Healthcare, Pittsburgh, PA). The following antibodies were used for 
indirect immunofluorescence: anti-BirA (NB600-1098; Novus Biologicals); NeutrAvidin-
DyLight 633 (22844; Thermo Fisher Scientific); anti-OGA (345), anti-chicken IgY-Alexa 
Fluor 488 (703-545-155; Jackson ImmunoResearch Laboratories, West Grove, PA). The 
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following antibodies were used for immunoprecipitation: rabbit isotype control IgG (P120-
101), anti-OGA (A304-345A), anti-FAS (A301-324A; Bethyl Laboratories); anti-V5 
(461157; Thermo Fisher Scientific). 
Cloning 
The following DNA constructs were gifts (Kyle Roux, Sanford Research; (Roux et 
al. 2012)): pcDNA3.1 Myc-mBirA-multiple cloning site (MCS; Plasmid #35700; 
Addgene, Cambridge, MA), pcDNA3.1 MCS-mBirA-HA (Plasmid #36047; Addgene). 
Myc-mBirA-OGA was generated by sub-cloning full-length human OGA (from 
pcDNA3.1 His6-OGA; gift, JHUSOM Core C4; (Gao et al. 2001)) into the MCS of 
pcDNA3.1 Myc-mBirA-MCS using NotI and PmeI. OGA-mBirA-HA was generated as 
follows: 1) PCR insertion of a start codon upstream of mBirA in pcDNA3.1 MCS-mBirA-
HA (Primers: BirAMetF, BirAMetR); 2) PCR deletion of 23 base pairs (bp) between the 
AgeI and BamHI restriction sites in pcDNA3.1 MCS-mBirA-HA (Primers: Del23bpF, 
Del23bpR); 3) PCR insertion of a NotI restriction site upstream of AgeI in pcDNA3.1 
MCS-mBirA-HA (Primers: BirAHAinsNotIF, BirAHAinsNotIR); 4) PCR insertion of an 
AgeI restriction site 3’ of full-length human OGA (from pcDNA3.1 His6-OGA; gift, 
JHUSOM Core C4; Primers: OGAinsAgeIF, OGAinsAgeIR (Gao et al. 2001)); and 5) 
subcloning full-length OGA (from pcDNA3.1 His6-OGA) into the MCS of pcDNA3.1 
MCS-mBirA-HA using NotI and AgeI. All of the mutagenesis PCR reactions described 
above were performed with KOD polymerase (EMD Millipore, Billerica, MA). Full-length 
untagged human FAS in pCMV-SPORT6 was a gift (Michael Wolfgang, JHUSOM). 
pCMV-SPORT6 His6-V5-TEV-FAS was generated by in-fusion using the SalI restriction 




CCACGCGTCCG-3’). His6-V5-TEV-FAS was sub-cloned into pcDNA3.1 using EcoRI 
and NotI. His6-V5-TEV-FAS will be referred to as V5-FAS. All primer sequences for site-
directed mutagenesis are listed in Appendix A. DNA constructs were verified by Sanger 
sequencing using an Applied Biosystems 3730xl DNA analyzer (Thermo Fisher Scientific; 
JHUSOM Synthesis and Sequencing Facility). 
Cell culture 
U2OS human osteosarcoma cells and HEPG2 human hepatocellular carcinoma 
cells (American Type Culture Collection) were cultured in high glucose (4.5 g/L) DMEM 
(Corning, Manassas, VA) supplemented with 10% (v/v) heat inactivated fetal bovine serum 
(Thermo Fisher Scientific) and 1% (v/v) penicillin/streptomycin (Corning) in a humidified 
water-jacketed CO2 (5%) incubator at 37°C. All experiments were performed in U2OS 
cells unless otherwise indicated (Figure 3-12 only). 
All plasmid DNA transfections were performed in Opti-MEM (Thermo Fisher 
Scientific) using FuGENE 6 (Promega, Madison, WI). Cells were harvested 45-50 h post-
transfection and 18-20 h post-feeding. Cell treatments included biotin (25 µM, 16 h; Sigma-
Aldrich), H2O2 (2.5 mM, 1-3 h as indicated; Sigma-Aldrich), and TMG (100 nM, 20 h). 
Vehicle control was complete media (biotin, H2O2) or HEPES pH 7.8 (TMG). 
For the SILAC experiment, U2OS cells were cultured in light (unlabeled arginine 
and lysine; Sigma-Aldrich), medium (13C6-arginine, lysine-D4; Cambridge Isotopes, 
Tewksbury, MA), or heavy (13C615N4-arginine, 13C615N2-lysine; Cambridge Isotopes) 
media (Ong et al. 2002; Amanchy et al. 2005). In all cases, low glucose (1 g/L) DMEM 
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(Athena Environmental Sciences, Baltimore, MD) was supplemented with unlabeled 
leucine (104.8 mg/L, Sigma-Aldrich) and methionine (30 mg/L, Sigma-Aldrich), 1 mM 
sodium pyruvate (Corning), 3.5 g/L glucose (Sigma-Aldrich), 10% (v/v) fetal bovine 
serum, and 1% (v/v) penicillin/streptomycin. Cells were passaged for 6 generations in 
SILAC media prior to transfection to ensure complete incorporation of the label (44, 45). 
Labeled cells were transfected with plasmid DNA encoding pcDNA3.1 (control vector), 
OGA-mBirA-HA, or Myc-mBirA-OGA, treated as indicated, and harvested 49 h post-
transfection. 
Generation of stable cell lines 
Stable constitutive overexpression of V5-FAS in U2OS cells was carried out as 
follows. A pcDNA3.1 plasmid encoding V5-FAS (or empty vector as a control) was 
linearized with ScaI. The digested DNA was precipitated with ethanol prior to transfection 
with FuGENE 6. Stable cell selection was initiated ~48 hours post-transfection, and 
continued for 14 days in 750 µg/mL G418 (Sigma-Aldrich). Cells were maintained in 375 
µg/mL G418.   
Murine tissue 
Male C57BL/6 mice (12-14 weeks of age) were obtained from Jackson 
Laboratories (Bar Harbor, ME). Animals were euthanized after anesthesia, and livers were 
rapidly removed, washed in ice cold phosphate-buffered saline (PBS), and snap frozen on 
liquid nitrogen. All animal procedures were performed in accordance with the National 
Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and approved 
by the Institutional Laboratory Animal Care and Use Committee. 
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Preparation of cell and tissue lysates 
The following lysis buffers were used in this study: TCL buffer (1% (v/v) Nonidet 
P-40, 2 mM ethylenediaminetetraacetic acid (EDTA) pH 8, 50 mM Tris pH 7.5, 150 mM 
sodium chloride (NaCl)); denaturing TCL buffer (1% (v/v) Nonidet P-40, 0.5 M urea, 2 
mM EDTA pH 8, 50 mM Tris pH 7.5, 150 mM NaCl); and NETN buffer (0.5% (v/v) 
Nonidet P-40, 5 mM EDTA pH 8, 50 mM Tris pH 8, 250 mM NaCl). Unless indicated 
otherwise, lysis buffers were supplemented with the following inhibitors immediately prior 
to use: protease inhibitor cocktail sets II and III (EMD Millipore), 10 µM β-hexosaminidase 
inhibitor (376820; EMD Millipore); 0.5 µM TMG; 0.1 mM phenylmethylsulfonyl fluoride 
(PMSF), 10 mM sodium fluoride, 10 mM β-glycerophosphate, 3 µM trichostatin A1 
(Sigma-Aldrich). Cells were extracted in the indicated lysis buffer for 30 min on ice with 
vortexing followed by sonication. Cell debris were pelleted at 17,111 x g (30 min, 4°C). 
Livers were extracted in NETN buffer for 10 min on ice followed by homogenization, 
sonication, and centrifugation (17,200 x g, 30 min, 4°C). Protein concentration was 
assessed using the 660 nm protein assay (Thermo Fisher Scientific). 
Immunoprecipitation 
For the SILAC study, cells were lysed in denaturing TCL buffer and equal amounts 
of protein from each sample (2.32 mg) were combined (6.96 mg total protein). Biotinylated 
proteins were isolated on high capacity NeutrAvidin-agarose (1.31 mL slurry, Thermo 
Fisher Scientific) with end-over-end rotation (2 h, 4°C). The beads were washed in TCL 
buffer supplemented with 2 M urea (3x) and subsequently in Tris-buffered saline (TBS) 
pH 7.5 (3x). Biotinylated proteins were eluted with 2% (w/v) SDS (1.5 mL, 5 min, 95°C, 
10x). The elution fractions containing biotinylated protein (fractions 1-8, as identified by 
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electrophoresis) were combined and precipitated with acetone (65 h, -20°C). Protein was 
recovered by centrifugation (5,000 x g, 30 min, 4°C). Each pellet was re-suspended in 2% 
(w/v) SDS and combined, and then the proteins were re-precipitated with acetone (18 h, -
20°C). The sample was centrifuged (25,000 x g, 30 min, 4°C), and the pellet was dried 
briefly under vacuum. 
For co-immunoprecipitation studies, NETN lysate was incubated with antibody 
overnight (16-20 h, 4°C, with rotation). Endogenous OGA and FAS were enriched with an 
anti-OGA antibody and an anti-FAS antibody (Bethyl Laboratories), respectively. Samples 
were also incubated with rabbit isotype control IgG to indicate non-specific binding. V5-
FAS was enriched with an anti-V5 antibody, and pcDNA3.1-overexpressing cells were 
used to control for non-specific binding. Antibody-protein complexes were captured using 
protein A/G magnetic beads (2 h, 4°C, with rotation; Thermo Fisher Scientific) pre-blocked 
with 1 mg/mL bovine serum albumin (BSA), washed extensively with NETN buffer, and 
then eluted and denatured in Laemmli sample buffer containing 25 mM dithiothreitol. For 
experiments in Figure 3-12, NETN lysate was pre-cleared with rabbit isotype control IgG 
and protein A/G magnetic beads (2-4 h, 4°C, with rotation) to reduce non-specific binding. 
Electrophoresis and Western blotting 
SDS-PAGE was performed using Tris-Glycine (TGX, Bio-Rad; Novex, Life 
Technologies) and Tris-Acetate (XT, Bio-Rad; Novex, Life Technologies) polyacrylamide 
gels. Equal sample volumes at equal concentration were loaded onto the gel, with the 
exception of immunoprecipitate fractions where the volume typically exceeded that of the 
input fractions. Proteins were electroblotted to nitrocellulose (0.45 µm; Bio-Rad). 
Membranes were blocked in 3% (w/v) non-fat milk in TBS with 0.05% (v/v) TWEEN-20 
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(1 h, 25°C), incubated with primary antibodies (16-20 h, 4°C), and then incubated with 
HRP-conjugated secondary antibodies (1 h, 25°C). Western blots were developed using 
Immobilon Western Chemiluminescent Substrate (EMD Millipore) and captured on 
autoradiography film or the Amersham Imager 600 RGB (GE Healthcare). Western blots 
were incubated with 0.1% (w/v) sodium azide in PBS (10 min, 25°C), stripped in 200 mM 
glycine pH 2.5 (1 h, 25°C), and then re-probed as described above. Stripped blots were re-
probed for proteins that migrate at a different molecular weight than the original signal. 
Protein load was assessed by Western blotting for a housekeeping protein (actin), 
total protein gel staining (colloidal Coomassie G-250), or total protein membrane staining 
(Sypro Ruby; Bio-Rad). Quantitation of Western blots and total protein stains was 
performed using ImageJ software (version 1.46; NIH, Bethesda, MD). Quantitation was 
performed on individual protein bands, except for O-GlcNAc Western blots and total 
protein stains where quantitation was performed on the entire lane signal.  
Indirect immunofluorescence 
U2OS cells were grown and transfected on glass cover slips. Mitochondria were 
stained in vivo with MitoTracker Orange CMTMRos (200 nM, 45 min, 37°C; Thermo 
Fisher Scientific). Cells were fixed in 4% (v/v) paraformaldehyde in PBS (15 min, on ice) 
and permeabilized with 0.5% (v/v) Triton X-100 in PBS (15 min, on ice). Slides were 
blocked in 3% (w/v) BSA in PBS (1-2 h, 25°C), incubated with primary antibodies in 3% 
(w/v) BSA-X (0.05% (v/v) Triton X-100; 16-20 h, 4°C), and then incubated with 
fluorophore-conjugated secondary antibodies in 3% (w/v) BSA-X (1 h, 25°C). Nuclei were 
stained with Hoechst 33342 (8 min, 25°C). Cover slips were mounted in VECTASHIELD 
Antifade Mounting Medium (Vector Laboratories, Burlingame, CA), sealed, and stored at 
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4°C. Images were captured at 25°C using an upright Zeiss (Carl Zeiss, Inc., Oberkochen, 
Germany) Axio Examiner 710NLO-Meta multiphoton and confocal laser-scanning 
microscope (C-Apochromat 63x/1.20 W Korr M27 water immersion objective) with 
spectral detection. Images were obtained on ZEN 2010 software (Carl Zeiss Inc.) and 
processed using Imaris software (version 7.6.5; Bitplane, Zurich, Switzerland). Image 
acquisition and processing was performed at the JHUSOM Microscope Facility.  
OGA activity assays 
Lysates for OGA assays were prepared as follows. For Figure 3-2C, lysates in TCL 
buffer at equal concentration (1 mg/mL) were desalted into desalting buffer (20 mM Tris 
pH 7.8, 20% (v/v) glycerol) using Zeba spin desalting columns (7,000 molecular weight 
cut off; Thermo Fisher Scientific), and then the protein concentration was re-assessed. For 
Figure 3-1G, 8C, and 8D, cells were lysed in NETN buffer without TMG. Lysates at equal 
concentration (1 mg/mL) were diluted 4-fold with ultrapure water (0.25x NETN), and 
assayed in a final concentration of 0.05x NETN.  
The activity of OGA was assessed in duplicate with 1 mM 4MU-GlcNAc or 4MU-
GalNAc (Sigma-Aldrich) fluorescent substrate, 100 mM GalNAc (Sigma-Aldrich), and 
OGA assay buffer (100 mM sodium cacodylate pH 6.4 (50 mM in Figure 3-2C), 0.3% 
(w/v) BSA) in a black flat/clear-bottomed 96-well plate as previously reported (Reeves et 
al. 2014). β-N-acetylhexosaminidasef (New England Biolabs, Ipswich, MA) diluted in 
desalting buffer or 0.25x NETN buffer was used as a positive control (5 units/well). Assays 
were quenched with glycine pH 10.75 (final concentration: 120 mM in 100 µL assays and 
150 mM in 50 µL assays), and the fluorescence intensity was measured using the Synergy 
HT microplate reader (BioTek Instruments, Inc., Winooski, VT; excitation 360 nm, 
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emission 460 nm). OGA activity in cell lysates was normalized by subtracting the 
fluorescence signal resulting from lysosomal hexosaminidase contamination, which was 
assessed using 4MU-GalNAc (Reeves et al. 2014). Activity was converted to 
pmoles/min/mg using a standard curve of free 4MU.  
To assay OGA on beads (Figure 3-13), U2OS cells stably overexpressing 
pcDNA3.1 or pcDNA3.1 V5-FAS were treated with vehicle or H2O2 (2.5 mM, 2 h). Cells 
were lysed in NETN buffer without TMG, and lysates were diluted to equal concentration 
(1 mg/mL). V5-FAS was enriched using an anti-V5 antibody (30 min, 4°C, with rotation) 
and captured using protein A/G magnetic beads (2 h, 4°C, with rotation) pre-blocked with 
BSA. Antibody-protein complexes were washed with 1x NETN buffer (5x) and 
subsequently with 0.25x NETN buffer (3x). OGA activity assays were performed on-bead 
(3 h, 37°C, with rotation) in duplicate (described above). The reaction product was 
transferred to a black flat/clear-bottomed 96-well plate for fluorescence measurements. 
Serial dilutions of lysates from the inputs and unbound fractions were prepared and 
processed in diluted NETN (described above). To assess the specific activity of OGA on-
bead (bound to FAS) and compare it to the specific activity of OGA in the unbound and 
input lysates, the amount of OGA on the beads was determined by Western blot 
quantitation of the bound fractions and serial dilutions of the inputs. To ensure accurate 
quantitation of OGA, the bound fractions from the V5-FAS cells were electroblotted to the 
same membrane as the corresponding V5-FAS input serial dilutions. Western blots for each 
antibody were exposed for equal lengths of time. Fluorescence values were converted to 
pmoles/min (Figure 3-13C) or pmoles/min/µg (Figure 3-13D) using a standard curve of 
free 4MU and the densitometric analysis described above. Finally, the data were 
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normalized to the pcDNA3.1 vehicle-treated input sample to control for variable baseline 
OGA activity between biological replicates (reported as fold change).  
OGT activity assays 
Cells were lysed in NETN buffer without sodium fluoride and β-glycerophosphate 
(phosphatase inhibitors). Lysates at equal concentration (2 mg/mL) were diluted 8-fold 
with ultrapure water (0.125x NETN), and assayed in a final concentration of 0.05x NETN. 
In a clear round-bottomed 96-well plate, 5 µg cell lysate was incubated (1 h, 25°C) in 
triplicate with 0.5 µCi 3H-UDP-GlcNAc (ART 0128; American Radiolabeled Chemicals, 
Saint Louis, MO; specific activity: 60 Ci/mmol), 1 mM casein kinase II (CKII) acceptor 
peptide (PGGSTPVSSANMM; JHUSOM Synthesis and Sequencing Facility), 2.5 units 
calf intestinal alkaline phosphatase (New England Biolabs), 0.25 mM 5’ adenosine 
monophosphate (AMP; Sigma-Aldrich), and OGT assay buffer (100 mM sodium 
cacodylate pH 6.4, 0.3% (w/v) BSA). Recombinant His6-OGT was purified in-house on 
Ni-NTA agarose (Qiagen, Venlo, The Netherlands), diluted in 0.125x NETN buffer, and 
used as a positive control (0.5 µg/well). Assays were quenched with 37.5 mM formate/750 
mM NaCl (final concentration). Samples were loaded onto a Strata C18 96-well plate (25 
mg/well; 8E-S001-CGB; Phenomenex) activated with 100% methanol and equilibrated 50 
mM formate/1 M NaCl (3x2 mL each). The C18 plate was subsequently washed with 50 
mM formate/1 M NaCl, water, and 50 mM formate (2x2 mL each). The reaction product 
was eluted from the column with 100% methanol (2 mL), and the incorporation of 
radiolabeled GlcNAc was assessed by liquid scintillation counting (Beckman Coulter Inc., 
Indianapolis, IN). Activity was normalized by subtracting the counts arising from the 
average of triplicate samples incubated without CKII acceptor peptide. Counts per minute 
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were converted to disintegrations per minute using a standard curve of 3H-UDP-GlcNAc, 
and then to fmoles/min/mg.  
Mass spectrometry sample preparation and analysis 
MS sample preparation and data acquisition was performed by the JHUSOM Mass 
Spectrometry and Proteomics Facility. Acetone protein pellets (described above) were 
resuspended in 100 µL of 100 mM ammonium bicarbonate (NH4HCO3) pH 7.8 and 1 µL 
of 1% Protease Max (Promega) and sonicated for 15 min. The sample was then reduced 
and alkylated with 10 mM dithiothreitol and 55 mM iodoacetamide, respectively, and 
digested with a Trypsin/LysC mixture (V5071; Promega). The resulting peptides were 
dried by vacuum centrifugation, and resuspended in 50 µL of 100 mM triethylammonium 
bicarbonate (TEAB). Subsequently, bRP micro-scale fractionation was performed using an 
Agilent 1200 capLC system with a multi-wavelength detector. Fractionation was 
performed at 5 µL/min on a 300 µm inner diameter fused silica column self-packed with 
Waters XBridge BEH130 C18 RP resin (3.5 µm, 130 Å; Milford, MA), and fractions were 
collected at 2 min intervals with a Probot (LC Packings) fraction collector (Dionex, 
Amsterdam, The Netherlands). After loading for 12 min onto the column, a gradient from 
0-30% (v/v) mobile phase A (10 mM TEAB) to B (90% (v/v) acetonitrile, 10 mM TEAB) 
was performed over a 50 min time interval before ramping to 100% (v/v) B over 10 min, 
and then holding for an additional 10 min. Fractions were concatenated into 12 fractions 
for subsequent LC-MS/MS analysis. Peptide fractions from bRP chromatography were 
injected onto a 2 cm desalting trap column packed with YMC C18 material (75 µm inner 
diameter, 5–15 µm, 120 Å; Allentown, PA) at 5 µL/min for 6 min before being eluted onto 
an analytical column packed with Michrom Magic C18 (75 µm × 15 cm, 5 µm, 120 Å; 
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Bruker Daltonics, Billerica, MA) using a nanoAquity nanoLC system (Waters, MA) with 
a nanoflow solvent delivery of 300 nL/min. Each sample was separated on a 90 min 
gradient (5%–90% (v/v) acetonitrile, 0.1% (v/v) formate) with a flow rate of 300 nL/min. 
The peptides were eluted and ionized via emitter tip (10 µm; New Objective, Woburn, MA) 
and maintained at 2.2 kV electrospray voltage into a Q-Exactive mass spectrometer 
(Thermo Fisher Scientific). Precursor ions were selected for MS/MS fragmentation using 
a data-dependent “Top 15” method operating in a tandem Fourier transform (FT-FT) 
acquisition mode. Precursor ions were scanned between m/z (mass/charge) 350–1800 Da 
at 70,000 resolution with a target maximum of 3e6 ions. Fragment ions (MS/MS scans) 
were analyzed at 17,500 resolution with a target of 1e5 ions. Maximum injection times for 
the precursor and fragment ions were set to 100 and 250 milliseconds, respectively. The 
ion selection threshold for triggering MS/MS fragmentation was set to 2e4 counts. An 
isolation width and offset of 2.0 Da and 0.5 Da, respectively, were used to perform high-
energy collision induced dissociation fragmentation with a normalized collision energy of 
27. The polysiloxane background peak at 371.101230 m/z was used as a lock mass for each 
scan to maintain mass accuracy. 
Search parameters and acceptance criteria  
Peptide identifications were determined using a 30 parts per million precursor ion 
tolerance, a 0.05 Da MS/MS fragment ion tolerance, and a maximum of 2 missed 
cleavages. Methylthio modification of cysteine residues was considered a static 
modification, while oxidation of methionine, biotinylation of lysine, and deamidation of 
asparagine and glutamine were set as variable modifications. For the SILAC labeling, 
variable modifications included lysine (2H4 and 13C615N2) and arginine (13C6 and 13C615N4) 
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(Light: no labels; Medium: Arg6, Lys4; Heavy: Arg10, Lys8). Spectra files (*.RAW) were 
searched through Proteome Discoverer 1.4 (Thermo Fisher Scientific) using the Mascot 
algorithm (V2.1, Matrix Sciences, United Kingdom) against the RefSeq2014 human 
database. The data were processed through the Xtract and MS2 processor nodes together 
with an unaltered search, and the combined searches were processed through Percolator 
node (Department of Genome Sciences, University of Washington, Seattle, WA) for FDR 
estimation. Raw protein and peptide identifications were validated employing a q-value of 
0.05 (5% FDR) and a peptide rank of 1 within Proteome Discoverer (Figure 3-8 (inclusion 
criteria, filter 1); Supplemental Tables 3-1 through 3-3 (HA dataset), 3-4 through 3-6 (Myc 
dataset)). The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the 
PRIDE partner repository (Martens et al. 2005; Côté et al. 2012; Vizcaíno et al. 2014; 
Perez-Riverol et al. 2016; Vizcaíno et al. 2016) with the dataset identifier PXD005039.  
The ratio of L/H (H2O2/Background), M/H (Vehicle/Background), and L/M 
(H2O2/Vehicle) were generated in Proteome Discoverer. The following criteria were used 
to select proteins for further analysis (Figure 3-8): First, proteins considered for analysis 
have ≥1 unique peptide, ≥2 total peptides, and ≥3 PSMs per identification (Figure 3-8 
(inclusion criteria, filter 2); Supplemental Tables 3-7 and 3-8). Second, the heavy sample 
represents background and is anticipated to contain the endogenously biotinylated proteins 
(carboxylases), proteins that associate with the carboxylases, and proteins that associate 
non-specifically with the NeutrAvidin resin used for biotin enrichment. To set a threshold 
at or below which proteins were considered background, the Log2 of the SILAC ratios 
(L/H; M/H) for the endogenous carboxylases from the HA and Myc datasets (Supplemental 
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Table 3-9) were converted to frequencies and plotted as histograms (Figure 3-9) using 
GraphPad Prism (version 7; GraphPad Software Inc., La Jolla, CA). We then used the Z-
score from a one–sided 95% confidence interval to calculate the Log2 threshold for each 
ratio (L/H; M/H) in each dataset (HA; Myc), which was then converted back to a SILAC 
ratio (HA dataset: L/H >1.867, M/H >1.874; Myc dataset: L/H >2.005, M/H >2.258; Figure 
3-8 (exclusion criteria 2), Figure 3-9; Supplemental Table 3-9). Proteins not meeting the 
background threshold were excluded (Supplemental Tables 3-10 and 3-11). Third, the 
majority of keratins were eliminated, as they are common environmental contaminants 
present in MS studies (Figure 3-8 (exclusion criteria 3); Supplemental Tables 3-10 and 3-
11). Of note, keratin 8 and 18 were not excluded, as they are known to be O-GlcNAc-
modified (Srikanth et al. 2010). Fourth, a variety of techniques have been used to set a 
threshold for signal-induced changes when using SILAC (Trinkle-Mulcahy et al. 2008; 
Boulon et al. 2010; Coombs et al. 2010; Neilson et al. 2013). As OGA is the “bait”, we 
assessed the L/M SILAC ratio of OGA (NCOAT; accession 1102469) in each dataset: 
1.057 and 1.308 for the HA and Myc datasets, respectively (Supplemental Tables 3-10 
through 3-12). We set an arbitrary threshold of 25% above or below this number: 1.32125 
and 0.79275, respectively, for the HA dataset; and 1.635 and 0.981, respectively, for the 
Myc dataset (Supplemental Tables 3-10 through 3-12). Our rationale for this threshold was 
as follows: as signal-induced changes are diluted out by the BioID labeling method, we set 
a lower threshold than we have used previously (30-50% change) (Zachara et al. 2011; 
Zhong et al. 2015; Lee et al. 2016). To validate this threshold, candidate proteins near the 
threshold (FAS, FLNA) were validated by co-IP. A summary of the protein identifications 
following each major exclusion criteria is in Supplemental Table 3-13. 
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Experimental design and statistical rationale 
Graphs and statistical analyses were prepared using GraphPad Prism (version 6). 
Data are presented as the mean with errors bars representing the standard error of the mean 
(SEM) unless otherwise indicated. Unless otherwise noted, three biological replicates (N) 
were performed for each experiment and are indicated in the figure legends. For OGA 
activity assays, each biological replicate was assessed in duplicate. In Figure 3-2C the 
transfection efficiency, and thus corresponding OGA activity, varies for each biological 
replicate. As such, the OGA activity values cannot be averaged and one representative 
experiment is shown. In this case, the error bars represent the standard deviation of the two 
technical replicates. Data with at least three matched groups (Figure 3-1: V, 1-3 h H2O2; 
Figure 3-13D: input, bound, unbound) were analyzed by a parametric RM-1ANOVA. 
Dunnett’s MCT was used to compare each H2O2-treated sample with the vehicle-treated 
control (Figure 3-1), and Tukey’s MCT was used to compare OGA activity in the input, 
bound, and unbound fractions (Figure 3-13D). Matched two-sample data (Figure 3-2C; 
pcDNA3.1 ± biotin) were analyzed by a parametric RPT (two-tails, 95% confidence). Data 
with at least three matched groups (V, 1-3 h H2O2) in two matched samples (pcDNA3.1, 
V5-FAS) were analyzed by a parametric RM-2ANOVA (Figure 3-14). Sidak’s MCT was 
used to compare differences between the two matched samples (pcDNA3.1, V5-FAS) at 
each H2O2 time point. For all statistical tests, differences were considered significant at 
p≤0.05 (*), p≤0.01 (**), p≤0.001 (***), and p≤0.0001 (****). SILAC-based MS analysis 
was performed once. Protein-protein interactions were validated by orthologous methods 
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Appendix A: Polymerase Chain Reaction Primers for Site-
Directed Mutagenesis 
 
Primer Name  Primer Sequence (5’®3’) 
BirAMetF  GATTCGAATTCGGATCCATGAAGGACAACACCGTGCC 
BirAMetR  GGCACGGTGTTGTCCTTCATGGATCCGAATTCGAATC 
Del23bpF  TAAGGCCTGTTAACCGGTGGATCCAAGGACAAC 
Del23bpR  GTTGTCCTTGGATCCACCGGTTAACAGGCCTTA 
BirAHAinsNotIF TATAGGGAGACCCAAGCGGCCGCTGGCTAGCGCTTAAG 
BirAHAinsNotIR CTTAAGCGCTAGCCAGCGGCCGCTTGGGTCTCCCTATA 
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